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SUMMARY 
Deregulation of promoter methylation is a well-defined phenomenon in prostate cancer (PCa). 
This does not only lead to the inactivation of tumor suppressors but also to the activation of 
oncogenes, enabling the acquisition of the hallmarks of cancer. Accumulating evidence suggests 
that long non-coding RNAs (lncRNAs) are involved in DNA methylation and demethylation 
processes through recruitment of DNA methylation modifiers to specific genomic locations.  
 
Since alterations in DNA methylation of protein-coding genes are associated with prostate 
carcinogenesis and might be regulated by cis transcribed RNAs, we aimed to identify lncRNAs 
involved in DNA (de)methylation mechanisms in PCa. By integrating DNA methylation and RNA 
sequencing data generated by collaborators from the International Cancer Genome Consortium 
(ICGC) project, we have identified the lncRNA DLX6-AS1 as the potential regulator of the cis 
protein-coding gene DLX6. 
 
DLX6 and DLX6-AS1 transcript expression is upregulated and significantly correlates in two 
independent cohorts of PCa patients, as well as in five different cancer entities. In line with 
elevated expression levels of DLX6/DLX6-AS1, the DLX6 promoter region is hypomethylated in 
tumor samples. The impact of elevated DLX6/DLX6-AS1 levels on patient’s prognosis varies with 
the tumor type.  
 
The clinical data corroborate our hypothesis that DLX6-AS1 can regulate the cis protein-coding 
gene DLX6 by decreasing DLX6 promoter DNA methylation. Nevertheless, we showed through 
loss- and gain-of-function approaches that DLX6-AS1 does not regulate DLX6 at the transcript 
level by influencing local DNA methylation levels. The sequence features as well as the 
association to polysomes of the major splice variant of DLX6-AS1 (DLX6-AS1 T1), suggests rather 
a DLX6 protein synthesis regulatory role for this transcript.  
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Detailed investigation of the function and expression pattern of all DLX6-AS1 splice variants in 
different cancer types will help to clarify the link between DLX6/DLX6-AS1 expression and 
patients’ prognosis.  
 
 
 
 
 
 
 
 
ZUSAMMENFASSUNG 
 
7 
 
ZUSAMMENFASSUNG 
Das Phänomen der Deregulation von Promoter-Methylierung wurde im Prostatakarzinom (PCa) 
ausführlich beschrieben. Diese Deregulation kann einerseits eine Inaktivierung von 
Tumorsuppressoren und andererseits eine Aktivierung von Onkogenen zur Folge haben, was 
wiederum die Anreicherung von Krebsmerkmalen ermöglichen kann. Studienergebnisse deuten 
darauf hin, dass lange, nicht-kodierende RNA (long non-coding RNA, lncRNA) eine Rolle in DNA 
Methylierungs- und Demethylierungsprozessen durch lokus-spezifische Rekrutierung von DNA 
Methylierungs-Modifizierern spielt. 
Da Veränderungen im DNA Methylierungsmuster protein-kodierender Gene mit der Entstehung 
von Protstatakrebs in Verbindung stehen und durch cis transkribierte RNAs reguliert sein können, 
war es unser Ziel lncRNAs zu identifizieren, die DNA (De-)Methylierungsmechanismen im PCa 
deregulieren können. Durch Integration von DNA Methylierungs- und RNA Sequenzierungs-
Daten, die von Kollaborationspartnern des International Cancer Genome Consortium (ICGC) 
Projekts erhoben wurden, konnten wir DLX6-AS1 als potentiellen Regulator des cis protein-
kodierenden Gens DLX6 identifizieren. 
In sowohl zwei unabhängigen Kohorten von PCa Patienten, als auch in fünf unterschiedlichen 
Krebsentitäten, konnte eine Korrelation sowie Hochregulierung der Expression von DLX6 und 
DLX6-AS1 Transkripten beobachtet werden. Im Einklang mit erhöhten Expressionsleveln von 
DLX6/DLX6-AS1 stellt sich die DLX6 Promoterregion als hypomethyliert dar. Der Einfluss der 
erhöhten DLX6/DLX6-AS1 Level auf die Prognose der Patienten ist dabei abhängig vom Tumortyp.  
Die klinischen Daten bestätigen unsere Hypothese, dass DLX6-AS1 das cis protein-kodierende Gen 
DLX6 durch Reduzierung der Promoter DNA-Methylierung reguliert. Wir konnten allerdings durch 
Überexpressions- und RNA Interferenz-Experimente zeigen, dass DLX6-AS1 die Transkriptlevel 
von DLX6 nicht über die DNA-Methylierung beeinflusst. Sowohl die Sequenzeigenschaften der 
Haupt-Spleißvariante DLX6-AS1 (DLX6-AS1 T1) als auch die direkte Assoziation mit Polysomen 
lässt darauf schließen, dass dieses Transkript eher die DLX6 Proteinsynthese reguliert. 
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Weitergehende Funktions- und Expressionsstudien aller DLX6-AS1 Spleißvarianten in 
unterschiedlichen Krebsformen sollten dabei helfen, den Zusammenhang zwischen 
DLX6/DLX6−AS1 Expression und Patientenprognose aufzuklären. 
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ABBREVIATIONS 
Abbreviations Full Name 
450k HumanMethylation450 BeadChip 
5’RACE Rapid amplification of 5’ cDNA ends 
5caC 5-carboxycytosine  
5fC 5-formylcytosine  
5hmC 5-hydroxymethylcytosine 
5mC 5-methylcytosine 
aa Amino acids 
ALAS1 5'-Aminolevulinate synthase 1 
AR Androgen receptor 
BER Base excision repair  
bp Base pairs 
CAGE Cap analysis of gene expression 
CGIs CpG islands 
ChIP-seq Chromatin immunoprecipitation and sequencing 
COAD Colon adenocarcinoma 
DLX5  Distal-less homeobox 5 
DLX6 Distal-less homeobox 6  
DLX6-AS1 DLX6 antisense RNA 1 
DMRs Differentially methylated regions 
DNMT1/3A/3B DNA methyltransferase 1/3A/3B 
DNMT3L DNA methyltransferase 3-like  
EO-PCa Early onset prostate cancer 
ERG- TMPRSS2:ERG fusion-negative prostate cancer patients 
ERG+ TMPRSS2:ERG fusion-positif prostate cancer patients 
Evf2 Mouse homologue of DLX6-AS1 lncRNA 
GADD45A DNA-damage-inducible protein 45A  
HDAC Histone deacetylase 
HNSC Head and neck squamous cell carcinoma 
HPRT1 Hypocanthine-guanine phosphoribosyltransferase 
ICGC International Cancer Genome Consortium 
KIRC Kidney renal clear cell carcinoma 
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lincRNA Long intergenic non-coding RNA 
lncRNA Long non-coding RNA 
LUAD Lung adenocarcinoma  
LUSC Lung squamous cell carcinoma 
MBD Methyl-CpG binding domain  
mCRPCa Metastatic castration-resistant prostate cancer  
MLN  Myoregulin  
mRNA Messenger RNA 
ncRNA Non-coding RNA 
ORF open reading frame 
PCa Prostate cancer 
Pol II  RNA polymerase II  
PSA Prostate-specific antigen  
PTMs Post-translational modifications  
RIP-seq RNA immunoprecipitation followed by deep sequencing  
SDHA Succinate dehydrogenase complex flavoprotein subunit A 
SWI/SNF  SWItch/Sucrose NonFermentable complex 
TCGA The Cancer Genome Atlas 
TDG Thymine-DNA glycosylase  
TET Ten-eleven translocation enzyme 
TSG Tumor suppressor gene  
TSS Transcription/Transcriptional start site 
TTS Transcriptional termination site 
 
 
INTRODUCTION 
 
11 
 
1. INTRODUCTION 
1.1 Epigenetic regulation of gene expression 
1.1.1 From epigenesis to the modern definition of epigenetics 
Until the 1940s the fields of genetics and developmental biology were separated. In 1942, Conrad 
H. Waddington united the two disciplines by coining the term “epigenetics” as a derivate of the 
Greek word “epigenesis” (theory by which an adult develops from the zygote by a series of steps) 
combined with the term “genetics”. He used the term “ epigenetics” to describe the process by 
which a zygote with a certain genotype gives rise to a complex organism with a specific 
phenotype (Waddington, 2012). Waddington’s notion of epigenetics was however broad, 
imprecise and not drastically different from the study of embryology. 
 
In 1975, two independent publications by Riggs and by Holliday & Pugh proposed a model for the 
switching of gene activity by DNA methylation during the developmental process (Holliday et al., 
1975, Riggs, 1975), subsequently experimentally proven in the mid-1980s (Doerfler, 1983). 
Nevertheless, DNA methylation was not linked to epigenetics until the finding that it is heritable, 
similar to genetic patterns (Holliday, 1987). Consequently, the field of epigenetics evolved to “the 
study of mitotically and/or meiotically heritable changes in gene function that cannot be 
explained by changes in DNA sequence” (Riggs et al., 1996) translating our 21st century view of 
epigenetics.  
 
The refinement to the actual definition of epigenetics was mainly the consequence of the 
discovery of DNA methylation. Epigenetic regulation of gene expression is however achieved 
through a complex interplay of epigenetic tools and mechanisms, establishing, reinforcing, 
spreading, transmitting and reversing epigenetic patterns. This includes DNA methylation, 
histone modifications, histone variants, chromatin remodelling and non-coding RNAs (ncRNAs). 
The coordinate action of this epigenetic toolbox controls physiological processes such as the 
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identity of over 200 human cell types or cell proliferation. We focus here on histone 
modifications, DNA methylation and non-coding RNAs.  
1.1.2 Histone modifications and chromatin remodeling 
The genome of a typical eukaryotic cell is wrapped into chromatin and folded onto itself to form 
high-order structures, in order to accommodate the 2 meters of DNA present in the nucleus 
(Fussner et al., 2011).  
 
The chromatin is a dynamic structure composed of nucleosomes. The main components of the 
nucleosome are histones, organized in an octamer comprising two copies of H2A/H2B dimer and 
one H3/H4 tetramer, surrounded by 146 base pairs of DNA and stabilized by histone H1 (Luger 
et al., 1997). Each individual histone possesses an N-terminal tail subjected to a variety of 
covalent post-translational modifications (PTMs). So far, more than 100 different histone 
modifications have been identified; the most widely studied comprise methylation, acetylation 
and phosphorylation (Kouzarides, 2007). Histone modifications are modulated by two families of 
enzymes, the histone “writers”, establishing specific modifications (e.g. histone acetyltransferase 
and methyltransferase), and the histone “erasers” (e.g. histone deacetylase and demethylase) 
that reverse the process. The combination of PMTs is known as “histone code” and organizes the 
genome into active regions of euchromatin, where DNA is accessible for transcription, and into 
inactive heterochromatin regions, where DNA is highly compacted and less accessible for 
transcription (telomeres, pericentric regions, repetitive sequences) (Strahl et al., 2000).  
 
A deeper look into the most modified histone, histone H3, and its well-studied methylation and 
acetylation modifications can distinguish functional elements of the genome and determine their 
active or repressive state. A transcriptionally active gene is decorated by the tri-methylation of 
lysine 4 (K4) on histone H3 (H3K4me3) in its gene promoter region, while tri-methylation of K36 
(H3K36me3) is associated with transcriptionally active gene bodies. Acetylation of lysine residues 
participate in the binding of transcription factors and are consequently enriched in the promoter 
INTRODUCTION 
 
13 
 
and gene bodies of active genes (Figure 1-1A). Promoters of repressed genes are instead marked 
by tri-methylation of K27 (H3K27me3) or K9 (H3K9me3) (Figure 1-1B) (Barski et al., 2007). Histone 
modifications are interpreted by chromatin “readers” harboring functional recognition domains 
such as bromodomains and are critical for transcriptional regulation (Figure 1-1). PMTs not only 
regulate chromatin structure, but they also allow the recruitment of remodeling complexes, such 
as the SWI/SNF (SWItch/Sucrose Non Fermentable) complex leading to nucleosome repositioning 
(Peterson et al.,2000).  
 
Figure 1-1: Modulation of chromatin marks from an active to a repressed transcriptional state 
(A) Transcriptionally active genes are marked by chromatin “writers” through acetylation of histone H3 
(Ac) and trimethylation of H3 lysine 4 (H3K4me3) in their promoter region. These marks can then be 
recognized by chromatin “readers”. (B) Histone acetylation is removed by the histone “eraser” histone 
deacetylase (HDACs), while repressive trimethylation of K9 (H3K9me3) and K27 (H3K27me3) residues are 
established by histone methyltransferases. This combination leads to chromatin condensation and 
subsequent gene silencing.  
1.1.3 DNA methylation and demethylation in mammals 
DNA methylation is a highly evolutionary conserved epigenetic mark that exists in both 
prokaryotic and eukaryotic genomes. It is also the first and best-studied epigenetic modification 
in mammals. In concert with histone modifications, DNA methylation is a crucial player in the 
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physiological and pathological regulation of gene expression, genomic imprinting and genome 
stability.  
A. Establishment and maintenance of DNA methylation patterns 
In humans, the addition of a methyl group from the methyl donor S-adenosylmethionine (SAM) 
occurs prevalently at the fifth position of cytosine (5-methylcytosine; 5mC) in a cytosine-guanine 
CpG dinucleotide context.  
 
In somatic cells, DNA methylation patterns are relatively stable compared to histone 
modifications and are mitotically and meiotically inherited. The faithful restoration of DNA 
methylation patterns on the newly-replicated DNA strand is ensured through the action of the 
maintenance DNA methyltransferase 1 (DNMT1) (Hermann et al., 2004).  
 
In contrast, DNA methylation patterns of the pre-implantation embryo are erased genome-wide 
and subsequently re-established at the blastocyst stage by the de novo methyltransferases 
DNMT3A and DNMT3B (Okano et al., 1999). Both enzymes cooperate with DNA 
methyltransferase 3-like (DNMT3L), the catalytically inactive member of the family. Indeed, 
DNMT3L favors de novo methylation of gene bodies of housekeeping genes in embryonic stem 
cells (Neri et al., 2013) and of imprinted genes in germ cells (Bourc'his et al., 2001, Hata et al., 
2002, Kareta et al., 2006). De novo DNA methyltransferases do not only establish methylation 
during development but also play a role in somatic cells. Gain of methylation was associated with 
aging in a fraction of CG rich promoters (Jones et al., 2015) and during tumorigenesis (reviewed 
in section 1.3.2). The gain of methylated CpGs in somatic cells is a very slow process, lasting from 
several weeks in a provirus (Lorincz et al., 2000), to several months in a cell line treated with the 
DNA methylation inhibitor 5-azacytidine (Flatau et al., 1984).  
 
In addition, de novo and maintenance methyltransferases have overlapping functions. Indeed, 
double DNMT3A/3B knockout of mouse or embryonic stem cells leads to a gradual loss of 
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methylation as cells divide. This supports a proofreading role for DNMT3A and DNMT3B by 
methylating CpG sites missed by DNMT1 (Jones et al., 2009, Jeltsch et al., 2014).  
B. DNA demethylation 
DNA methylation is a dynamic and reversible epigenetic modification, as a result of the interplay 
between active and/or passive DNA demethylation.  
 
The inhibition, degradation, or nuclear exclusion of DNMT1 result in a progressive dilution of DNA 
methylation patterns in the process of passive demethylation (Figure 1-2A). Passive 
demethylation is relatively slow and is restricted to dividing cells. This mechanism was 
exemplified by the replication-dependent dilution of 5mC in the maternal pronucleus during 
preimplantation development (Rougier et al., 1998).  
 
Research during the past years has identified the dioxygenase family of ten-eleven translocation 
(TET) enzymes as mediators of active DNA demethylation processes. TET 1, 2 and 3 catalyze the 
hydroxylation of 5mC, yielding 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) through iterative oxidation (Iyer et al.,2009, Tahiliani et al., 2009). Active 
DNA demethylation is accompanied by an enzymatic modification of 5mC followed either by 
passive dilution (Figure 1-2B) or by DNA repair of the methyl marks (Figure 1-2C). The presence 
of 5hmC, 5fC or 5caC moieties interferes and prevents the binding of DNMT1 during DNA 
replication, resulting in a passive dilution of the methylation patterns (Figure 1-2B).  
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Figure 1-2: Passive and active DNA demethylation 
5-Methylcytosine marks (5mC) are established and maintained by DNMT enzymes and then reversed by 
(A) passive or (B and C) active DNA demethylation. Iterative oxidation of 5-methylcytosine leads to the 
formation of 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). (A) 
Passive DNA demethylation of 5mC through successive replication. Active DNA demethylation includes 
(B) replication dependent demethylation of 5hmC, 5fC or 5caC residues, (C) while 5fC and 5caC can be 
replaced by an unmodified cytosine after excision by thymine DNA glycosylase (TDG), followed by base 
excision repair (BER).   
 
Alternatively, 5fC and 5caC can be recognized and excised by thymine-DNA glycosylase (TDG). 
The generated abasic site is subsequently recognized by the base excision repair (BER) pathway 
and replaced by an unmodified cytosine (Figure 1-2C) (He et al., 2011) (Maiti et al., 2011). 
Consistent with this model, TDG null mice are lethal around embryonic day 12.5 and exhibit 
increased 5mC levels in gene promoters (Cortazar et al., 2011, Cortellino et al., 2011). Evidence 
suggests that this mechanism is used for the global 5mC erasure of the paternal pronucleus a few 
hours after fertilization as well as in primordial germ cells (Mayer et al., 2000, Oswald et al., 
2000). However, this notion has recently been challenged as the formation of 5hmC is observed 
after demethylation (Amouroux et al., 2016). 
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Active DNA demethylation is not restricted to development but can also affect specific loci in 
somatic cells. For example, p15 (also known as CDKN2B or INK4B) and SP2 (SP2 transcription 
factor) promoters are actively demethylated through the interplay of TDG and BER in response 
to the addition of TGFβ (Thillainadesan et al., 2012) or to the binding of estrogen to the estrogen 
receptor (Metivier et al., 2008), respectively.  
 
Alternatively, DNA-damage-inducible protein 45A (GADD45A) was reported to stimulate active 
DNA demethylation by promoting DNA repair via the nucleotide exchange repair (NER) pathway 
(Barreto et al., 2007). The role of GADD45A in DNA demethylation remains controversial. 
Evidence suggests a role for GADD45A in active demethylation in mammalian cells (Schmitz et 
al., 2009, Arab et al., 2014) but conflicting results have also been reported (Jin et al., 2008). 
C. Regulation of gene expression by DNA methylation 
Of the 29 million CpGs in the human genome, 60 to 80% are methylated in somatic tissues. Most 
genomic regions are methylated according to their CG content. DNA methylation mainly affects 
repetitive elements (e.g. retrotransposons) and non-coding regions (e.g. centromere). 
Hypermethylation of repetitive elements prevents translocations and consequently 
chromosomal instability (Deaton et al., 2011).  
 
In contrast, regions longer than 200 base pairs (bp) enriched for CpG dinucleotides (GC content 
>50%), designated as CpG islands (CGIs), are mainly unmethylated in normal cells. Promoter 
regions remain unmethylated and protected from de novo methylation through binding of CFP1 
(CXXC finger protein 1) and KDM2A proteins to unmethylated DNA (Blackledge et al., 2010, 
Thomson et al., 2010, Blackledge et al., 2013). CGIs are mostly located at transcription start sites 
(Consortium et al.) of gene promoters, flanked by regions termed as shores (up to 2kb away from 
a CGI) and followed by shelves (located 2 to 4kb from a CGI). Approximatively 70% of genes have 
a CGI associated to their promoter region. In general, levels of DNA methylation in CGI-associated 
promoters (including shores) are negatively correlated with the level of gene expression, whereas 
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in gene body, DNA methylation is positively associated with transcriptional activity (Irizarry et al., 
2009, Deaton et al., 2011).  
 
The presence of 5mC in promoter regions is believed to repress gene transcription through 
interference with the recognition sequence of transcription factors or with the transcriptional 
machinery. In lieu of interference, DNA methylation can also attract proteins belonging to the 
methyl-CpG binding domain (MBD) family that establish a repressive chromatin state through 
recruitment of chromatin remodeling complexes or histone deacetylases (Du et al., 2015). 
1.1.4 Interplay between DNA methylation and histone modifications 
A coordinated cross-talk between histone modifications and DNA methylation allows precise and 
dynamic regulation of gene expression. Most proteins responsible for the establishment, 
removal, or reading of epigenetic marks, leading to a common active or repressive chromatin 
state, are part of large protein complexes.  
 
MeCP2 (Methyl CpG Binding Protein 2), a member of the MBD family of transcriptional 
repressors, can be shown as an example that establishes the link between histone and DNA 
modifications for gene repression. On one side MeCP2 selectively binds to methylated DNA, while 
simultaneously recruiting histone deacetylases (HDAC) through interaction with the corepressor 
Sin3A (SIN3 transcription regulator family member A). The MeCP2-Sin3a-HDAC complex 
establishes a strong transcriptional repression via histone deacetylation (Jones et al., 1998, Nan 
et al., 1998). Unmethylated CGIs, on the other hand, are recognized by zinc finger-CxxC domain 
containing proteins, such as CFP1. In addition to binding to unmethylated DNA, CFP1 recruits 
SETD1A (SET Domain containing 1A), a H3K4 methyltransferase, that in turn creates new 
H3K4me3 marks allowing access of the transcriptional machinery (Thomson et al., 2010). 
 
In 1975, Paul & Duerksen found that in chromatin, RNA is twice more prevalent than DNA, 
suggesting that RNA may have important roles in establishing chromatin structures (Paul et al., 
1975). Since the past years it has become evident that RNA, especially long non-coding RNAs 
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(lncRNAs), participate in the epigenetic cross-talk by influencing the access or dismissal of 
chromatin complexes.  
1.2 Non-coding RNAs  
Protein coding genes account for less than 2% of the human genome; the remaining non-coding 
space is composed of repetitive elements (de Koning et al., 2011) and was therefore merely 
considered as “junk DNA” (Comings, 1972, Ohno, 1972). The field of ncRNAs received an 
increased interest with the advent of next-generation sequencing techniques allowing the finding 
that 70% of our genome can be transcribed into ncRNAs (Lander et al., 2001, Venter et al., 2001, 
Consortium, 2012, Djebali et al., 2012).  
 
1.2.1 General characteristics of long non-coding RNAs (lncRNAs) 
Non-coding RNAs have been arbitrarily divided into short ncRNAs with a size below 200 nt (e.g. 
microRNAs, Piwi-associated RNAs, ribosomal RNAs) and lncRNAs being longer than 200 nt 
(Ponting et al.,2009). LncRNAs have no or limited protein-coding potential but resemble 
messenger RNAs (mRNAs) in terms of their biogenesis and form. They are generally transcribed 
by the RNA polymerase II, have a 5’ terminal methylguanosine cap, are polyadenylated, often 
spliced, and share similar chromatin states (Derrien et al., 2012). Alternate transcription by the 
RNA polymerase III can also produce non-polyadenylated lncRNAs but they are poorly 
characterized (Kapranov et al., 2007). Compared to their protein-coding counterparts, lncRNAs 
are more tissue-specific (78% for lncRNAs versus 18% for mRNAs), less expressed, and enriched 
in the nucleus (Quinn et al., 2016).  
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Based on their localization relative to nearby protein-coding genes, lncRNAs have been 
subdivided into i) antisense lncRNAs encoded in opposite direction and overlapping at least 
partially with the exonic sequence of a protein-coding gene, ii) intronic lncRNAs that are encoded 
within introns of coding genes, and iii) intergenic lncRNA (lincRNA) that are entirely encoded 
within the region between successive coding genes (Figure 1-3) (Rinn et al., 2012).  
Figure 1-3: Classification of lncRNAs 
LncRNAs are defined as antisense, intergenic and intronic lncRNA based on their location relative to 
neighboring protein-coding genes. Grey or orange rectangles depict exonic regions of an mRNA or lncRNA, 
respectively, whereas black lines represent intronic regions.  
 
RNA-seq data across 24 human tissues and cell lines identified a catalog of 8195 lncRNAs (Cabili 
et al., 2011). This number expanded to about 101,700 lncRNA genes in humans according to the 
NONCODE database (Zhao et al., 2016). Despite their abundance, only 184 lncRNAs (lncRNA 
database, version from May 2016) are so far functionally validated in humans (Quek et al., 2015). 
Functional studies have associated lncRNAs with numerous roles, ranging from alternative 
splicing regulation to mRNA stability and modulation of translation (Rashid et al.,2016). A broad 
area of their function involves transcriptional regulation, notably through the binding of 
transcriptional regulators and chromatin modifiers (Maruyama et al., 2012). Experimental 
evidence suggests that lncRNAs play key roles in the recruitment, scaffolding, sequestration and 
guiding of such complexes in the genome (Rinn et al., 2012).  
 
Dependent on the expression level, stability, and cellular context of a specific RNA as well as the 
three-dimensional folding of chromatin, the targeting of a lncRNA occurs either on local genes 
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(cis regulation) or on more distant chromosomal domains or different chromosomes (trans 
regulation) (Guttman et al., 2011). Around 70% of the coding sense transcripts have a reported 
antisense non-coding counterpart (He et al., 2008) and often share a coordinated expression 
pattern. In many cases, the antisense RNA has been shown to be involved in the cis regulation of 
the sense transcript (Orom et al., 2010).  
1.2.2 Involvement of lncRNAs in epigenetic regulation  
A single lncRNA can modulate gene expression through the recruitment of various writers, 
erasers, and readers of functionally related chromatin marks, and guide or titrate them away to 
the cis or trans location of their targets. Initial evidence into how lncRNAs are involved in 
epigenetic regulation came from the study of the lincRNA XIST (X inactive-specific transcript) 
during X chromosome inactivation. XIST is expressed from one of the two female X chromosomes 
and locally recruits the polycomb repressive complex 2 (PRC2) (Rinn et al., 2007). This 
recruitment results in H3K27me3 deposition leading to transcriptional silencing of the X 
chromosome from which XIST is transcribed (Figure 1-4).  
 
Figure 1-4: Epigenetic repression mediated by the lncRNA XIST 
XIST lncRNA mediates X chromosome inactivation (chr Xi) through binding to the PRC2 complex and 
subsequent deposition of the repressive H3K27me3 mark on the entire Xi chromosome.  
 
Interaction of lncRNAs and the PRC2 complex was demonstrated through sequencing of PRC2-
bound RNAs to be a common feature for thousands of lncRNAs. Knockdown of selected lncRNAs 
associated with PRC2 components proved their requirement for proper epigenetic and 
transcriptional repression of PRC2 targets (Khalil et al., 2009, Zhao et al., 2010).  
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More recent studies have also demonstrated the recruitment of gene activating activities. For 
instance, the lncRNA TARID (TCF21 antisense RNA inducing demethylation) keeps the TCF21 gene 
(transcription factor 21) in a transcriptionally active state through recruitment of the GADD45A-
TDG-TET DNA demethylation complex (Arab et al., 2014) (Figure 1-5A). In another example, 
ecCEBPA (extra-coding CEBPA) binds to DNMT1 protein and in a decoy mechanism prevents the 
methylation of CEBPA gene promoter (Figure 1-5B). This notion has been extended by 
sequencing the RNAs that co-immunoprecipitate with DNMT1, suggesting that local lncRNA-
DNMT1 interaction is a prevalent mechanism in regulating the methylation pattern of genes 
located in cis (Di Ruscio et al., 2013). 
 
 
Figure 1-5: Epigenetic activation mediated by lncRNAs 
(A) TARID activates TCF21 transcription through binding and recruitment of the GADD45A-TDG-TET DNA 
demethylation complex to the TCF21 promoter. (B) The lncRNA ecCEBPA binds and sequesters DNMT1 to 
prevent CEBPA promoter methylation.  
 
These reports imply that lncRNAs can bind to histone and DNA methylation modifiers, which in 
turn can modulate the chromatin status of specific target genes, via either specific targeting or 
the sequestration of epigenetic modifiers. 
1.2.3 Do lncRNAs code for proteins?  
Among the plethora of identified lncRNAs, only a minority has been linked to a function, which 
addresses the question whether some of them may actually encode for short functional peptides. 
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LncRNAs and mRNAs are generated by the same transcriptional machinery and thus share many 
features (section 1.2.1). LncRNAs differ from mRNAs by their lack of an extended open reading 
frame (ORF) encompassing a minimum of 100 amino acids (aa). The detection of ORFs is therefore 
fundamental for the definition of lncRNAs and has been assessed by searching for evolutionary 
conservation, matches to proteomic or domain databases (e.g, BLASTP, Swissport, PFAM) and for 
codon occurrence patterns. These tools, however, are designed to identify conserved and larger 
ORFs (>100 aa) enriched for these features (Andrews et al., 2014). Ribosomal profiling has been 
used to assess the number of lncRNAs bound and scanned by ribosomes. Interestingly, several 
studies found that many lncRNAs engage to ribosomes, and their footprints correspond to 
potential short ORFs (Ingolia et al., 2011, Bazzini et al., 2014, van Heesch et al., 2014). Others 
however argued that the ribosome patterns seen for lncRNAs are similar to the ones from known 
non-coding RNAs, suggesting that lncRNAs are not translated (Guttman et al., 2013).  
 
The interpretation of the association of lncRNAs to ribosomes is therefore controversial, and 
lncRNA translation does not guaranty the production of a functional and stable peptide. In 
concordance with this observation, proteomic analysis by mass spectrometry indicated that 92% 
of lncRNAs annotated in GENCODE are not translated in the leukemic K562 and in the 
B−lymphocytic GM12878 cell lines (Banfai et al., 2012). This is in line with another study where 
only eight lncRNAs harbored a micropeptide in K562 cells (Slavoff et al., 2013). These reports are 
in contrast with a study by Kuster and colleagues that delineated a set of 430 peptides from 404 
lncRNAs detected in 16,857 mass spectrometry data from human tissues, cell lines and body 
fluids (Wilhelm et al., 2014). Reanalysis of these data by Tress and colleagues concluded, 
however, that the results contain many false positives due to poor data filtering (Ezkurdia et al., 
2014). Genome wide identification of lncRNAs encoding peptides is limited to a handful. This is 
possibly due to the limited resolution to peptide smaller than 50 amino acids of the current mass 
spectrometry technology along with a low stability of potential peptides (Bazzini et al., 2014).  
Olson and colleagues have recently identified two peptides MLN (myoregulin) (Anderson et al., 
2015) and DWORF (dwarf open reading frame) (Nelson et al., 2016) encoded in two transcripts 
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annotated as lncRNA. These reports demonstrate that lncRNAs can indeed code for stable and 
functional peptides.  
 
In addition to their coding potential, lncRNAs may function as RNA molecules. The SRA (steroid 
receptor RNA activator) gene is a well characterized lncRNA, but also produces a protein-coding 
variant; both are independently involved in the co-activation of nuclear receptors (Lanz et al., 
1999, Chooniedass-Kothari et al., 2004, Cooper et al., 2011). Future studies and advances in the 
peptidomic field may reveal other lncRNAs that encode functional small ORFs.  
1.3 Prostate cancer  
1.3.1 Prostate Cancer: Clinical and Genetic features  
Prostate adenocarcinoma (PCa) is the most common type of cancer and the third cause of cancer-
related deaths among men in developed countries (Society, 2015). The incidence of PCa has been 
rising, since the approval of PCa detection in blood by prostate-specific antigen (PSA) testing by 
the Food and Drug Administration in 1987 (Potosky et al., 1995). With 758,700 men diagnosed 
and an estimated 142,000 death cases in developed countries in 2012, PCa is the cancer with the 
highest incidence in men (Society, 2015). The incidence increases with age, with a median age of 
about 70 years at diagnosis. About 2% of PCa patients are however detected earlier at the age of 
50 years or below and are defined as early-onset prostate cancer (EO-PCa) patients. This subset 
of patients is believed to represent a different cancer entity compared to the late onset PCa 
cancer cases (LO-PCa) (Weischenfeldt et al., 2013). Since the 1990s, most men diagnosed with 
PCa have an improved survival rate over 5 years, reaching 99% in developed countries (Siegel et 
al., 2016). Notably, EO-PCa was associated with slightly lower survival rates (98%) compared to 
elderly patients in other studies (Salinas et al., 2014).  
 
Normal prostate epithelium is composed of a balanced amount of basal and luminal cells with 
rare neuroendocrine cells (Abate-Shen et al., 2000). The prostate carcinogenic tissue was instead 
shown by lineage marking to preferentially stem from luminal cells (Wang et al., 2014). PCa 
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develops in a series of steps from prostatic intraepithelial neoplasia (PIN) to localized tumors, 
which can further progress to metastatic castration-resistant prostate cancer (mCRPCa). The 
staging of a prostate tumor is assigned by the TNM (Tumor Node Metastasis) classification, 
combining the information about the extent of the primary tumor (T category) and the spread to 
nearby lymph nodes (N category) or to other body parts (M category), further subdivided in 
function of their aggressiveness from T0 to T4, NX to N1 and M0 to M1c, respectively. The 
aggressiveness of the tumor is, in addition, measured by PSA levels and through evaluation of the 
cancer architecture by the Gleason score ranging from 6 (low grade, lowly aggressive) to 10 (high 
grade, highly aggressive) (N. Mottet, 2015).  
The etiology underlying PCa development and progression remains poorly understood. The risk 
factors include, but are not limited to, increasing age, family history of PCa or breast cancer, 
single nucleotide polymorphisms in the 8q24 region (Al Olama et al.,2009) and African decent 
(Pienta et al., 1993).  
 
Genome-wide studies have improved our understanding of the genetic alterations contributing 
to the malignant transformation and progression of PCa. Overall, only a few genes are mutated 
in PCa with a somatic mutation rate of 1.4 per Megabase (Barbieri et al., 2012) compared to 3.8 
mutations per Megabase in lung adenocarcinoma (Kan et al., 2010). Whole-exome sequencing 
enabled the detection of twelve recurrently mutated genes, with a prevalence for alterations in 
SPOP (Speckle-type POZ Protein), TP53 (Tumor Protein P53) and PTEN (Phosphatase and Tensin 
Homolog) genes (Barbieri et al., 2012). In mCRPCa, the most frequently mutated gene is the 
androgen receptor (AR). Alterations of AR through mutations, expression of splice variants, focal 
gene amplification (Xq12) and/or upregulation (Taylor et al., 2010, Grasso et al., 2012), enable 
the cells to overcome AR deprivation therapy, and result in the constant activation of the 
receptor or its activation by alternative ligands than steroids (Mills, 2014).  
 
Gene fusions dominate in PCa, involving members of the ETS transcription factor family and the 
androgen-regulated TMPRSS2 (transmembrane protease serine 2) gene. In approximately 50% 
of all the PCa cases, TMPRSS2 promoter is fused to ERG (v-ets erythroblastosis E26 oncogene 
homolog) gene (TMPRSS2:ERG), leading to androgen-dependent ERG overexpression (Tomlins et 
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al., 2005). The impact of the TMPRSS2:ERG fusion on PCa outcome is controversial, reported to 
be linked with good prognosis in early-onset patients (Steurer et al., 2014), bad prognosis or not 
linked to any clinical outcome in other reports (Kumar-Sinha et al., 2008). Nevertheless, this 
fusion gene along with a second oncogenic event such as PTEN (phosphatase and tensin homolog 
gene) deletion on 10q23 or PI3-kinase (phosphoinositide 3-kinase) pathway activation was shown 
to be necessary for the formation of PIN lesions as precursors of PCa (Carver et al., 2009, King et 
al., 2009). Focal deletion of the region spanning FOXP1 (Forkhead box protein P1), RYBP (Ring 
andYY1 binding protein) and SHQ1 genes on 3p14, and TP53 on 17p31 were also associated with 
TMPRSS:ERG fusions (Taylor et al., 2010). Other common rearrangements are the recurrently 
deleted regions targeting in 30 to 50% of cases; NKX3.1 (NK3 Homeobox 1) on 8q21, RB1 
(Retinoblastoma 1) on 13q14, and the amplification of 8q chromosome harboring, notably c-Myc 
(V-Myc Avian Myelocytomatosis Viral Oncogene Homolog) gene in 20 to 40% of the cases 
(Tomlins et al., 2005, Taylor et al., 2010). Compared to elderly patients, structural 
rearrangements in EO-PCa patients affect mainly androgen-driven genes, especially with a higher 
frequency of TMPRSS2:ERG fusion. The authors suggest that this phenomenon is the cause of 
elevated androgen levels in younger men (Weischenfeldt et al., 2013). 
1.3.2 Epigenetic alterations in prostate cancer  
Cancer genomes display frequent alterations in epigenetic enzymes (Plass et al., 2013). A number 
of chromatin/histone remodelers exhibit single nucleotide variations in primary tumors (Barbieri 
et al., 2012) and more prominently in castration-resistant PCa (Grasso et al., 2012). This supports 
the existence of a close interplay between genetic and epigenetic mechanisms during 
carcinogenesis. Integration of epigenetic and genetic profiles demonstrated a global increase in 
DNA methylation in TMPRSS2:ERG fusion negative patients, in comparison to patients harbouring 
the fusion gene (Kim et al., 2011, Borno et al., 2012). The link between genetic and epigenetic 
alterations was also demonstrated through the concomitant acquisition of CNVs along with 
changes in DNA methylation patterns during PCa tumor evolution (Brocks et al., 2014). 
Investigation of the three-dimensional chromatin organization by Hi-C (Genome-wide 
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Chromosome Conformation Capture) in LNCaP and PC3 prostate cancer cell lines, compared to 
the normal cell line PrEC, mechanistically linked the coevolution of genetic and epigenetic 
aberrations. Indeed, Clark and colleagues demonstrated that the presence of CNVs in cancer cells 
coincide with a different genome spatial organization. The authors linked the acquisition of novel 
topological domain boundaries to an altered chromatin and transcriptional state (Taberlay et al., 
2016).  
 
Alteration of the normal epigenetic landscape is known to participate in tumor development by 
enabling the acquisition of the hallmarks of cancer (Hanahan et al., 2011). Cancer genomes are 
characterized by a global loss of 5mC (hypomethylation) mainly affecting gene poor regions such 
as repetitive elements, centromeres and telomeres as well as gene bodies. The degree of 
hypomethylation was shown to increase from benign to metastatic stage in PCa cell lines 
(Yegnasubramanian et al., 2008). Decondensation of the chromatin structure through DNA 
hypomethylation leads to chromosome instability, allowing the reactivation of transposable 
elements (Ehrlich, 2002). In addition to genomic instability, loss of methylation in repeats was 
associated with the activation of not only alternative transcription (Wolff et al., 2010), but also 
oncogenes (Lamprecht et al., 2010). Hypomethylation of promoters is less common, but was 
reported in metastatic PCa cell lines and tissue to affect predominantly a large fraction of genes 
belonging to the family of cancer-testis antigens (Yegnasubramanian et al., 2008).  
 
Hypermethylation is instead rather restricted to promoter regions of genes, especially in CGIs, 
and is associated with tumor suppressor gene (TSG) repression and gain of repressive histone 
marks (Jones et al., 2007). Characterization of genome-wide DNA methylation patterns in 
prostate tissue and cell lines delineated hundreds of differentially methylated CGI-associated 
genes (Kron et al., 2009, Kim et al., 2011, Kobayashi et al., 2011, Borno et al., 2012). These studies 
revealed that various cancer-relevant cellular pathways are deregulated by a gain of DNA 
methylation in PCa, such as cell cycle regulation (e.g, p16 also known as CDKN2A or INK4a), 
hormonal response (e.g, Retinoic Acid Receptor β (RARB)) or DNA repair (e.g, glutathione S-
transferase Pi (GSTP1)). However, the role of DNA methylation in gene repression and PCa 
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progression has recently been challenged. Indeed, Pellacani and colleagues demonstrated that 
among all genes reported to be hypermethylated and repressed in PCa, 5% of them including 
GSTP1 are not repressed as a consequence of DNA methylation gain, but as a result of loss of 
active histone marks during the differentiation process of normal luminal cells (Pellacani et al., 
2014).   
Epigenetic inactivation is not only restricted to single genes but can also encompass multiple 
adjacent CGIs in PCa. Indeed, gain of DNA methylation, repressive histone marks and histone 
deacetylation were associated with the epigenetic silencing of multiple TSGs across domains of 
several Megabases (Coolen et al., 2010).  
 
Intriguingly, CGIs associated with active transcription were more frequently hypermethylated 
than hypomethylated in PCa cells. Clark and colleagues found that gain of DNA methylation 
across CGI or in CGI borders along with gain of active and loss of repressive histone marks is 
associated with long range epigenetic activation. The authors proposed that hypermethylation 
in CGI borders could hinder the binding of transcriptional repressor, while methylation 
throughout the CGI is related to gene activation by H3K4me3 gain of alternate gene promoter 
usage (Bert et al., 2013).  
 
DNA methylation or chromatin modifications are collectively and significantly altered in PCa. 
Nevertheless, the specific mechanism by which epigenetic marks are established and removed at 
specific loci remains unclear. In the past years, accumulating evidence has suggested that non-
coding RNAs might be involved in this process.  
1.3.3 Epigenetic regulation by lncRNAs in prostate cancer 
Recent large scale RNA profiling projects have identified a multitude of novel lncRNAs 
dysregulated in PCa. About 121 lncRNAs dysregulated in PCa termed the PCAT family (Prostate 
Cancer Associated intergenic non-coding RNA Transcripts) were discovered by Prensner and 
colleagues (Prensner et al., 2011). Transcriptional profiling of fourteen tumors derived from 
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Chinese PCa patients identified 406 differentially expressed lncRNAs during prostate 
carcinogenesis (Ren et al., 2012). Independent of RNA-sequencing, Liu and colleagues have 
developed a reannotation pipeline of the Affymetrix microarray probes that map to lncRNAs. 
With this methodology and based on available expression data, they characterized a set of 102 
novel lncRNAs upregulated in PCa (Du et al., 2013).  
Despite the growing number of lncRNAs identified in PCa, only a few have been functionally 
characterized so far. Emerging mechanisms that involve lncRNAs trigger PCa development and 
progression by influencing PTEN/AKT pathway, AR signaling, and transcriptional regulation. 
These roles are predominantly accomplished in a lncRNA-dependent recruitment and guiding of 
chromatin modifiers to specific loci, and can be related to the altered chromatin patterns 
reported in cancer cells leading to oncogene activation and TSG inactivation (Gregory et al., 
2004).  
 
The current knowledge of lncRNAs that are deregulated in PCa and implicated in the targeting of 
chromatin remodeling complexes with an activation and/or repressive transcriptional outcome 
is summarized in Table 1-1.  
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Only two lncRNAs, PCGEM1 (prostate cancer gene expression marker 1) and PRNCR1 (prostate 
cancer non-coding RNA 1), both overexpressed in PCa (Petrovics et al., 2004) (Chung et al., 2011), 
have so far been associated with chromatin-mediated gene activation. They have been shown to 
activate the AR even in the absence of its ligand. RNA immunoprecipitation experiments 
demonstrated the interaction between PRNCR1 and the AR. This binding leads to the recruitment 
of DOT1L (DOT1-like histone H3K79 methyltransferase) methyltransferase, which methylates AR, 
resulting in its subsequent interaction with PCGEM1. In turn, PCGEM1 recruits PYGO2 (Pygopus 
2), which enables the interaction of AR to H3K4me3 chromatin marks in the promoter regions of 
AR-regulated genes and leads to their activation (Yang et al., 2013). However, neither the 
reported PRNCR1 overexpression in PCa, nor the interaction of both lncRNAs with the AR could 
be confirmed or recapitulated by Chinnaiyan and colleagues (Prensner et al., 2014).  
 
CTBP1 (C-terminal binding domain protein 1) is a transcriptional co-repressor of the AR. The 
interaction of its antisense transcript CTBP1-AS (C-terminal binding protein 1 antisense RNA) with 
the transcriptional repressor PSF (PTB-associated splicing factor) and HDAC/Sin3A complex leads 
to the repression of the sense transcript CTBP1. Indirectly, via the repression of CTBP1, CTBP1-
AS leads to AR target gene reactivation and cell cycle promotion. Moreover, CTBP1-AS was 
suggested to directly repress the expression of other genes in trans (Takayama et al., 2013).  
 
Epigenetic silencing through the coupling of lncRNAs with the Polycomb complex was 
demonstrated for three lncRNAs in PCa. The nuclear fraction of the lincRNA PCAT-1 (prostate 
cancer associated transcript-1) interacts with the PRC2 complex and mediates the trans 
repression of BRCA2 (breast cancer 2, early onset) and the centromere-associated proteins E and 
F (CENPE and CENPF) genes. Consequently, PCAT-1 upregulation promotes cell proliferation and 
impairs homologous repair in PCa (Prensner et al., 2011). ANRASSF1 (antisense intronic non-
coding RASSF1A) (Beckedorff et al., 2013) and ANRIL (antisense non-coding RNA in the INK4 
locus) (Kotake et al., 2011) were also shown to mediate transcriptional repression through their 
binding to the Polycomb complex. Elevated expression of ANRASSF1 and ANRIL in PCa was 
associated with increased proliferation and impaired cell death, as a result of the repression of 
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the TSG CDKN2A/B (Kotake et al., 2011) and RASSF1A (Ras association domain family 1, isoform 
A) (Beckedorff et al., 2013), respectively.  
 
Gene expression is regulated by chromatin modifiers in concert with the remodeling of 
nucleosomes along the chromatin. The lincRNA SChLAP1 (second chromosome locus associated 
with prostate 1, also called LINC00913), upregulated in about 25% of aggressive PCa, is involved 
in nucleosome remodeling by interacting with the SWI/SNF subunit SNF5/INI1 (also known as 
SMARCB1). Upregulation of this lincRNA in PCa cells was associated with decreased SNF5 
recruitment to DNA, thus antagonizing the genome-wide localization and regulatory functions of 
the SWI/SNF complex. SChLAP1 silencing in castration-resistant 22Rv1 cells have reduced 
propensity to form secondary lesions in vivo, further supporting its role in cancer progression to 
metastasis (Prensner et al., 2013).  
 
Overall, these data have demonstrated that lncRNAs are involved in the activation and/or 
repression of genes participating in prostate carcinogenesis by binding to diverse epigenetic 
regulators, in particular the Polycomb complex.  
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2. AIM OF THE THESIS 
Dysregulation of promoter methylation is a well-defined phenomenon in PCa, resulting in the 
malfunction of cellular pathways (section 1.3.2). The actors of DNA methylation establishment, 
maintenance, and reversal are well documented (section 1.1.3). Nevertheless, the specific 
mechanism by which DNA methylation modifiers are recruited in a spatial and temporal manner 
remains unclear. Accumulating evidence suggests that lncRNAs are involved in the modulation of 
the DNA methylation status of specific target genes via either scaffolding, sequestration and/or 
targeting of DNA methylation modifiers to specific loci (section 1.2.2). Despite the growing 
number of lncRNAs identified and deregulated in prostate tissue, our knowledge regarding their 
mechanism of action is limited to a handful, and none of them have so far been documented  to 
be implicated in DNA (de)methylation mechanisms (section 1.3.3, Table 1).  
Since alterations in DNA methylation of protein-coding genes are associated with prostate 
carcinogenesis and might be regulated by RNAs transcribed in cis, we aimed to investigate 
lncRNAs as potential mediators of DNA (de)methylation in PCa through:  
 Identification of lncRNAs involved in cis DNA (de)methylation mechanisms in PCa.  
By integrating DNA methylation and RNA sequencing data generated by collaborators from the 
International Cancer Genome Consortium (ICGC) project on EO-PCa patients, we planned to 
identify lncRNAs regulating the transcription of protein-coding gene in cis, through modulation 
of their promoter DNA methylation patterns (simplified as mRNA/lncRNA pairs). 
 Investigation of the clinical relevance of a candidate lncRNA in cancer. 
The dysregulation of a selected mRNA/lncRNA pair will be evaluated in PCa validation cohorts, as 
well as in other tumor entities. The association between the expression of the pair with clinical 
and genetic features will be evaluated to select a pair crucial for carcinogenesis. 
 
 
AIM OF THE THESIS 
 
34 
 
 Characterization of the expression of the lncRNA in vitro 
Detailed investigation of the lncRNA variant being deregulated and the specific chromatin marks 
associated with its expression in various cancer cell lines will be investigated.  
 Investigating if the lncRNA mediates in cis DNA (de)methylation in vitro 
Interdependency between the expression of the lncRNA and the methylation status of the gene 
in cis will be evaluated. This will be achieved by comparing the methylation and expression levels 
of the corresponding transcripts, by Mass Array and RT-qPCR, after modulation of the lncRNA 
expression through knockdown or overexpression. 
 Investigating if the coding potential of the lncRNA 
We tested first in silico and then in vitro whether DLX6-AS1 could exert its function through the 
production a small protein or peptide.  
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3. MATERIAL AND METHODS 
3.1 Patient material and utilized datasets 
All ICGC EO-PCa samples originate from radical prostatectomy of patients diagnosed with PCa 
and obtained from the Martini Clinics at the University Medical Center Hamburg-Eppendorf. 
Genome-wide DNA methylation was analyzed on Illumina HumanMethylation450 beadChip 
arrays (450k) (Illumina). PolyA+ RNA-sequencing was carried out on the Illumina HiSeq2000 
instrument and mapped to the reference human transcriptome Gencode version 21. Both RNA-
seq and 450k data of EO-PCa patients were generated and processed by collaborators of the ICGC 
project on EO-PCa.  
RNA-seq and 450k data generated and processed as part of The Cancer Genome Atlas (TCGA) 
project on late-onset PCa, lung squamous cell carcinoma (LUSC), colon adenocarcinoma (COAD), 
head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD) and kidney renal 
clear cell carcinoma (KIRC) were downloaded from the TCGA Data Matrix (https://tcga-
data.nci.nih.gov/).  
For the genome-wide screening of mRNA/lncRNA pairs (section 4.1), we employed three datasets 
referred to as the “screening set” in Table 3-1. Among them are two different RNA-seq sample 
sets of ICGC EO-PCa patients analyzed at the MPI in Berlin named “EO-PCa Berlin” and at the 
DKFZ in Heidelberg termed “EO-PCa Heidelberg”, as well as one combined dataset of ICGC EO-
PCa and TCGA PCa 450k data (TCGA data release 2013) named as “EO-PCa +TCGA”.  
The datasets designed as “validation set” in Table 3-1 were used to confirm the result of the 
screening strategy (section 4.2.1). At the time of the screening for mRNA/lncRNA pairs, the initial 
ICGC cohort for EO-PCa patients was restricted to 6 normal and 25 PCa tissue samples 
(Berlin+Heidelberg). Major sequencing efforts extended the EO-PCa set to 10 normal and 91 
tumors samples, after exclusion of samples failing to pass RNA-seq quality metrics based on 
strand specificity, ribosomal RNA contamination, sequence duplicates, 5’ and 3’ coverage bias of 
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transcripts, gene body coverage, and transcript integrity number. The corresponding 450k 
profiles from patients with both transcriptome and DNA methylation profiles were used in this 
validation set.  
An independent cohort of late-onset PCa patients available from the TCGA database (TCGA data 
release 2015) was used to validate the result from the ICGC cohort. In the PCa TCGA dataset, we 
restricted our analysis to patient-matched tumor/normal samples. Corresponding 450k data 
from patients with both RNA-seq and 450k data were used for this validation. The clinical 
characteristics of each cohort within both the screening and the validation datasets are 
summarized in Table 3-1. 
Table 3-1 Clinical characterization of PCa sample sets  
  SCREENING SET VALIDATION SET 
Type of data  RNA-seq 450k RNA-seq 450k RNA-seq 450k 
Cohort  
EO-PCa 
Berlin 
EO-PCa 
Heidelberg 
EO-PCa + 
TCGA 
EO-PCa EO-PCa 
TCGA 
matched 
TCGA 
matched 
Number of 
Normal/ 
Tumor 
 2/12 4/13 60/342 10/91 8/89 52/52 34/34 
Age 
Median 48 47 60 48 48 61 62 
Range 38-51 40-50 32-72 32-52 32-52 43-72 44-72 
Gleason score 
(n) 
N/A 0 0 5 4 3 0 0 
6 0 1 49 12 12 5 2 
7 11 12 238 63 62 40 27 
8 0 0 8 1 1 3 2 
9 1 0 42 11 11 4 3 
Pathological  
T stage (n) 
N/A 0 0 8 3 3 0 0 
T2 7 10 214 60 58 29 19 
T3 5 3 103 24 24 21 13 
T4 0 0 17 4 4 2 2 
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To characterize DLX6/DLX6-AS1 expression across multiple cancers (section 4.2.2), we used TCGA 
data on LUSC, COAD HNSC, LUAD and KIRC (TCGA data release 2015). Corresponding 450k data 
from patients with both RNA-seq and 450k data were employed. The clinical characteristics of 
each cohort are summarized in Table 3-2. 
Table 3-2 Clinical characterization of additional TCGA cancer datasets 
  RNA-seq 450k 
Dataset  LUSC COAD HNSC LUAD KIRC LUSC COAD HNSC LUAD KIRC 
Number of 
Normal/ 
Tumor 
 
50/ 
503 
41/ 
286 
43/ 
519 
58/ 
511 
72/ 
533 
8/ 
359 
19/ 
246 
20/ 
448 
21/ 
416 
24/ 
291 
Age 
Median 68 67 61 66 61 69 66 61 67 61 
Range 39-90 31-90 19-90 38-88 26-90 40-90 31-90 19-90 40-88 26-90 
Pathological 
T stage (n) 
T1 113 6 33 169 272 85 6 29 139 136 
T2 287 43 149 273 69 196 35 135 224 38 
T3 69 193 131 47 180 57 174 117 36 109 
T4 22 39 179 19 11 11 30 146 15 8 
Tx 0 0 27 2 0 0 0 21 2 0 
Tis 0 1 0 0 0 0 1 0 0 0 
N/A 12 4 0 1 1 10 0 0 0 0 
Abbreviations: Tx=primary tumor cannot be evaluated, Tis=carcinoma in situ, N/A=non-available 
To characterize the impact of DLX6/DLX6-AS1 overexpression on overall and disease-free survival 
time (section 4.2.3B), we used the TCGA cohorts on PRAD, LUSC, COAD HNSC, LUAD and KIRC 
described as the “RNA-seq” datasets in Table 3-2. Each cohort was separated into “LOW” and 
“HIGH” subgroup based on the median expression value of DLX6-AS1 lncRNA (median value for 
PRAD=2.99, LUSC=4.79, COAD=1.18, HNSC=3.21, LUAD=0.609, KIRC=1.77). The numbers of 
events for both subgroups in each dataset are summarized in Table 3-3.  
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Table 3-3 Clinical characterization of “LOW” and “HIGH” expression subgroups in the TCGA 
cancer datasets 
  PRAD LUSC COAD HNSC LUAD KIRC 
Subgroup 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
Number of 
Tumor (n) 
250 248 251 250 142 143 260 259 256 255 266 267 
O
ve
ra
ll 
su
rv
iv
a
l (
n
) Living 244 243 135 149 104 109 146 151 165 161 167 190 
Deceased 5 5 116 100 38 31 113 108 91 93 99 76 
N/A 1 0 0 1 0 3 1 0 0 1 0 1 
D
is
e
a
se
 F
re
e
 
Su
rv
iv
a
l (
n
) Disease 
Free 
198 201 119 126 87 89 124 123 127 123 146 162 
Recurred 48 44 66 64 37 34 58 66 92 90 68 58 
N/A 4 3 66 60 18 20 78 70 37 42 52 47 
Abbreviation: N/A=non-available 
 
Table 3-4 Clinical characterization of “LOW” and “HIGH” expression subgroups in LUAD 
 
LUAD 
DLX6 probe ID 242940_x_at 239309_at 221289_at 
Subgroup 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
LO
W
 
H
IG
H
 
Number of 
Tumor (n) 
338 335 339 334 387 333 
O
ve
ra
ll 
su
rv
iv
a
l Living 217 189 219 187 260 173 
Deceased 121 146 120 147 127 160 
 
In addition, an independent and larger cohort of LUAD cases was retrieved from the Kaplan Maier 
online survival analysis software (Gyorffy et al., 2013). Similarly to TCGA datasets, this cohort was 
divided into “LOW” and “HIGH” groups based on the mean expression value of DLX6 measured 
by expression arrays with the three following probes 242940_x_at, 239309_at and 221289_at. 
The numbers of events for every probe in both subgroups are summarized in Table 3-4. 
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3.2 Human cell lines and cell culture 
Table 3-5 Cell culture material  
 
The benign immortalized prostate cell lines BPH1 and PNT2 as well as the cancerous cells 
originating from prostate ( LNCaP, PC3, DU145, VCaP and 22RV1), colon (HCT116 and HCT116 
DKO), lung (A549 and H1299) and embryonal kidney (HEK293T) tissue were cultured in their 
respective medium supplemented with 10% FBS (Table 3-6). All cells were grown under S1 
biosafety level with the exception of VCaP cells cultured under S2 biosafety level. The cell lines 
were grown in humidified atmosphere with 5% CO2 at 37°C. Cell lines were passaged every three 
to four days by dissociating D-PBS-washed cells with trypsin-EDTA and reseeding the cells at a 
dilution ranging from 1:3 for the slow growing cells VCaP and LNCaP and 1:10 for the remaining 
cell lines. All cell lines were regularly confirmed to be free of mycoplasma contamination by using 
the Venor®GEM Classic kit.  
 
 
 
 
 
Material Manufacturer 
Trypsin EDTA (1x) phenol red free GE Healthcare 
DMEM, RPMI-1640 and F12-K Nutrient Mix medium with phenol red  Gibco, Invitrogen, Life Technologies 
RPMI-1640 Medium without phenol red and NaHCO3 -powder Sigma-Aldrich 
Dulbecco’s Phosphate-Buffered Saline (D-PBS) Gibco, Invitrogen, Life Technologies 
Fetal Bovine Serum (FBS) Biochrom, Millipore 
Androstan-17β-ol-3-one (testosterone) Sigma-Aldrich 
Hydrocortisone (≥98% purity) Sigma-Aldrich 
Insuline solution, human Sigma-Aldrich 
Transferrin (≥98% purity) Sigma-Aldrich 
D-(+)-Glucose (≥99.5%  purity) Sigma-Aldrich 
NaHCO3 ACS reagent (≥99.7% purity) Sigma-Aldrich 
HEPES (≥99.5% purity) Sigma-Aldrich 
Sodium Pyruvate, 100 mM Gibco, Invitrogen, Life Technologies 
Venor®GeM Classic   Minerva Biolabs GmbH 
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Table 3-6 Human cell lines and culture conditions 
3.3 Knockdown experiments 
3.3.1 Cloning of shRNAs into shRNA expression vector 
Table 3-7 Material used for cloning 
 
Tissue Material Medium Origin 
PROSTATE 
BPH1 RPMI-1640 
25 µg/ml testosterone, 0.5 mg/ml 
hydrocortisone, 100 µg/ml 
insulin, 25 mg/ml transferrin 
(Hayward et al.,1995) 
PNT2 RPMI-1640 
 
Prof. Dr. W. Schulz, 
Düsseldorf, Germany 
LNCaP RPMI-1640 medium without 
phenol red and NaHCO3 
4.5 g/L D-glucose, 1.5 g/L 
NaHCO3, 2.283 g/L HEPES,  
0.11 g/L sodium pyruvate 
pH 7.2 
ATCC  clone FGC  CRL-
1740 
PC3 RPMI-1640 ATCC CRL-1435 
DU145 RPMI-1640 ATCC HTB-81 
VCaP DMEM  ATCC CRL-2876 
22RV1 45% DMEM +45% RPMI-1640 DSMZ ACC438 
COLON 
HCT116 DMEM Dr. B. Vogelstein, 
Baltimore, USA 
HCT116 DNMT1-/-, DNMT3B-/- 
(HCT116 DKO) 
DMEM Dr. B. Vogelstein, 
Baltimore, USA 
LUNG 
A549 F12-K Nutrient mix ATCC CCL-185 
H1299 RPMI-1640 Prof. Dr. Sültmann, 
DKFZ Heidelberg 
KIDNEY HEK293T DMEM Prof. Dr. Boutros, DKFZ, 
Heidelberg 
Material Manufacturer 
shRNA template oligonucleotides, desalted Sigma-Aldrich 
pRSI9-U6-(sh)-HTS3-UbiC-TagRFP-2A-Puro Cellecta, Inc 
BbsI (10 u/µl) New England Biolabs Inc.  
Shrimp alkaline phosphatase (1 u/µl) (rSAP)  New England Biolabs Inc. 
T4 Polynucleotide Kinase (PNK, 10 u/µl) New England Biolabs Inc. 
T4 DNA ligase (40 u/µl) New England Biolabs Inc. 
One Shot TOP10 chemically competent E. coli Thermo Fisher Scientific 
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shRNA sequences used for cloning and targeting either human DLX6 (targeting DLX6 3’UTR or 
second exon), DLX6-AS1 (targeting the common last exon of both DLX6-AS1 T1 and T2 variants) 
or luciferase transcripts as control have been designed according to the DECIPHER Human 
Module 1-3 database and are listed in the Appendix (Table 7-1).  
To clone shRNA template into the lentiviral expression vector pRSI9-U6-(sh)-HTS3-UbiC-TagRFP-
2A-Puro plasmid, 2 µg of this plasmid was digested with 10 units BbsI enzyme and 
dephosphorylated with 1 µl rSAP overnight at 37°C in a final volume of 50 µl. Digestion product 
was loaded on an agarose gel, before gel extraction and purification of the digested plasmid. 2.5 
µl of corresponding single stranded forward and reverse shRNA oligonucleotides (10 µM each) 
were simultaneously annealed and phosphorylated by adding 0.2 µl PNK and 1 µl of T4 ligase 
buffer to a final volume of 10 µl and incubated under following conditions: phosphorylation for 
1 h at 37°C, inactivation of the enzyme for 20 minutes (min) at 65°C and annealing by gradual 
cooling (-0.1°C/sec) from 95°C to 4°C. Annealed oligonucleotides (diluted 1:10) were ligated with 
about 25 ng of the digested plasmid by using 0.4 µl of T4 DNA ligase in a final volume of 10 µl. 
The ligation reaction was incubated overnight at 16°C, followed by 10 min enzyme inactivation 
at 65°C. One Shot TOP10 E.coli (10 µl) were transformed with 1 µl of the ligation reaction by 
chemical transformation according to the manufacturer’s instructions. Positive clones were 
identified by Sanger sequencing (GATC) using the “pRS” primer indicated in the Appendix (Table 
7-7).  
3.3.2 Lentivirus production and target cells transduction 
Table 3-8 Material for Lentivirus production and target cells transduction  
 
Material Manufacturer 
psPAX2 vector Addgene 
pMD2.G vector Addgene 
pRSI9-u6-sh-UbiC-TagRFP-2A-Puro plasmid Cellecta 
TransIT-LT1 Mirus Bio LLC 
Puromycin Sigma-Aldrich 
RPMI-1640 medium with phenol red Gibco, Invitrogen, Life Technologies 
Puradisc FP30 Cellulose Acetate Syringe filter, 0.2µm, sterile GE Healthcare Life Sciences 
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HEK293T were seeded in 6 well plates at a concentration of 5.25x105 cells per well in 1.5 ml 
medium 24 h prior to transfection. To produce lentiviral particles, HEK293T cells were co-
transfected with 1 µg pRSI9-U6-(sh)-HTS3-UbiC-TagRFP-2A-Puro shRNA vector along with 667 ng 
and 333 ng of the lentiviral packaging vectors psPAX2 and pMD2.G, respectively, using 7.5 µl 
TransIT-LT1 transfection reagent according to manufacturer’s recommendation. 24 h after 
transfection 1 ml of medium was added to the cells. After one additional day, lentiviral particles 
present in the cell medium were collected and filtered through Puradisc filters to remove any 
contaminating cells. Supernatant containing lentivirus was either directly used for transduction 
or aliquoted before storage at -80°C.  
VCaP cells were seeded in 6 well plates at a concentration of 5.25x105 cells per well in 1.5 ml 
medium 24 h prior to lentiviral transduction. Virus titer was tested by qPCR after treating the 
cells with volumes ranging from 60 to 250 µl of supernatant containing virus particles. 24 h after 
transduction, virus containing media was exchanged. Stable clones were selected with puromycin 
48 h after transduction. VCaP cells were harvested 8 days after the start of transduction.  
3.3.3 siRNA and LNA (locked nucleic acids) transfection 
Table 3-9 Material for siRNA or LNA transfection 
 
siRNA or LNA directed against DLX6, DLX6-AS1 or non-targeting control listed in the appendix 
(Table 7-2) were supplied by GE Dharmacon as single or pool of 4. HEK293T cells were seeded in 
6 well plates at a concentration of 5.1x105 cells per well in 1.5 ml  medium 24 h prior to 
transfection. LNA or siRNA at a final concentration of 25 nM were transfected with 10 µl TransIT-
TKO according to the manufacturer’s instructions. 72 h after transfection, cells were harvested 
and stored at -80°C until nucleic acids extraction.  
Material Manufacturer 
TransIT-TKO transfection reagent Mirus Bio LLC 
RPMI-1640 medium  Gibco, Invitrogen, Life Technologies 
Locked nucleic acids (LNA) Exiqon 
ON-TARGETplus siRNA  GE Dharmacon  
Lincode siRNA GE Dharmacon 
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3.4 RNA expression analysis 
3.4.1 RNA fractionation 
Table 3-10 Material for RNA fractionation 
 
Partition of cellular RNA into cytoplasmic and nuclear fractions was performed with VCaP, DU145 
and HEK293T cells, based on Gagnon and colleagues protocol (Gagnon et al.,2014). For each cell 
line, two cell pellets of equal cell number (minimum 2.5x106 cells) were collected and washed 
once with D-PBS. One of the cell pellets was prepared for RNA extraction by direct addition of 
600 µl RLT lysis buffer supplement with 0.6 µl β-mercaptoethanol and represents the whole cell 
RNA content of the cell, whereas the second pellet was subjected to cellular fractionation. The 
second cell pellet was resuspended by gentle pipetting in 380 µl of ice-cold HLB hypotonic buffer 
(10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.3% NP-40 and 10% glycerol) supplemented with 
100 units of RNasin and incubated on ice for 10 min. After centrifugation at 1,000 g for 3 min at 
4°C, the first supernatant and the first HLB-wash were retained as the cytoplasmic fraction. The 
cytoplasmic fraction was immediately resuspended with 1 ml ice-cold RNA precipitation solution 
(0.5 ml 3 M NaAc (pH 5.5) and 9.5 ml 100% ethanol) and stored at -20°C for a minimum of 1 h. 
The nuclear pellet was subjected to two additional washes in ice-cold HLB buffer and was then 
centrifuged at 200 xg for 3 min at 4°C. To assess the integrity and purity of nuclei preparation by 
microscopic inspection, 10 µl of the nuclei suspension was mixed with the same amount of 
Trypan blue. After the last centrifugation step and removing remaining HLB buffer, nuclei were 
resuspended in 600 µl RLT buffer supplemented with 0.6 µl β-mercaptoethanol and stored at -
20°C. RNA from the previously collected cytoplasmic fraction was pelleted by centrifugation at 
full speed for 20 min and subsequently washed with ice-cold 70% ethanol, before air-drying the 
Material Manufacturer 
Dulbecco’s Phosphate-Buffered Saline (D-PBS) Gibco, Invitrogen, Life Technologies 
RNasin ribonuclease inhibitors (40 u/µl) Promega Corporation 
Trypan Blue solution 0,4% Thermo Fisher Scientific 
2-Mercaptoethanol (≥99.0% purity) Sigma-Aldrich 
RLT buffer (RNeasy Mini kit) Qiagen 
Ethanol absolute (≥99.8% purity) Sigma-Aldrich 
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pellet. The cytoplasmic pellet was then resuspended in 600 µl RLT buffer supplemented with 0.6 
µl beta-mercaptoethanol and stored at -20°C until RNA extraction.  
Whole cell, nuclear and cytoplasmic fraction in RLT buffer were thawed at room temperature 
before incubation at 37°C for 10 min. RNA was extracted from all fractions using the RNeasy kit 
with the procedure detailed in the next section. The relative enrichment of RNA species in the 
nuclear and cytoplasmic fraction measured by RT-qPCR was normalized to the whole cell RNA 
content of the cell by using the following formula 2ˆ(CT whole cell RNA)-(CT fraction).  
3.4.2 RNA isolation and quantification of RNA by Reverse 
Transcription-quantitative PCR (RT-qPCR) 
Table 3-11 Material for RNA isolation and RT-qPCR 
 
Total RNA was extracted either by using the RNeasy Mini kit or the All Prep RNA/DNA extraction 
kit according to manual instructions. Residual genomic DNA was digested on-column with DNase 
for 15 min. After RNA quantification by Nanodrop ND-1000, RNA was reverse transcribed. First, 
2 µg total RNA was incubated at 65°C for 5 min with 200 ng random primers in a final volume of 
46 µl. Then, first-strand synthesis was carried out by adding 16µl 5x first-strand buffer, 8 µl DTT, 
4 µl dNTPs, 1 µl SuperScript II reverse transcriptase and 1 µl RNasin to a final volume of 80 µl 
under the following cycling conditions: 3 min at 25°C, 50 min at 42°C followed by a linear 
amplification at 70°C for 15 min.  
 
Relative expression levels were determined by quantitative real time PCR, carried out with 2.5 µl 
diluted cDNA (dilution 1:2.5) along with 3.5 µl probes master, 1 µl gene specific primer mix (10 
Material Manufacturer 
RNeasy Mini kit or All Prep DNA/RNA Mini kit Qiagen  
RNasin ribonuclease inhibitors(40 u/µl) Promega Corporation 
RNase-free DNase set Qiagen 
Random primers  Thermo Fisher Scientific 
SuperScript II Reverse Transcriptase kit Thermo Fisher Scientific  
Lightcycler®480 Real-Time PCR system  Roche Diagnostics 
Lightcycler®480 Probes Master  Roche Diagnostics 
Universal probe Library Roche Diagnostics 
Nanodrop ND-1000 Thermo Scientific 
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µM) and 0.05 µl universal probe to a final volume of 7 µl per well. The reaction was run on the 
Lightcycler 480 system under following conditions: 10 min initial denaturation at 95°C, 45 cycles 
of 10 sec at 95°C, 20 sec at 55°C and 10 sec at 72°C. All qPCRs were run in duplicates, HPRT1 
(hypocanthine-guanine phosphoribosyltransferase), ALAS1 (5'-aminolevulinate synthase 1) 
(ALAS1) and SDHA (succinate dehydrogenase complex flavoprotein subunit A) housekeeping 
genes were used for normalization using the ΔΔCT-method (Livak et al.,2001). All gene-specific 
primers listed in the appendix (Table 7-3) were designed with the Roche Universal Probe Library 
Assay Design Center, synthesized and desalted by Sigma-Aldrich. 
3.5 Rapid amplification of 5’ cDNA ends (5’RACE) 
Table 3-12 5’RACE material  
To determine the transcription start site of DLX6-AS1 transcript in VCaP cells we employed the 
5’RACE assay adapted from Frohman and colleagues (Scotto-Lavino et al., 2006). Three DLX6-AS1 
gene-specific primers (GSP1 to 3) were designed in the know sequence of the second exon of 
DLX6-AS1 and are indicated in the appendix (Table 7-4). The region between GSP3 and the 5’ end 
of DLX6-AS1 second exon was selected by Blast in order to be able to discriminate the sequence 
of this lncRNA from other transcripts (Altschul et al., 1990). In addition, three primers QT, Q0 and 
Q1 recognizing the poly-A tail added to the 3’ end of the cDNA as described below, serve as 
binding site upstream of the unknown 5’ sequence of DLX6-AS1 and are indicated in the appendix 
(Table 7-4). 
Material Manufacturer 
dNTPs (mix of 10 mM each) Fermentas 
ThermoScript™ Reverse Transcriptase Thermo Fisher Scientific 
RNasin ribonuclease inhibitors (40 u/µl) Promega Corporation 
RNase H (5 u/µl) Thermo Fisher Scientific 
Agencourt® RNAClean® XP Beckman Coulter 
Terminal Deoxynucleotidyl Transferase kit Thermo Fisher Scientific 
dATPs, 100 mM Thermo Fisher Scientific 
Expand High Fidelity PCR system enzyme Roche Diagnostics 
TOPO-TA cloning kit Thermo Fisher Scientific 
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After denaturation for 3 min at 80°C of 5 µg of DNA-free RNA, 10 pmol of GSP1 was annealed for 
5 minutes at 65°C with 1 µg of denatured RNA and 1.7 mM dNTPs mix in a final volume of  12 µl. 
cDNA specific for DLX6-AS1 5’end was then reverse transcribed using Thermoscript™ Reverse 
Transcriptase supplemented with 40 units of RNasin. To obtain complete DLX6-AS1 5’ cDNA ends 
the reverse transcription mix was incubated for 1 hour at 65°C, followed by 10 min at 70°C. After 
heat-inactivation of the reverse transcriptase for 5 min at 85°C, the template RNA engaged in 
cDNA-RNA hybrids was digested by adding 2 units of RNase H and incubated for 20 min at 37°C 
with subsequent inactivation of the enzyme for 20 min at 65°C. In order to avoid the presence of 
excess of GSP1 primers and non-incorporated dNTPs, cDNA was purified using 40 µl Agencourt 
RNA clean XP magnetic beads following manufacturer instructions. To tail the 3’end of the newly 
synthesized cDNA a poly-A adapter was added via the addition of dATPs (130 pmol) with 30 units 
of the terminal deoxynucleotidyl transferase to 1 pmol of ssDNA and incubated at 37°C for 15 
min, followed by heat-inactivation at 70°C for 10 min and dilution by addition of 20 µl H2O. The 
poly(A) tail provides a binding site upstream of the unknown 5’ sequence of the target mRNA for 
the QT primer during the first round of amplification. The first round of PCR amplification was 
carried out with the Expand High fidelity PCR system supplemented with 1.5 µl of the diluted 
5’end tailed cDNA, 25 pmol of GSP2 and Q0 primers and 2 pmol of QT primer under the following 
cycling conditions: 2 min denaturation at 95°C, 2 min annealing of QT primer at 48°C followed by 
a linear amplification at 68°C for 40 min. This step was directly followed by an exponential 
amplification carried out first for 10 cycles under following conditions: 15 sec denaturation at 
95°C, 30 sec annealing of Q0 primer at 60°C (-0.5°C per cycle) and extension for 2 min at 68°C 
followed by 30 cycles at an annealing temperature of 55°C pursued with a 10 min final extension 
at 72°C.  
A second round of PCR was used to increase the specificity of the amplification for our target 
through the use of GSP3 and Q1 primers. Expand High fidelity PCR system supplemented with 1.5 
µl of 1:20 diluted PCR product, 10 pmol of GSP3 and Q1 primers were used under identical cycling 
conditions as for the previous exponential amplification. The PCR was loaded on a 1.5% agarose 
gel before gel purification of the appropriate PCR product, cloned into the pCR2.1 TOPO-TA 
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vector and identified by Sanger sequencing (GATC Biotech) with a primer binding to the M13 
promoter (Appendix Table 7-7“M13”) included in this vector.  
3.6 Quantitative DNA methylation analysis  
Table 3-13 Material for DNA methylation analysis   
 
DNA was extracted using the All Prep RNA/DNA extraction kit following manual instructions. To 
distinguish methylated from unmethylated cytosine by converting unmethylated cytosine into 
uracil, 1 µg of DNA was bisulfite-converted using the EZ DNA methylation kit and eluted twice in 
30 µl M-Elution buffer.  
 
DLX6 promoter regions were PCR amplified by adding to 1µl of bisulfite converted DNA, 0.056 µl 
HotStar Taq DNA polymerase, 0.14 µl dNTPs (10 mM) and 0.14 µl of 10 µM primers specific for 
bisulfite converted DNA to a final volume of 7 µl. Reactions were hot-started at 95°C for 5 min 
and followed for 45 cycles of 94°C for 30 sec, 56°C for 30 sec, 72°C for 1 min with a final 5 min 
extension step at 72°C. PCR amplification specificity and efficiency was verified by gel 
electrophoresis with 1.5 µl of the PCR product. Unincorporated dNTPs were dephosphorylated 
from the PCR reaction by adding 0.3 µl SAP diluted with 1.7 µl H2O and incubated for 20 min at 
37°C, followed by enzyme inactivation at 85°C for 5 min. 2 µl of dephosphorylated PCR product 
was simultaneously in vitro transcribed and base-specifically cleaved by RNAseA for 3h at 37°C 
Material Manufacturer 
QIAmp DNA Mini kit or All Prep DNA/RNA Mini kit  Qiagen 
EZ DNA methylation kit  Zymo Research 
HotStarTaq DNA Polymerase kit  Qiagen 
dNTPs (mix of 10 mM each) Fermentas 
RNaseA Sequenom 
Shrimp alkaline phosphatase (Goldstein et al.) Sequenom 
“T” cleavage MassCLEAVE reagent kit Sequenom 
RNaseA Sequenom 
MassARRAY Nanodispenser Sequenom 
Sequenom MassARRAY MALDI-TOF Mass Spectrometer Sequenom 
Sequenom EpiTYPER software 1.2 Sequenom 
Mastercycler 384 Sequenom 
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by adding to a final volume of 5 µl 0.22 µl “T” cleavage MassCLEAVE reagent, 0.22 µl DTT, 0.4 µl 
T7 RNA polymerase and 0.06 µl RNaseA. After in vitro transcription, uracil residues are converted 
into adenine, whereas cytosines are transformed into guanine. Cleavage reactions were desalted 
for 30 min on a rotator after the addition of 20 µl water and 6 mg resin. The unique RNA 
fragments created by digestion were further analyzed by matrix-assisted laser desorption 
ionization time of flight mass spectrometry (MALDI-TOF). DNA methylation levels were quantified 
based on the mass spectra peak shift of 16 Da between adenine (former unmethylated) and 
guanine (former methylated) using the Epityper software.  
Bisulfite specific primers were designed manually and appended with a 10 nt mass tag on the 
5’end of the forward primer (5’- aggaagagag-3’) and with a T7 RNA polymerase promoter on the 
5’ end of the reverse primer (‘5-cagtaatacgactcactatagggagaaggct-3’), and are indicated in the 
appendix (Table 7-5).  
3.7 RNA synthesis and transfection 
3.7.1 PCR amplification and cloning of DLX6-AS1 cDNA 
Table 3-14 Material for PCR amplification and cloning of DLX6-AS1 cDNA    
 
High quality cDNA was generated from 4 µg VCaP RNA with 1 µl oligodT (50 µM), 2 µl dNTPs (10 
mM) in a final volume of 12 µl and annealed for 5 minutes at 65°C. Reverse transcription was 
Material Manufacturer 
ThermoScriptTM Reverse Transcriptase Invitrogen  
RNasin ribonuclease inhibitors (40 u/µl) Promega Corporation 
dNTPs (mix of 10 mM each) Fermentas 
oligodT  Thermo Fisher Scientific 
Rnase H (5 u/µl)  Thermo Fisher Scientific 
Expand Long Template PCR system  Roche Diagnostics 
MluI (10 u/µl) New England Biolabs Inc. 
HindIII-HF (20u/µl) New England Biolabs Inc. 
QIAquick PCR purification kit  Qiagen 
T4 Polynucleotide Kinase (10 u/µl) New England Biolabs Inc. 
T4 DNA ligase (40 u/µl) New England Biolabs Inc. 
One Shot TOP10 chemically competent E. coli Thermo Fisher Scientific 
MEGAscript® T7 Transcription kit  Ambion, Life technologies  
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performed after addition of 1 µl ThermoScriptTM reverse transcriptase supplemented with 40 
units RNasin to a final volume of 20 µl. This reaction was incubated for 1 h at 65°C. After heat-
inactivation of the reverse transcription reaction for 5 minutes at 85°C, template RNA engaged 
in cDNA-RNA hybrids were digested for 20 minutes at 37°C by adding 2 units of RNaseH with 
subsequent inactivation of the enzyme for 20 minutes at 65°C.  
 
DLX6-AS1 was PCR amplified from VCaP cells cDNA using a forward primer harboring the T7 RNA 
polymerase promoter and MluI restriction site, while the reverse primer harbored a HindIII 
restriction site (Appendix Table 7-6). DLX6-AS1 was PCR amplified from high quality cDNA using 
0.75 µl Expand Long Template enzyme mix along with 5 µl PCR buffer 1.350 µM dNTPs, 300 µM 
forward and reverse primers and 100 ng cDNA in a final volume of 50 µl. The reaction was 
incubated under following conditions: initial denaturation at 94°C for 2 min, 10 cycles at 94°C for 
10 sec, annealing for 30 sec at 65°C (-0.1°C per cycle), extension at 68°C for 4 min, followed by 
30 cycles under same conditions but at a stable annealing temperature of 60°C and increased 
extension time of 20 sec per cycle with a final extension step at 68°C for 15 min.  
 
After gel extraction and purification of the appropriate PCR products, they were overnight 
digested at 37°C with 20 units MluI and HindIII-HF enzymes in 50 µl. Subsequent to heat-
inactivation of the enzymes at 80°C for 20 min, digested PCR products were purified with the 
QIAquick PCR purification kit and eluted in 30 µl water. Similarly, 3 µg of pcDNA3.1(-) was 
overnight digested at 37°C with 20 units of MluI and HindIII-HF enzymes in a final volume of    50 
µl, before enzyme inactivation at 80°C for 20 min. After gel extraction of the digested plasmid, 
25 ng digested plasmid was ligated with 25 ng digested cDNA with 0.5 µl T4 DNA ligase in 25 µl 
and incubated overnight at 16°C. One Shot TOP10 E.Coli (15 µl) were then transformed by 
chemical transformation with 2 µl of the ligation product. Positive clones harbouring the 
pcDNA3.1(-)ΔMluI-HindIII_DLX6-AS1 plasmid were identified by Sanger sequencing (GATC) 
employing a primer binding to the T7 promoter (Table 7-7 “T7”). 
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3.7.2 In vitro transcription 
Table 3-15 Material for in vitro transcription  
 
5 µg of pcDNA3.1(-)ΔMluI-HindIII_DLX6-AS1 or pT-Rex-DEST30-LACZ plasmid was prepared for in 
vitro transcription by linearization of the plasmids in a final volume of 50 µl with 20 units of 
HindIII-HF or AgeI-HF enzyme, respectively. 1 µg of linearized and phenol/chloroform purified 
plasmid was in vitro transcribed using the MEGAscript kit with T7 RNA polymerase incubated for 
4 h at 37°C. After the DNA template got digested with 1 µl DNase for 15 min at 37°C, 4 µl of RNA 
supplemented with 6 µl RNA loading buffer (250 µl 100% formamide, 83 µl 37% formaldehyde, 
50 µl 10x MOPS, 50 µl 100% glycerol, 5 µl 1mg/ml ethidium bromide, 20 µl 1.25% bromophenol 
blue and 45 µl H2O) was loaded on a denaturing agarose/formaldehyde gel (1.8 g agarose, 142 
ml 1x MOPS buffer and 8.1 ml 37% formaldehyde) along with 4 µl of low range ssRNA ladder. 
RNA was extracted from agarose gel through centrifugation of the agarose piece through 
Whatman filter paper. To the flow-through were added 0.5 volumes LiCl (7.5 M), 2.5 volumes 
100% ethanol and 20 µg glycogen for overnight RNA precipation at -20°C. The next day, RNA was 
collected by full speed centrifugation for 30 min at 4°C, followed by a wash with 1 ml ice-cold 
70% ethanol and air-dried at room temperature. RNA pellet was then resuspended in 20 µl water 
and quantified by Qubit using the Qubit RNA HS Assay kit.  
 
 
 
Material Manufacturer 
HindIII-HF (20 u/µl) New England Biolabs Inc. 
AgeI-HF (20 u/µl) New England Biolabs Inc. 
MEGAscript® T7 Transcription kit  Ambion, Life technologies  
Formamide (≥99.5% purity) Sigma-Aldrich 
Formaldehyde solution 37% Sigma-Aldrich 
10x MOPS buffer Maxim Biotech, Inc 
Low range ssRNA ladder New England Biolabs Inc. 
Glycogen from oyster Sigma-Aldrich 
Qubit RNA HS Assay kit  Thermo Fisher Scientific 
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3.7.3 RNA transfection 
Table 3-16 Material for RNA transfection 
 
A549 and PC3 cells were seeded 24h prior to transfection in 6 well plates at a concentration of 
1.5x105 and 2x105 cells per well, respectively, in a final volume of 1.5 ml. 400 fmol of T1, T2S, T2L 
DLX6-AS1 RNA or LACZ control RNA supplemented with EGFP mRNA to a final concentration of 1 
µg were transfected with 5 µl TransIT-mRNA and 9.9 µl mRNA Boost reagent according to 
manufacturer’s instructions. 48 h after transfection, cells were harvested and stored at -80°C 
until nucleic acids extraction.  
3.8 In vitro translation  
Table 3-17 Material used for the in vitro translation 
 
pcDNA3.1(-)ΔMluI-HindIII_DLX6-AS1 plasmid with DLX6-AS1 T1, T2 or T3 transcript variants 
generated by cloning as described in section 3.7.1 were used as template for the amplification of 
the different transcript variants with a forward primer harboring the T7 RNA polymerase 
Material Manufacturer 
TransIT-mRNA transfection kit Mirus Bio LLC 
RPMI-1640 medium  Gibco, Invitrogen, Life Technologies 
EGFP mRNA Trilink Biotechnologies  
Material Manufacturer 
Phusion® High-Fidelity PCR kit  New England Biolabs 
dNTPs (mix of 10 mM each) Fermentas 
QIAquick PCR purification kit  Qiagen 
RNasin ribonuclease inhibitors (40 u/µl) Promega Corporation 
TnT®T7 coupled reticulocyte lysate systems Promega 
16.5% Mini-Protean® Tris-Tricine Gel, 10 well, 50 µl  Biorad  
Amino acid mixture, minus leucine 1mM Promega 
L-[14C(U)]-Leucine, Specific Activity: >300 mCi (11.1GBq)/mMol, >97%, 250 
µCi (9.25 MBq) 
Perkin Elmer 
Spectra Multicolor Low range protein ladder  Thermo Fisher Scientific 
Tricine ≥99% Sigma-Aldrich 
BioMax® MS film Kodak 
BioMax TranScreen LE intensifying screen Kodak 
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promoter. Similarly, CS2_T7_MLN and CS2_T7_MLN (FS) plasmid provided by Dr. Douglas M. 
Anderson served as template to amplify the mouse lncRNA 2310015B20RiK harboring the 
peptide MLN with (FS) or without a frameshift mutation (Anderson et al., 2015). All primers used 
for amplification can be found in the appendix (Table 7-6). 50 pg of plasmid was used to PCR 
amplify the different transcripts with 0.5 µl Phusion® High-Fidelity DNA polymerase, 0.5 µM of 
each primer, 10 µl Phusion HF buffer and 1 µl dNTPs in 50 µl. The reaction was initially 
denaturated at 98°C for 2 min, then amplified for 40 cycles of 10 sec at 98°C, 30 sec at 60°C and 
2 min at 72°C with a final extension step at 72°C for 10 min. PCR reactions were purified with the 
QIAquick PCR purification kit, eluted with 20 µl water supplemented with 40 units RNasin and 
incubated for 30 min at 37°C.  
 
Coupled in vitro transcription/translation assay of 850 fmol purified PCR product was performed 
using 12.5 µl TnT rabbit reticulocyte lysate, 2.5 µl 14C labelled leucine amino acid, 0.5 µl amino 
acid mixture, 1 µl TnT reaction buffer, 0.5 µl RNasin, 0.7 µl TnT T7 RNA polymerase in a final 
volume of 25 µl and incubated for 90 min at 37°C. One tenth of the coupled in vitro 
transcription/translation reaction was denatured for 10 min at 70°C, after addition of 2.5µl SDS 
loading buffer (200 mM Tris-HCl, pH 6.8, 2% SDS, 40% glycerol, 0.04% Coomassie Brilliant Blue G-
250 and 2% β-mercaptoethanol). Proteins and peptides were separated on a 16.5% Tris-Tricine 
gel in 1x Tris-Tricine buffer (10 mM Tris, 10 mM Tricine, 1% SDS at pH 8.3) at a constant voltage 
of 100V along with 10 µl of low range protein ladder. After electrophoresis, the gel was 
immediately immersed in fixative solution (10% glacial acetic acid, 50% methanol and 40% H2O) 
for 30 min, to prevent the diffusion of peptides. The gel was then soaked for 5 min in a solution 
(7% acetic acid, 7% methanol, 1% glycerol) preventing gel cracking, which can occur during the 
drying process under vaccum performed on a gel dryer for 40 min at 70°C. The gel was then 
exposed for two weeks to a Biomax® MS film with a BioMax® TranScreen LE intensifying screen.  
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3.9 Polysome fractionation  
Table 3-18 Material used for polysome fractionation 
 
H1299 cells were treated by Dr. Michael Daskalakis (DKFZ, Heidelberg) for 48 h with dimethyl 
sulfoxide (DMSO). To distinguish coding versus non-coding transcripts by inhibition of translation 
initiation, we treated one part of the cells with harringtonine for 15 min at a final concentration 
of 10 µg/ml, whereas another part remained untreated. Both treated and untreated cell fractions 
were washed in ice-cold D-PBS containing 100 µg/ml cycloheximide to arrest translation 
elongation. After washing the cells, polysomal fractionation was performed by Dr. Johanna Schott 
(ZMBH, University of Heidelberg). In brief, cells were lysed in 200 µl polysome lysis buffer (15 mM 
Tris-HCl pH 7.4, 15 mM MgCl2, 300 mM NaCl, 100 μg/ml cycloheximide , 1% Triton-X-100, 0.1% 
β-mercaptoethanol, 200 u/ml RNAsin, 1 complete Mini Protease Inhibitor Tablet per 10 ml). 
Nuclei were removed by centrifugation at 9,300 xg for 10 min at 4°C, while the cytoplasmic lysate 
was subjected to fractionation on a sucrose density gradient (17.5–50% in 15 mM Tris-HCl pH 
7.4, 15 mM MgCl2, 300 mM NaCl). After ultracentrifugation (2.5 h, 35 000 rpm at 4°C in a SW60Ti 
rotor), gradients were eluted with a Teledyne Isco Foxy Jr. system into 14 fractions of similar 
volume and directly supplemented with 300 µl solution II (10 mM Tris pH 7.5, 350 mM NaCl, 10 
mM EDTA, 1% SDS, 7 M urea), and 300 μl Phenol/Chloroform/Isoamyl alcohol, before storage at 
-20°C. 25 fmol of a rabbit HBB2 (hemoglobin subunit beta 2) in vitro transcript was added to each 
fraction as a spike-in control.  
Material Manufacturer 
Dimethylsulfoxid ≥99.5% purity bioscience-grade (DMSO) Carl-Roth 
Harringtonine from Cephalotaxus harringtonia ≥90% (HPLC) Sigma-Aldrich 
Cycloheximide from microbial, ≥94% (TLC) Sigma-Aldrich 
Phenol non stabilized:chloroform:isoamyl alcohol 25:24:1 AppliChem GmbH 
Complete™,Mini Protease Inhibitor Cocktail  Sigma-Aldrich 
Glycogen from oyster Sigma-Aldrich 
TURBO DNA-free™ kit  Ambion, Life Technologies 
SuperScript® III Reverse Transcriptase  Thermo Fisher Scientific 
Random primers  Thermo Fisher Scientific 
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Before RNA extraction, samples were thawed at 65°C for 10 min and centrifuged for 20 min at 
full speed. The upper aqueous phase was then collected and supplemented with 20 µg glycogen 
and 600 µl isopropanol before overnight RNA precipitation at -20°C. On the next day, RNA was 
collected by full speed centrifugation for 20 min at 4°C, followed by a wash with 1 ml ice-cold 
70% ethanol. RNA pellets were dried at room temperature and resuspended at 65°C for 15 min 
in 20 µl water. Residual genomic DNA was digested with the TURBO™ DNase kit. 4 µl of DNase-
treated RNA was reverse transcribed using the Superscript™ III reverse transcriptase, with 200 
ng random primers, and 200 nM gene specific primers following manufacturer’s instructions. 
qPCR was performed with the same protocol as described previously in section 3.4.2.  
3.10 Software and statistical analysis  
Figures and statistical analysis were generated either with GraphPad Prism 5 software or 
Microsoft Excel 2010. Heatmaps were created with the Multi Experiment Viewer. Multiple 
sequence alignments were generated with Jalview version 2-a (Waterhouse et al., 2009) by using 
JABAWS 2.1 web services (Troshin et al., 2011).  
 
To test the significant difference of patient-matched tumor/normal samples data, the non-
parametric Wilcoxon signed-rank test was used. The non-parametric Mann-Whitney U test was 
applied to compare the statistical significance of data between unpaired normal/tumor samples. 
All experimental data were compared with unpaired two-tailed Student’s t-test. The following 
levels of p-value apply in all figures: ns= non-significant, * = p<0.05; ** = p<0.01; *** = p<0.001 
and **** = p<0.0001.  
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4. RESULTS 
4.1 Genome-wide screens identifies DLX6/DLX6-AS1 pair 
The aim of the first part of the thesis was to identify lncRNAs involved in the regulation of DNA 
methylation patterns, which in turn influence the expression of mRNAs in cis (simplified as 
mRNA/lncRNA pairs). To this end, we integrated RNA-seq and 450k data referred to as the 
“screening set” in Table 3.1 through the strategy explained below and depicted in Figure 4-1.  
 
The first step was to retrieve from GENCODE release v17 the positions of lncRNAs overlapping 
the genomic region of a coding gene. For the analysis we included all genes annotated either as 
lincRNA or antisense RNA based on GENCODE descriptions (n= 10,609 lncRNA genes). The 
overlapping region of a given coding gene was defined as its genomic region expanded by 1 kb 
upstream and downstream of the transcriptional start site (TSS) and transcriptional termination 
site (TTS) of the gene, respectively. An overlap between an mRNA and an lncRNA was considered 
valid when the lncRNA gene overlapped the mRNA region by at least 1 nucleotide. Through this 
approach, we identified 413 mRNA/lncRNA pairs of transcripts (Figure 4-1 A).  
 
To select mRNA/lncRNA pairs associated with prostate carcinogenesis, we used high-throughput 
RNA sequencing data from EO-PCa ICGC patients (screening set, RNA-seq -Table 3-1) to select 
pairs with significant differential expression (p-value ≤ 0.05 and -0.5≤ Log2 fold change ≥0.5) in 
tumor versus normal prostate samples (Figure 4-1 B). RNA sequencing data from the ICGC 
consortium were generated in two different centers, namely Berlin and Heidelberg (EO-PCA 
Berlin and Heidelberg-Table 3-1). To avoid possible batch effects, differentially expressed genes 
were identified independently in the two datasets. Only mRNA/lncRNA pairs significantly 
differentially expressed in both set of samples were selected. 
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Figure 4-1 Integrative analysis strategy for the identification of candidate mRNA/lncRNA pairs  
Schematic overview of the methodological strategy for the identification of mRNA/lncRNA pairs in 
prostate cancer. Abbreviations: TSS= transcriptional start sites, TTS= transcriptional termination site, 
log2FC= log2 transformed expression fold changes.  
 
The selection was further restricted to mRNA/lncRNA pairs expressed with a significant Spearman 
correlation coefficient ranging between -0.6 ≤ r ≥ 0.6, indicating that the lncRNA might regulate 
the expression of the protein-coding gene in cis.  
Additionally, to exclude lncRNAs not sufficiently expressed and thus not detectable in an 
experimental setting, only pairs reaching a minimum differential expression threshold of 100 
reads in the tumor samples were considered as candidates. Overall, with the aforementioned 
criteria we found nine mRNA/lncRNA pairs of transcripts (Table 4-1). 
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Among the five overexpressed lncRNAs, DLX6-AS1 (also named Evf2 in mice or DLX6 antisense 
RNA 1) and FBXL19-AS1 (FBXL19 antisense) have been previously linked to the regulation of DNA 
methylation patterns. DLX6-AS1 has been reported to alter the methylation level of an 
ultraconserved enhancer region leading to DLX6 (distal-less homeobox 6) and DLX5 (distal-less 
homeobox 5) transcriptional activation in mice during brain development (Berghoff et al., 2013). 
In addition, LongTarget algorithm predicted DLX6-AS1 binding in DLX6 promoter region through 
the formation of a triplex structure by Hoogsten base-pairing, suggesting a regulatory role for the 
lncRNA on DLX6 expression (He et al., 2015). In concordance with this finding, DLX6-AS1 silencing 
by siRNA (small interfering RNA) in A549 and H1650 lung adenocarcinoma cell lines was shown 
to decrease DLX6 RNA and protein expression (Li et al., 2015).  
 
RNA immunoprecipitation followed by deep sequencing (RIP-seq) analysis of DNMT1-associated 
transcripts, identified RNA partners matching the FBXL19 (F-Box and leucine-rich repeat protein 
19) /FBXL19-AS1 locus (Di Ruscio et al., 2013). From this report it remains unclear if the coding 
or non-coding RNA was bound to DNMT1, but DNMT1 binding was associated with FBXL19 
transcription and hypomethylation of FBXL19 promoter in HL-60 cells. The authors propose that 
the RNA-DNMT1 complex protects FBXL19 promoter from DNA methylation by a decoy 
mechanism. Thus, FBXL19-AS1 upregulation could potentially lead to hypomethylation of FBXL19 
promoter.  
 
All the identified downregulated mRNAs were linked to polycomb-mediated repression. JAZF1 
(JAZF Zinc Finger 1), MKX (Mohawk Homeobox)(Nuytten et al., 2008) and UBXN10 (UBX Domain 
Protein 10) (Kondo et al., 2008) were shown to be upregulated after knockdown of PRC2 
components, whereas RBPMS (RNA Binding Protein With Multiple Splicing promoter) was 
marked by increased H3K27me3 levels in hepatocellular carcinoma compared to normal liver 
tissue (Acevedo et al., 2008). In line with a regulation of the aforementioned coding genes by the 
PRC2 complex, the transcripts located on the reverse strand of JAZF1, RBPMS and UBXN10 mouse 
homologs were found by RIP-seq to be associated with the PRC2 complex in mouse embryonic 
stem cells (Zhao et al., 2010). This raises the possibility that JAZF1-AS1, CTD-3107M8.4 and RP3-
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34ON1.5 mouse lncRNA homologs binding to PRC2 prevents in a decoy mechanism the epigenetic 
repression of the corresponding coding gene in cis.  
 
In line with our result in EO-PCa patients (Table 4-1), the MCF2L (MCF.2 cell line derived 
transforming sequence-like)/MCF2L-AS1 (MCF2 antisense RNA 1) pair was reported to be 
recurrently upregulated among a set of 4055 different tumor types from the TCGA (Kaczkowski 
et al., 2016). The regulation of MCF2L expression is however not documented. In contrast, PCSK6 
(also named PACE4, proprotein convertase subtilisin/kexin type 6) was demonstrated to be 
upregulated in response to several stimuli, such as miR-124 downregulation in PCa (Kang et al., 
2014), DNA demethylation by 5-azacytidine in ovarian cancer (Fu et al., 2003), and by 
upregulation of the transcription factor E2F (Yuasa et al., 2007). Last, THBS4 (Thrombospondin-
4) promoter was shown to be marked by higher methylation levels in colorectal cancer, but could 
not be associated with altered THBS4 expression levels (Greco et al., 2010).  
 
Based on these reports, six of the lncRNA candidates are potential epigenetic regulators (DLX6-
AS1, FBXL-19AS1, JAZF1-AS1, CTD-3107M8.4, RP11-360I20.2 and RP3-340N1.5), whereas MCF2L-
AS1, RP11-299G20.2 and CTD-3107M8.4 have not been previously studied. In order to identify 
lncRNAs regulating mRNA by influencing DNA methylation in cis, we further restricted our 
selection of pairs to protein-coding genes presumably regulated by a differentially methylated 
promoter region.  
 
A combined set of HumanMethylation450k Beadchip data from ICGC and the TCGA consortium 
(screening set, 450k, EO-PCa + TCGA - Table 3-1) was used to identify differentially methylated 
regions (DMRs) in the promoter regions of the aberrantly expressed protein-coding genes (Figure 
4-1 C). Promoter regions covered the genomic region located 2kb upstream and 2kb downstream 
of the gene TSS. These regions were separated in 300 bp non-overlapping windows and defined 
as a DMR when significantly (FDR<0.01, p-value<0.05) enriched for differentially methylated 
CpGs (methylation difference ≥5%) in tumor samples. After addition of these criteria the 
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following mRNA/lncRNA pairs remained; DLX6/DLX6-AS1, MKX/RP11-360I20.2 and UBXN10/RP3-
340N1.5 (Table 4-2).  
 
Table 4-2 Differentially expressed and methylated candidate mRNA/lncRNA pairs 
mRNA lncRNA Distance between TSS 
DLX6 DLX6-AS1 8517 bp 
MKX RP11-360I20.2 1274 bp 
UBXN10 RP3-340N1.5 401 bp 
Result of the screening strategy after integration of DNA methylation data. In each row are indicated for 
one mRNA/lncRNA pair the distance between the transcriptional start sites (Consortium et al.) of each 
respective pair of transcripts. 
 
About 10% of human protein-coding genes share their promoter with another gene transcribed 
on the opposite DNA strand and are defined as bidirectional promoters (Trinklein et al.,2004). To 
exclude mRNA/lncRNA pairs concomitantly expressed in response to a common bidirectional 
promoter, only pairs were considered as candidates when the TSS of both RNA components were 
separated by more than 1,500 bp (Figure 4-1 C). Among the three identified mRNA/lncRNA pairs, 
MKX and UBXN10 coding genes are separated from the TSS of the adjacent lncRNA gene by 1274 
bp and 401 bp, respectively. In contrast, DLX6 and DLX6-AS1 TSSs are separated by 8517 bp and 
seemed therefore not to be regulated by a common promoter (Table 4-2). 
 
In summary, this screening approach allowed the identification of a single mRNA/lncRNA pair, 
DLX6/DLX6-AS1, overexpressed and positively correlated in EO-PCA patients. Based on the 
existing evidence DLX6-AS1 was selected as promising lncRNA candidate for the regulation of the 
expression of DLX6 mRNA in cis through alteration of the DNA methylation pattern of DLX6 
promoter region.  
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4.2 Clinical Characterization of DLX6/DLX6-AS1 pair  
In order to corroborate the in silico identification of DLX6/DLX6-AS1 pair, we investigated in more 
details the RNA expression and DNA methylation levels and their interdependency in two 
independent cohort of PCa patients (section 4.2.1) and in other tumor entities (section 4.2.2) 
before this pair in vitro (section 4.3).  
4.2.1 Clinical characterization of DLX6/DLX6-AS1 expression in PCa 
patients 
In the validation cohort of EO-PCa patients (validation set, RNA-seq, EO-PCa - Table 3-1), DLX6-
AS1 along with DLX6 are highly and significantly overexpressed compared to normal prostate (p-
value<0.0001) (Figure 4-3A). In line with the hypothesis that the pair of transcripts is coordinately 
expressed, expression levels of DLX6 and DLX6-AS1 are associated by a positive, linear and 
significant Spearman correlation (r=0.8256, p-value<0.0001) (Figure 4-3B). 
 
Figure 4-3 Coordinated upregulation of DLX6 and DLX6-AS1 in EO-PCA cohort   
(A) DLX6 and DLX6-AS1 RNA expression levels measured by RNA sequencing in tumors compared to 
normal tissue (NORMAL=10, TUMOR=91) from ICGC EO-PCa cohort. The horizontal bar represents the 
mean ± SEM. Mann-Whitney U test ****p<0.0001 (B) Corresponding Spearman correlation plot of DLX6-
AS1 and DLX6 expression measured by RNA sequencing in the ICGC EO-PCa cohort.  
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An independent cohort of patient-matched tumor/normal samples of late-onset PCa patients 
from the TCGA was used to validate the result from the ICGC cohort (Validation cohort, RNA-seq, 
TCGA matched - Table 3-1). Similar to the ICGC cohort, DLX6-AS1 expression is highly and 
significantly overexpressed (p<0.001), whereas DLX6 expression is not significantly different 
compared to their matched normal tissues (Figure 4-4A). Indeed, DLX6 expression separates into 
two groups with expression values from 0 to 5.7 RPKM and thus seemed to be upregulated in a 
subset of prostate tumors. We therefore divided the TCGA dataset in “LOW” and “HIGH” 
expression groups according to the median expression value of DLX6-AS1 (median= 4.11). When 
comparing “TUMOR-HIGH” PCa cases with their matched normal prostate tissues (“NORMAL-
HIGH”), DLX6-AS1 along with DLX6 were significantly overexpressed (p<0.0001). DLX6-AS1 
expression in the “TUMOR-LOW” subgroup was not significantly different compared to matched 
normal tissue (“NORMAL-LOW”), whereas DLX6 expression in the same subgroup was 
significantly downregulated in comparison to its matched normal counterpart (Figure 4-4A). 
Similarly to the ICGC dataset, the expression of DLX6-AS1 and DLX6 was significantly and 
positively correlated (Spearman r=0.7848, p-value<0.0001) (Figure 4-4B). 
 
Figure 4-4 Coordinated upregulation of DLX6 and DLX6-AS1 in TCGA PCa cohort 
(A) DLX6-AS1 and DLX6 RNA expression levels measured by RNA sequencing separated into LOW and HIGH 
tumor subgroups compared to matched normal tissue (NORMAL-LOW=26 , TUMOR-LOW=26, NORMAL-
HIGH=26 and TUMOR-HIGH=26) from TCGA late-onset PCa cohort. Patients were divided into LOW and 
HIGH expression groups according to the median expression value of DLX6-AS1 in tumor tissue. The 
horizontal bar represents the mean ± SEM. Wilcoxon signed-rank test ****p<0.0001, ***p<0.001, 
**p<0.01, ns= non-significant. (B) Spearman correlation plot of DLX6-AS1 and DLX6 expression measured 
by RNA sequencing in the TCGA PCa cohort.   
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Overall, DLX6/DLX6-AS1 pair is overexpressed in a subset of PCa patients and the expression of 
both genes is positively associated independently of the age at diagnosis of patients.  
 
To examine whether DLX6 expression is regulated by DNA methylation in both datasets, 
corresponding 450k data were used. Direct comparison of the normal versus tumor samples from 
the ICGC cohort did not reveal a difference at the DNA level (Figure 4-5B). Since DLX6 
overexpression was restricted to a subgroup in the TCGA dataset, we also divided the cancerous 
patients of the ICGC cohort into “LOW” and “HIGH” subgroups according to DLX6-AS1 median 
expression value (median= 0.89) (Appendix Figure 7-1). In agreement with elevated DLX6 
expression in the “HIGH” PCa samples (Appendix Figure 7-1) the DLX6 promoter region is 
significantly hypomethylated in the “HIGH” versus “LOW” patients in the ICGC cohort (Figure 4-
5B). DNA methylation changes are even more pronounced when comparing the “TUMOR-HIGH” 
and “TUMOR-LOW” subgroup in the TCGA cohort. Indeed, DNA methylation in samples of 
patients belonging to the “TUMOR-HIGH” subgroup shows a similar profile at the DLX6 promoter 
as the matched (“NORMAL-HIGH”) and non-matched (“NORMAL-LOW”) normal samples. In 
contrast, in the subset of patients associated with low DLX6-AS1 expression (“TUMOR-LOW”) the 
DLX6 promoter is hypermethylated compared to matched “NORMAL-LOW” or to the “TUMOR-
HIGH” subgroup of samples (Figure 4-5C).  
 
Noteworthy, in both cohort the most pronounced DNA methylation differences are observed in 
eight CpG probes (cg09327602, cg01229860, cg05663341, cg04599026, cg02898094, 
cg20479774, cg07598549 and cg20703729) (Figure 4-5A probes highlighted with blue), 
suggesting that the regulatory elements controlling DLX6 expression overlap with these regions.  
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Figure 4-5 Hypomethylation of DLX6 promoter in “HIGH” subset of PCa patients 
(A) Representation of HumanMethylation450 beadchip probes and Mass-Array amplicons overlapping 
with DLX6 promoter region and CGIs. (B and C) DNA methylation levels are displayed on the y-axis as a 
percentage ranging from 0% to 100%. (B) Each point represents mean methylation levels of single CpG 
sites in normal prostate, tumors as well as tumors separated into the HIGH or LOW subgroups of EO-PCa 
patients from the ICGC cohort. (C) Each point represents mean methylation levels of single CpG sites in 
matched normal/tumor samples subdivided into HIGH and LOW subgroups of late-onset patients from 
TCGA. (B) Mann-Whitney U test or (C) Wilcoxon signed-rank test was used to calculate statistical 
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significances between each group by comparing the mean DNA methylation levels across the eight CpG 
sites highlighted in light blue.  ****p<0.0001, ***p<0.001, ns= non-significant.  
 
We further tested whether DLX6 expression levels are inversely proportional to DLX6 promoter 
methylation levels. Based on the combined average DNA methylation of the eight CpG probes 
correlated with DLX6 expression, we could show that DLX6 expression and DLX6 promoter 
methylation are significantly and negatively correlated in both ICGC (r= -0.7720, p-value<0.0001) 
(Figure 4-6A) and TCGA datasets (r= -0.5337, p-value<0. 0001) (Figure 4-6B).  
 
 
Figure 4-6 DLX6 expression is inversely correlated with DLX6 promoter DNA methylation  
Spearman correlation plot of DLX6 expression measured by RNA-sequencing and the average DNA 
methylation across the eight CpG sites for each sample in (A) ICGC or (B) TCGA datasets.  
 
Collectively, these results show that elevated DLX6/DLX6-AS1 expressions along with DLX6 
promoter hypomethylation are linked to a subset of cancer patients. The positive correlation 
between DLX6 and DLX6-AS1 suggests that the expression of these two genes is linked by a 
common mechanism. Our hypothesis is that DLX6-AS1 expression regulates DLX6 mRNA 
expression through hypomethylation of the DLX6 promoter region in a mechanism that might 
involve DNA demethylation. 
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4.2.2 Clinical characterization of DLX6/DLX6-AS1 expression across 
cancers 
Comprehensive analysis of lncRNAs in seven tumor types analysed by the TCGA consortium, 
revealed that 60% (n=4512) of dysregulated lncRNAs are expressed in a cancer-type specific 
manner. The remaining lncRNAs are expressed in two or more cancers and only 29 were 
significantly upregulated in at least six tumor entities, among them DLX6-AS1. Besides PCa, DLX6-
AS1 was reported to be overexpressed in LUSC, COAD, HNSC, LUAD and KIRC (Yan et al.,2015). 
Independent differential expression enrichment analysis of lncRNAs in 25 cancer types confirmed 
the upregulation of DLX6 and DLX6-AS1 in LUSC and LUAD (Iyer et al., 2015).  
 
To analyse if the observed relationship between DLX6 and DLX6-AS1 in PCa (section 4.2.1) can be 
confirmed in the five above mentioned cancer entities from TCGA, we compared the expression 
of both transcripts (Figure 4-7A) and analysed the involvement of DNA methylation in DLX6 
regulation (Figure 4-7B). Since the number of patient-matched tumor/normal samples with both 
RNA-seq and 450k data was too low, we included for this analysis all available samples (Table 3-
2). Across all five cancer types, DLX6-AS1 expression significantly and positively correlated with 
DLX6 expression (p-value<0.0001), with the highest correlation observed for LUSC (r=0.8952). 
KIRC had the lowest Spearman correlation (r=0.6524), and the expression range of 0 to 6.9 RPKM 
of the pair is also the lowest among the five cancer types (Figure 4-7A).  
 
To examine whether DLX6 expression is regulated by DNA methylation in the five datasets, 
corresponding 450k data were used (Table 3-2 - 450k). In agreement with elevated DLX6 
expression in LUSC, COAD, HNSC and LUAD tumor samples, the DLX6 promoter region was 
consistently hypomethylated. Indeed, DLX6 expression and DLX6 promoter methylation are 
significantly and negatively correlated in the four datasets (r=-0.4801 p-value<0.0001 for LUSC, 
r=-0.5192 p-value<0.0001 for COAD, r=-0.4543 p-value<0.0001 for HNSC and r=-0.4694 p-
value<0.0001 for LUAD).  
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Figure 4-7 Coordinated upregulation of DLX6 and DLX6-AS1 in cancer and assessment of DLX6 
regulation by DNA methylation 
(A) Spearman correlation plot between DLX6-AS1 and DLX6 expression measured by RNA sequencing from 
multiple TCGA datasets detailed in Table 3-2. (B) Spearman correlation plot between DLX6 expression 
measured by RNA-sequencing and the average DNA methylation across the eight CpG sites for each 
sample in multiple TCGA datasets. Abbreviations: r= Spearman correlation, ns= non-significant. 
RESULTS 
 
68 
 
Among the four datasets, the correlation coefficients in COAD and LUAD are affected by the 
presence of a distinct subgroup of tumors where DLX6 expression is not dependent on DNA 
methylation levels. Indeed, in COAD a subgroup of tumors cluster with normal samples and are 
characterized by concomitant low DLX6 expression and DNA methylation levels. In LUAD a 
fraction of tumors are instead defined by low DLX6 expression with different ranges of DLX6 DNA 
methylation (Figure 4-7B).  
 
In contrast, DLX6 promoter DNA methylation levels in KIRC were not significantly correlated with 
expression. The correlation coefficient was very low and statistically not significant, that is, there 
is negligible or no relationship between DLX6 expression levels and the methylation levels at its 
promoter in KIRC (Figure 4-7B). 
 
In summary, DLX6-AS1 overexpression correlates with DLX6 expression in five different cancer 
types. The significant relationship between DLX6 expression and promoter methylation in LUSC, 
COAD, HNSC and LUAD suggests that DLX6 can be regulated through DNA methylation in these 
cancers. In contrast, DLX6 seems not to be regulated by altered DNA methylation levels in KIRC 
and in a subgroup of samples in COAD and LUAD.  
4.2.3 Clinical evaluation of DLX6/DLX6-AS1 overexpression  
A. Clinical significance of DLX6/DLX6-AS1 overexpression in PCa 
DLX6/DLX6-AS1 pair is overexpressed and negatively correlates with DLX6 DNA methylation 
levels in a subset of PCa patients designed previously as the “HIGH” expression group in ICGC or 
TCGA datasets (section 4.2.1). We sought to determine whether this expression subgroup is 
associated with distinct clinical or genomic parameters compared to the “LOW” expression 
subset of patients (Table 4-3).  
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Table 4-3 Correlation of “LOW” and “HIGH” DLX6-AS1 expression subgroups with clinical 
parameters 
 ICGC EO-PCa TCGA Late-onset PCa 
All samples 
LOW 
(n=46) 
HIGH 
(n=45) 
P-VALUE  LOW  
(n=250) 
HIGH 
(n=248) 
P-VALUE 
Age Median 48 49 0.644T  62 61 0.1234T 
Gleason score 
n=88 
6 7(15.6) 5(11.6) 
0.2406CT  n= 497 
20(8) 24(9.7) 
0.2642C  
7 29(64.4) 35(81.4) 116(46.6) 131(52.8) 
8 1(2.2) 0 31(12.5) 33(13.3) 
9 8(17.8) 3(7) 79(31.7) 59(23.8) 
10 0 0 3(1.2) 1(0.4) 
Pathological T 
stage 
n=88 
T1 0 0 
0.5520  n=490 
0 0 
0.3805 
T2 31(68.9) 29(67.5) 98(40) 88(35.9) 
T3 11(24.4) 13(30.2) 140(57.2) 153(62.5) 
T4 3(6.7) 1(2.3) 7(2.8) 4(1.6) 
ERG fusion 
n=41 
ERG + 6(27.3) 17(89.5) 
<0.0001  n=333 
24(15.8) 128(70.7) 
<0.0001 
ERG - 16(72.7) 2(10.5) 128(84.2) 53(29.3) 
Deletion 3p13 
n=57 
Deleted 3(14.3) 16(44.4) 
0.0230  Non 
deleted 
18(85.7) 20(55.6) 
Deletion 5q21.1 
n=57 
Deleted 4(19.1) 2(5.6) 
0.7250 Non 
deleted 
17(80.9) 34(94.4) 
Deletion 
10q23.31 
n=57 
Deleted 5(23.8) 12(33.3) 
0.5549  Non 
deleted 
16(76.2) 24(66.7) 
Deletion 17p31 
n=57 
Deleted 5(23.8) 16(44.4) 
0.1589 Non 
deleted 
16(76.2) 20(55.6) 
For each feature the number of patients affected is indicated and within brackets the respective 
percentage is given. To calculate the statistical differences among groups the following test were applied: 
T= Student’s t-test, CT=chi-squared test trend, C=chi-squared test and if not otherwise stated Fisher’s exact 
test was employed.  
 
There was no statistical significant association between DLX6-AS1 expression and age, Gleason 
score or the pathological T stage in both ICGC and TCGA cohorts (Table 4-3). Indeed, DLX6/DLX6-
AS1 overexpression is not dependent on the age at diagnosis of patients and did not differ 
significantly between the two groups (48 versus 49 years old) in ICGC EO-PCa patients and in 
TCGA late-onset PCa patients (62 versus 61 years old). Alterations in DLX6/DLX6-AS1 levels were 
also independent of Gleason scores with a prevalence of patients reaching a Gleason score of 7 
in both the “LOW” and “HIGH” subgroups in ICGC and TCGA datasets. Similarly, the two 
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subgroups could not be separated by distinct pathologic T stages, with preponderance for the T2 
and T3 stage in the ICGC and TCGA cohorts, respectively.   
 
In contrast, DLX6/DLX6-AS1 overexpression (“HIGH”) is highly and significantly associated with 
tumors harbouring the TMPRSS2:ERG fusion gene (ERG+) in ICGC (89.5% versus 27.3%) and TCGA 
(70.7% versus 18.8%) datasets (p-value<0.0001). Consistently the “LOW” subgroup is linked to 
patients not harbouring the fusion gene (ERG-) in ICGC (72.7% versus 10.5%) and TCGA (84.2% 
versus 29.3%) cohorts.  
 
The abundance of ERG+ patients within the “HIGH” expression subgroup prompted us to 
investigate the absence of 5q21 deletion and the presence of deletions on 3p13, 10q23 and 
17p31 described to frequently co-occur in patients harbouring the fusion gene (section 1.3.1). 
We found that the absence of deletions on the 5q21 locus (p-value 0.7050) and the presence of 
deletions on 10q23 (p-value 0.5549) and 17p31 (p-value 0.1589) were not significantly enriched 
in the “HIGH” compared to the “LOW” expression subgroup. In contrast, predominance of 
patients (85.7%) without a deletion on the 3p13 locus is significantly linked to the “LOW” 
expression group (p-value 0.0230) (Table 4-3).  
Overall, our comparison of DLX6/DLX6-AS1 expression with clinical and genetic parameters 
revealed, that high-level of DLX6/DLX6-AS1 expression are particularly linked with the occurrence 
of both TMPRSS2:ERG fusion gene and 3p13 deletion.  
B. Impact of DLX6/DLX6-AS1 overexpression on prognosis 
Two clinical endpoints, overall (Figure 4-8A) and disease-free survival (Figure 4-8B) were 
evaluated by Kaplan-Meier survival analysis to assess the relationship between DLX6-AS1 
expression and survival times in the TCGA datasets on PRAD, LUSC, COAD, HNSC, LUAD and KIRC. 
To study the clinical significance of DLX6-AS1 expression, we divided each dataset into two groups 
(LOW and HIGH) with the median DLX6-AS1 expression value serving as the cut-off point (Table 
3-3). 
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Figure 4-8 DLX6-AS1 expression subgroups association with overall and disease-free survival in 
TCGA datasets 
Kaplan-Meier analyses of the overall survival time (A) or disease-free time (B). Subjects were stratified 
into “LOW” and “HIGH” subgroups according to DLX6-AS1 expression levels in PRAD, LUSC, COAD, HNSC, 
LUAD and KIRC from the TCGA (Table 3-3). P-values were determined using the log-rank test. Also shown 
is the Hazard ratio (HR) with their respective 95% confidence intervals indicate within brackets.  
 
Elevated DLX6-AS1 expression (“HIGH”) was not significantly associated with altered overall 
survival time in PRAD, COAD, HNSC and LUAD (Figure 4-8A). This result should however, be 
interpreted with caution for PCa patients, since only a limited number of events (n= 10) are 
available to assess the difference in overall survival times in this cohort (Table 3-3 - PRAD). In 
contrast, high DLX6-AS1 expression was associated with longer overall survival times in LUSC (p-
value 0.0327) and KIRC (p-value 0.0180), respectively. In addition, for the six cohorts, higher 
DLX6-AS1 expression was not associated with increased disease-free survival (Figure 4-8B).  
 
Figure 4-9 Elevated DLX6-AS1 expression predicts overall survival in LUAD 
Kaplan-Meier analyses of the overall survival time. Subjects were stratified into “LOW” and “HIGH” 
subgroups according to DLX6 expression levels in LUAD extracted from the KM plotter (Table 3-4). P-values 
were determined using the log-rank test. Also shown is the Hazard ratio (HR) with its respective 
confidence interval indicate in brackets. 
 
In the TCGA cohort for LUAD patients, high DLX6-AS1 expression did not significantly impact the 
overall survival time of patients (Figure 4-8A). We extended our analysis to an independent and 
larger cohort of LUAD patients (n=673 for 242940_x_at and 239309_at and n=720 for 221289_at) 
extracted from the Kaplan-Meier plotter software (Table 3-4). These data are based on 
expression microarrays not including probes mapped to the lncRNA DLX6-AS1. Since DLX6 and 
DLX6-AS1 expression are significantly and positively correlated in LUAD (Figure 4-7A), we used 
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the DLX6 median expression value to stratify the patients into “LOW” and “HIGH” expression 
subgroups. In this cohort, elevated DLX6 expression levels in the three probes for DLX6 present 
on the array (242940_x_at, 239309_at and 221289_at) are significantly associated with 
decreased overall survival (for 242940_x_at p-value=0.0024, for 239309_at p-value=0.0006 and 
for 221289_at p-value=0.002) (Figure 4-9).  
In summary, elevated DLX6-AS1 levels are associated with a favourable survival in LUSC and KIRC, 
whereas in LUAD the overexpression is linked to worse overall survival.  
4.3 In vitro characterization of DLX6/DLX6-AS1 expression 
4.3.1 Identification of the DLX6-AS1 major transcript variant 
The lncRNA DLX6-AS1 is an intergenic RNA located on chromosome 7q22 antisense to the protein 
coding gene DLX6. DLX6 is a homeobox transcription factor, located tail-to-tail with DLX5 
(GENCODE - Figure 4-10).  
 
Of the transcript variants that have been described for DLX6-AS1, RNA sequencing reads of EO-
PCa patients (RNA-seq TUMOR - Figure 4-10) used for the screening approach mapped most 
accurately to the second and the beginning of the third exon of the ENST00000430027 transcript, 
whereas no peak could be detected for its first exon lying within the intergenic region between 
DLX6 and DLX5 genes (Gencode and RNA-seq TUMOR- Figure 4-10). Ab initio assembly of RNA 
sequencing data from 27 human tumor or tissue types recently has expanded the landscape of 
DLX6-AS1 transcripts to variants encompassing alternative 5’ends (MiTranscriptome - Figure 4-
10) (Iyer et al., 2015) . The first exon of the two alternative variants depicted in Figure 4-2 
corresponds to a RNA-seq peak lying next to a peak corresponding to DLX6 first exon.  
We identified the transcriptional start site of DLX6-AS1 by 5’RACE (Rapid Amplification of 5’ cDNA 
Ends) using nested PCR-primers located within the DLX6-AS1 second exon (5´RACE primers - 
Figure 4-10) in the VCaP prostate cancer cell line (5´RACE VCaP - Figure 4-10) where the pair of 
transcripts is highly expressed (Figure 4-13). The TSS was mapped to the first intron of DLX6 and 
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fitted best to DLX6-AS1 transcript variants annotated as G077079|T328744 (renamed as DLX6-
AS1 T1) and G077079|T328743 (renamed as DLX6-AS1 T2) from the MiTranscriptome catalog 
(Figure 4-10).  
 
Figure 4-10 Characterization of DLX6-AS1 transcript variants and transcription start site  
Transcript structure of DLX6-AS1 variants from GENCODE version 19 as well as determined by the de novo 
assembly in the MiTranscriptome catalog. Representative RNA sequencing reads mapping to DLX6-AS1, 
DLX6 and DLX5 from one representative normal and one early-onset ICGC prostate cancer patient. The 
mapping of DLX6-AS1 TSS was determined by 5’RACE and depicted is the sequencing result along with the 
position of primers used for the nested PCR in VCaP cells. Also shown are the location of the primers used 
to amplify DLX6-AS1 cDNA by PCR and the resulting genomic structure of DLX6-AS1 PCR products 
identified by sequencing of gel extracted PCR products. In the last panel is also shown the location of 
primers use to detect DLX6-AS1 T1 and T2 variants by RT-qPCR.  
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Figure 4-11 Confirmation of the localization of DLX6-AS1 TSS 
Enlargement of the region overlapping the first exon of DLX6 and DLX6-AS1 T1/T2 transcripts. Depicted 
are the sequencing profiles of the CAGE data for the (-) and (+) DNA strand in duplicates (N1 and N2) 
generated in H1299 cells treated with dimethyl sulfoxide (data generated by Dr. C. Schmidt).  
 
This result was confirmed by strand specific CAGE (Cap analysis of gene expression) followed by 
sequencing (data provided by Dr. C. Schmidt) (CAGE-seq(-)strand N1 and N2 - Figure 4-11), 
performed in the lung cancer cell line H1299 also exhibiting high expression levels of DLX6 and 
DLX6-AS1 (Figure 4-13).  
 
To confirm the existence of DLX6-AS1 T1 and T2 variants we PCR-amplified in VCaP cells both 
variants based on the annotation described in the MiTranscriptome database, 5’RACE result, and 
on the RNA-sequencing profiles in EO-PCa patients. The forward primer T1/T2_F1 was localized 
at the 5’ end of the first exon common for the T1 and T2 transcripts. Two reverse primers, T1_R1 
and T2_R3 correspond to alternative polyadenylation sites overlapping with the RNA-seq reads 
matching DLX6-AS1 lncRNA (Figure 4-10). We identified three different DLX6-AS1 products with 
the two sets of primers. Indeed, the reverse primer T1_R1 allowed the amplification of two 
products corresponding to T1 and T2 transcripts, while with T2_R3 only a single PCR product 
coinciding with an elongated form of the T2 transcript could be detected (Figure 4-12). These 
results suggest that DLX6-AS1 T1 and T2 variants have different 3’ ends that are formed by 
polyadenylation at distinct sites. DLX6-AS1 T2 transcript with an extended 3’ end was named T2L 
(long), whereas the shorter form was referred to as T2S (DLX6-AS1 PCR products-Figure 4-10).  
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Figure 4-12 DLX6-AS1 codes for two splice variants  
DLX6-AS1 PCR product generated from cDNA using the two indicated set of primers.  
 
4.3.2 Characterization of DLX6/DLX6-AS1 expression in cell lines  
To confirm the differential and coordinated expression of DLX6 with DLX6-AS1 observed in 
patients, we measured and correlated their expression in two benign prostate epithelial cell lines 
(BPH1 and PNT2) and ten cancerous cell lines from different tissue types (Figure 4-13). The two 
DLX6-AS1 transcripts T1 and T2 (T2S and T2L) differ by the presence of an additional exon in the 
T1 variant. This unique sequence information allowed us to determine the levels of both splice 
variants with the two sets of RT-qPCR primers depicted in Figure 4-10. RT-PCR analysis revealed 
that both DLX6-AS1 variants are expressed, with a predominant expression of the T1 variant in 
all cell lines expressing the pair of transcripts. In concordance with our screening strategy, the 
expression of DLX6 and DLX6-AS1 variant T1 or T2 are highly and significantly correlated in the 
twelve different screened cell lines (Spearman correlation =0.9841 for T1 and 0.9714 for T2) 
(Figure 4-13). Moreover, the DLX6/DLX6-AS1 pair exhibits higher expression levels in the PCa cell 
lines VCaP and DU145 compared to the benign prostate epithelial cells BPH1 and PNT2. The 
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expression of the sense and antisense transcript is not restricted to prostate, but can also be 
detected in the non-prostate cancerous cell lines HEK293T, H1299 and HCT116 DKO. In 
comparison to the DNMT1 and DNMT3B double knock out cell line HCT116 DKO, the 
sense/antisense pair is not expressed in HCT116 cells, suggesting a role for DNA methylation in 
DLX6/DLX6-AS1 expression regulation.  
 
 
Figure 4-13 DLX6/DLX6-AS1 are coordinately expressed in cell lines  
Spearman correlation plot between DLX6-AS1 T1 or T2 variants and DLX6 expression measured by RT-
qPCR and normalized to HPRT1, SDHA and ALAS1 housekeeping genes. Each point in the correlation plot 
is attributed an identifier (ID) ranging from a to l and corresponding to a cell line indicated in the table. 
Mean expression values for each transcript in each cell lines is also reported in the table. Data are depicted 
as the mean, n= 3 biological replicates.   
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Figure 4-14 DLX6 promoter is differentially methylated in cell lines  
(A) Representation of MassArray amplicons overlapping with DLX6 and DLX6-AS1 promoter region and 
CpG islands. Quantitative DNA methylation levels are displayed as a heatmap at the DLX6 and DLX6-AS1 
promoter region in VCaP (a), HEK293T (b), H1299 (c), DU145 (d), HCT116 DKO (e), BPH1 (f), A549 (g), 
LNCaP (h), 22RV1 (i), PNT2 (j), PC3 (k) and HCT116 (l) cell lines. Each column represents the mean 
methylation value of single or multiple CpG sites in the corresponding MassArray amplicon for every 
sample in each row. Mean DNA methylation levels of n= 3 biological replicates are depicted as a 
percentage ranging from 0% (light blue) to 100% (dark blue). (B) Spearman correlation plot between DLX6 
expression measured by RT-qPCR and the mean DNA methylation of all amplicons for each cell line. Each 
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point on the correlation plot is attributed an identifier number (ID) ranging from a to l corresponding to a 
cell line indicated in the upper panel.  
 
In line with DLX6/DLX6-AS1 expression patterns in cell lines, the region of DLX6 promoter 
overlapping Amplicon 1 - 3 is lowly methylated in cell lines expressing the pair of transcripts, 
while higher methylation levels are measured in cell lines g-l not expressing DLX6/DLX6-AS1. In 
contrast, Amplicon 4 located in DLX6 gene body exhibits higher DNA methylation levels with 
increasing DLX6/DLX6-AS1 expression (Figure 4-14 A). In addition, DLX6 expression levels are 
significantly and inversely correlated with DLX6 promoter methylation levels in all cell lines 
(r=−0.7577, p-value=0.0055) (Figure 4-14 B). 
4.3.3 Characterization of DLX6 promoter 
Inverse correlation of DLX6 and DLX6-AS1 expression and methylation of the DLX6 promoter 
region in all cell lines corroborated our initial hypothesis that the lncRNA regulates the coding 
mRNA by modulating DNA methylation levels. Nevertheless, the proximity of DLX6-AS1 TSS to 
DLX6 transcription start (distance of 900 bp) identified by 5’RACE implicate that both RNAs could 
be regulated by this shared genomic region (Figure 4-15). Publicly available chromatin 
immunoprecipitation and sequencing (ChIP-seq) data for RNA polymerase II (Pol II) binding and 
H3K4 trimethylation indicating active transcription (Yu et al., 2010) were inspected for a common 
regulatory region of the sense and antisense RNAs in VCaP and LNCaP cells. In VCaP cells, active 
expression of the DLX6/DLX6-AS1 transcript pair is supported by the presence of H3K4me3 along 
with a single Pol II binding site in the DLX6 promoter (in the region of the CGI covered by 
MassArray Amplicon 1), both characterizing active promoters. This result is in line with the idea 
that a common promoter regulates DLX6 and DLX6-AS1 transcription. By contrast, neither active 
histone marks nor Pol II binding were identified in the region between DLX6 and DLX6-AS1 TSSs 
in LNCaP cells (Figure 4-15).  
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Figure 4-15 DLX6/DLX6-AS1 share a common promoter    
Profiles of H3K4me3 and RNA polymerase II ChIP-seq data in VCaP and LNCaP cell lines from Yu and 
colleagues (Yu et al.,2010) overlapping with DLX6 promoter region. 
 
In summary, DLX6 and DLX6-AS1 are coordinately expressed, and DLX6 expression inversely 
correlates with DNA methylation levels in the DLX6 promoter region. The coordinated expression 
of the sense and antisense transcript could be the sign for interdependency of their expression, 
or the result of a shared promoter.  
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4.4 Study of the influence of DLX6-AS1 on DLX6 expression 
The following set of experiments was designed to test the screening hypothesis and delineate 
the interrelationship between the expression of DLX6 and DLX6-AS1 either by knockdown or 
overexpression of the antisense transcript in experimental conditions where the genes are 
expressed or lowly expressed, respectively. The potential epigenetic regulation between the 
sense and antisense transcripts was determined by RT-qPCR and DNA methylation analysis by 
MassArray.  
4.4.1 Downregulation of DLX6-AS1 does not influence DLX6 
expression  
We observed a positive correlation between DLX6 and DLX6-AS1 expression and, through 
knockdown of DLX6-AS1, wanted to investigate whether DLX6 is directly regulated by the 
antisense lncRNA DLX6-AS1.  
 
First, we downregulated DLX6-AS1 by stable expression of shRNAs in VCaP cells and by transient 
siRNA or LNA transfection in HEK293T cells. Even though DLX6-AS1 T1 and T2 transcripts 
expression were drastically reduced in VCaP cells with a respective minimum knockdown 
efficiency of 80% and 65%, DLX6 transcript levels remained unaffected (Figure 4-16A-upper 
panel). RNA interference (RNAi)-based techniques such as shRNA and siRNA are believed to 
target mainly cytoplasmic RNAs (Bassett et al., 2014). Our hypothesis relies however on a nuclear 
role of DLX6-AS1. For this reason, we employed additionally LNA GapmeRs. Their chimeric RNA-
DNA nature triggers RNase H dependent degradation of nuclear RNAs more efficiently than RNAi-
based techniques (Bassett et al., 2014). DLX6-AS1 knockdown by siRNA or LNA in HEK293T cells 
did however, not reduce DLX6 expression (Figure 4-16B- upper panel).  
 
While DLX6-AS1 does not regulate DLX6 at the RNA level, we additionally tested whether 
knockdown of the transcription factor DLX6 could influence DLX6-AS1 expression. 
Downregulation of DLX6 mRNA levels by shRNAs, although not as effective as for DLX6-AS1, lead 
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to a weak, non-significant decrease of DLX6-AS1 T1 levels by about 20% in VCaP cells (mean rel. 
expression level=0,83 for sh#6 and =0,64 for sh#2) without affecting the DLX6-AS1 T2 variant 
(Figure 4-16A - lower panel). This effect could not be observed with a pool of four different 
siRNAs targeting DLX6 mRNA in HEK293T cells, although the knockdown was more effective than 
by shRNA in VCaP cells (mean rel. expression =0,29 in HEK293T versus mean rel. expression=0,49 
after transfection of VCaP with sh#2) (Figure 4-16B - lower panel). This suggests that DLX6-AS1 
T1 alteration after DLX6 knockdown in VCaP cells is not related to DLX6 function.  
 
Figure 4-16 Downregulation of DLX6-AS1 lncRNA does not impact DLX6 expression 
(A) Relative expression levels of DLX6-AS1 and DLX6 8 days after knockdown of DLX6-AS1 (AS) (upper 
panel) or DLX6 (lower panel) relative to control scrambled shRNA in VCaP prostate cancer cells.  Data are 
depicted as the mean +/- s.e.m., n= 4 biological replicates. (B) Relative expression levels of DLX6-AS1 and 
DLX6 72h after knockdown of DLX6-AS1 (upper panel) or DLX6 (lower panel) with 25nM siRNA or LNA 
relative to control scrambled shRNA or LNA in HEK293T cells. Data are depicted as the mean +/- s.e.m., 
n= 3 biological replicates. Two-tailed unpaired t-test was used to calculate statistical significance in 
comparison with the control group and annotated as follow:  ****p<0.0001, ***p<0.001, **p<0.01. If not 
otherwise indicated there is no significant difference between samples. 
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Consistent with a lack of changes in DLX6 transcript levels, DLX6-AS1 downregulation did not 
influence DNA methylation levels in the region around the TSS of DLX6 gene covered by four 
MassArray Amplicons in VCaP (Figure 4-17B) and HEK293T cells (Figure 4-17C).  
 
If according to our initial hypothesis DLX6-AS1 would affect DLX6 mRNA expression via targeting 
of DNA demethylating enzymes to the DLX6 promoter, after DLX6-AS1 silencing we would expect 
a gain in DLX6 promoter DNA methylation resulting in lower DLX6 expression. However, gain in 
DNA methylation can be dependent on the cell cycle, and in slow cycling cell lines (see 
introduction section 1.1.3 A) such as VCaP (doubling time 4-5 days) this process might take longer 
than the time frame of the knockdown.  
 
Figure 4-17 Downregulation of DLX6-AS1 lncRNA does not impact DLX6 promoter methylation 
(A) Representation of MassArray amplicons overlapping with the DLX6 promoter region. (B and C) DNA 
methylation levels at the DLX6 promoter region are displayed on the y-axis as a percentage ranging from 
0% to 100% in VCaP (B) or HEK293T (C) cells after knockdown of DLX6-AS1. Each depicted value represents 
the mean methylation level of all CpG sites within one amplicon. Data are depicted as the mean +/- s.e.m., 
n= 3 biological replicates. We detected no statistically significant differences between the control group 
and each knockdown experiment using two-tailed unpaired t-test.  
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4.4.2 Upregulation of DLX6-AS1 does not influence DLX6 expression  
Since DLX6-AS1 downregulation did not influence DLX6 expression or promoter methylation, we 
next tested the reverse strategy by elevating levels of DLX6-AS1 in cells lines with low antisense 
expression. 
 
DLX6-AS1 RNA variants T1, T2S and T2L (Figure 4-10) were synthesized by in vitro transcription 
and transfected in A549 lung adenocarcinoma or PC3 prostate cancer cell lines. Both cell lines 
are characterized by absent expression of the DLX6/DLX6-AS1 pair of transcripts. Expression is 
repressed by moderate (A549 cells) to high levels (PC3 cells) of DNA methylation in the region 
covered by MassArray Amplicons 1 - 3 when compared to VCaP cells expressing both transcripts 
(Figure 4-14). DLX6-AS1 T1, T2S and T2L transcript expression was consistently upregulated in 
the two cell lines in comparison to the constitutive expression levels of T1 and T2 transcripts in 
VCaP cells (Figure 4-18A). DLX6-AS1 transfection did however not lead to DLX6 re-expression (no 
expression detectable).  
 
In a similar manner, overexpression of different amounts of a plasmid encoding for DLX6 cDNA 
in LNCaP cells (Figure 4-18B) did not cause DLX6-AS1 re-expression (no expression detectable).  
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Figure 4-18 Elevated levels of DLX6-AS1 does not impact DLX6 expression 
(A) Relative expression levels of DLX6-AS1, 48h after transfection of 400 fmol of LACZ (control), T1, T2S or 
T2L DLX6-AS1 transcript in A549 or PC3 cells. DLX6-AS1 T1 and T2 transcripts levels are compared to the 
expression measured in VCaP cells. Data are depicted as the mean +/- s.e.m., n= 3 biological replicates. 
(B) Relative expression levels of DLX6, 72h after transfection of 0.5, 1 or 2µg of plasmid encoding for DLX6 
cDNA in LNCaP cells. Data are depicted as the mean +/- s.e.m., n= 2 biological replicates. 
 
In agreement with unchanged DLX6 mRNA expression levels after DLX6-AS1 overexpression, DNA 
methylation in DLX6 promoter region was not consistently changed across all four Amplicons in 
A549 (Figure 4-19A) and PC3 cell lines (Figure 4-19B). However, following transfection of the T1 
variant, we observed a weak but significant 2.4% decrease in DNA methylation of Amplicon 4 in 
A549 cells and a 7% increase in methylation of Amplicon 2 in PC3 cells. These weak effects were 
specific for the respective cell lines, and were not associated with DNA methylation alterations 
in the other tested Amplicons.  
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Figure 4-19 Elevated levels of DLX6-AS1 does not impact DLX6 promoter methylation 
(A) Representation of MassArray amplicons overlapping with DLX6 promoter region. (B and C) DNA 
methylation levels at the DLX6 promoter region are displayed on the y-axis as a percentage ranging from 
0% to 100% in A549 (B) or PC3 (C) cells after knockdown of DLX6-AS1. Each depicted value represents the 
mean methylation level of all CpG sites within one amplicon. Data are depicted as the mean +/- s.e.m., n= 
3 biological replicates. Two-tailed unpaired t-test was used to calculate statistical significances between 
control versus each overexpression experiment.  
 
Collectively, these results show that the lncRNA DLX6-AS1 does not regulate expression of DLX6 
at the transcriptional level by influencing DNA methylation. In turn modulation of DLX6 
expression levels did as well not affect DLX6-AS1 expression. This suggests that the coordinated 
expression of the pair of transcripts is the consequence of a shared regulation by differential 
methylation of the bidirectional DLX6 promoter region.  
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4.5 Does DLX6-AS1 have coding potential?  
Accumulating evidence suggests that lncRNAs may encode functional micropeptides (section 
1.2.3) (Anderson et al., 2015, Nelson et al., 2016). For this reason, we investigated by in silico and 
in vitro analyses whether DLX6-AS1 might exert a biological function through translation into a 
small protein or peptide.   
4.5.1 DLX6-AS1 T1 has coding potential in silico  
To identify potential small proteins or peptides in DLX6-AS1 T1 (Figure 4-20A), T2S and T2L 
variants (Figure 4-20B) we employed ORFinder (NCBI). Translation efficiency is influenced by the 
sequence context surrounding a potential ORF. Therefore, we complemented the search for 
hypothetical proteins with the evaluation of potential translation start sites and optimal Kozak 
sequences by NETStart (Pedersen et al., 1997) and ATGpr (Salamov et al., 1998) algorithms, 
respectively. With this approach we identified four predicted ORFs in DLX6-AS1 T1. Among them, 
an ORF of 65 aa long referred as ORF1 was located in the second exon of DLX6-AS1 T1 and was 
the only predicted ORF associated with a potential translation start site (Figure 4-20A). ORF1 
starts at the first AUG codon in the DLX6-AS1 T1 transcript sequence and therefore adheres to 
the first-AUG rule stating that the AUG codon is the exclusive initiation site in eukaryotes (Kozak, 
1999).  
 
DLX6-AS1 T2S and T2L share the first and third exon of DLX6-AS1 T1 variant. Consequently, the 
two ORFs predicted for T1 and not overlapping with the second exon of the latter are shared by 
T2S and T2L variants. For DLX6-AS1 T2S or T2L, none of the predicted ORFS were associated with 
both a reliable Kozak sequence and a potential translation start site. The highest translational 
start site score (0.71) was associated with an ORF of 34 aa localized in the second exon of DLX6-
AS1 T2L, which we named ORF2 (Figure 4-20B). 
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Figure 4-20 DLX6-AS1 transcript coding potential  
Representation of all ORFs predicted with ORFinder (version January 2016) overlapping DLX6-AS1 (A) T1 
or (B) DLX6-AS1 T2S and T2L transcripts. For each ORF, the sequence matching the consensus Kozak 
sequence is given, within brackets the percentage of reliability of this motif calculated by ATGpr program. 
Depicted with red lines are all positively scored translation start sites predicted by NETStart with the 
corresponding reliability score ranging from 0 to 1 with increasing translation initiation site potential. 
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To assess whether ORF1 and/or ORF2 are biologically relevant, first we examined the 
conservation of both ORFs among primates by cross-species comparison, then we searched for 
the existence of similar proteins.  
 
First, to assess the conservation of ORF1 and ORF2, we predicted with ORFinder proteins or 
peptides encoded in the cDNA homologues of DLX6-AS1 T1 and T2S/L identified by nucleotide 
BLAST (NCBI). The protein coding sequence with the best match for ORF1 or ORF2 in each species 
was used for the multiple sequence alignment presented in Figure 4-21. The seven primate ORF1 
homologues were highly similar with 75.7% overall sequence identity (Figure 4-21A). In contrast, 
ORF2 is poorly conserved with 11.8% sequence identity across six primates (Appendix Figure 7-
2) but reaches 73.5% sequence identity when the comparison is restricted to the three ORF2 
homologues predicted from Nomascus leucogenesys (northern white cheeked gibbon), 
Rhynopithecus roxellana (golden snub-nosed monkey) and Collobus angolensis (Angola colobus) 
(Figure 4-21B).  
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Figure 4-21 DLX6-AS1 T1 ORF1 is conserved in primates  
Multiple sequence alignment of Homo sapiens (A) ORF1 and (B) ORF2 homologs in primates using Mafft 
version 7. ORF1 and ORF2 homologs were predicted by ORFinder (NCBI) in DLX6-AS1 cDNA homologs 
found by nucleotide BLAST (NCBI) of human DLX6-AS1 cDNA sequence (Appendix 7.8). All the cDNA 
sequences were retrieved from Genbank with the following accession numbers; Pan troglodytes 
(LOC104007329), Pongo abelii (LOC103891166), Nomascus leucogenys (LOC100579968), Rhynopithecus 
roxellana (LOC104662289), Colobus angolensis (LOC105512765) and Mandrillus leucophaeus 
(LOC105535579). Identical amino acid residues are highlighted in blue, and below the conservation plot 
is a key denoting conserved sequence (*) and conservative mutations (+). Also indicated is the consensus 
sequence.  
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Next, to gain insights into a probable functional and biological relevance of both ORFs, we 
assessed whether ORF1 or ORF2 shares identity with other proteins or peptides.  
For ORF2, a single homologous protein WP_020429213.1 could be identified by protein BLAST 
(Figure 4-22). This protein was annotated in the evolutionary distant bacterium Paenibacillus 
riograndensis, is of unknown function, and shares relatively low sequence identity of 33% with 
ORF2 with an expected value (e-value) inferred by protein BLAST of 3 (Appendix Table 7-9). 
Altogether, ORF2 is lowly conserved across primates and the low identity score with 
WP_020429213.1 suggests that this peptide is more likely to be a random sequence not encoding 
a functional peptide.  
 
Figure 4-22 ORF2 shares low identity with a bacterial protein  
Pairwise sequence alignment created with Clustal Omega of ORF2 amino acid sequence (Appendix 7.4) 
with WP_020429213.1 protein identified by protein BLAST. WP_020429213.1 amino acid sequence was 
retrieved from GenPept. Identical amino acid residues are highlighted in blue and below the conservation 
plot, is a key denoting conserved sequence (*) and conservative mutations (+). Also indicated is the 
consensus sequence.   
 
ORF1 is the only one of the predicted ORFs for which we obtained by protein BLAST (NCBI) 
numerous identity matches belonging exclusively to the order of Primates (n=72 with identity 
≥70%) (Appendix Table 7-8). In addition, the alignment of ORF1 with the proteins reaching a 
minimum bit-score of 80 and revealed a shared conserved domain spanning the 52 first aa in 
ORF1 (Figure 4-23). The search for functional domains and/or motifs in this sequence by 
comparison with Pfam (Finn et al., 2016), PROSITE (Sigrist et al., 2013), and the conserved 
domains databank (CDD) (Marchler-Bauer et al., 2015) was, however, negative.  
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Figure 4-23 ORF1 sequence shares identity with multiple proteins  
Multiple sequence alignment created with Clustal Omega of ORF1 amino acid sequence (Appendix 7.4) 
with proteins identified by protein BLAST (NCBI) with a minimum bit-score of 80. All cDNA sequences were 
retrieved from GenPept (NCBI) with the indicated accession numbers. Identical amino acid residues are 
highlighted in blue and below the conservation plot is a key denoting conserved sequence (*) and 
conservative mutations (+). Also indicated is the consensus sequence and the conserved domain of 52 aa 
surrounded by a black box. 
 
With the exception of the last 44 nt, the ORF1 coding sequence overlaps with and is almost 
entirely encoded within the repetitive element AlusZ (Figure 4-24A). Alu elements are primate-
specific repeats and also the most common repetitive sequences in humans comprising 11% of 
our genome (Deininger, 2011). Due to the abundance of Alu elements and the high number of 
proteins sharing similarity with ORF1 by protein BLAST exclusively found in the order of Primates 
(Figure 4-23), we examined if this is the consequence of the presence of an Alu element in these 
proteins. To test this hypothesis, we compared the sequence of the consensus AlusZ element 
(Appendix 7-3- sequence AlusZ) with the coding nucleotide sequence of all nineteen proteins 
identified by BLAST with a minimum bit-score of 80 (Figure 4-24B). Multiple alignments revealed 
that the coding sequences of all ORFs are highly similar to the consensus AlusZ sequence starting 
from nucleotide 128 to 283, the end of the AlusZ sequence. 
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Figure 4-24 ORF1 originates from the AlusZ repetitive element 
(A) Representation of the second exon of DLX6-AS1 T1 encoding ORF1 and overlapping with the consensus 
AlusZ repetitive element retrieved from Repbase(Bao et al.,2015). (B) Multiple sequence alignments 
created with Clustal Omega of ORF1 coding sequence with the coding sequence of proteins identified by 
protein BLAST (NCBI) with a minimum bit-score of 80 (Appendix - Table 7.8). All coding DNA sequences 
were retrieved from Genbank with the accession numbers and coordinates indicated in the Appendix in 
Table 7-10. The alignment is colored according to the degree of sequence conservation ranging from 50 
to 100 percent. Also indicated is the conserved domain surrounded by a black box and the AlusZ sequence 
derived into the ATG codon surrounded by a red box. 
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This sequence (with an additional nucleotide to complete the last codon) corresponds to the 
previously identified conserved domain of 52 aa for ORF1 and shared with the other nineteen 
ORFs (Figure 4-23). The nucleotide sequence not covered by the AlusZ element corresponds to 
the amino acids not conserved between ORF1 and the nineteen other ORFs in Figure 4-23.  
The first three nucleotides of ORF1 matching with AlusZ from position 128-132 have diverged 
from GCG to the ATG start codon present in ORF1, EAX04212.1, BAC87498.1, BAC85949.1, 
EHH21096.1 and EAW56895.1 (Figure 4-24B).  
 
Although ORF1 possess a high number of protein homologues, the data suggest that this is not 
the result of a conserved function, but the consequence of the insertion of Alu elements in the 
ORFs identified by protein BLAST. In addition, the majority of ORFs were annotated not based on 
experimental evidences, but using gene prediction models and are consequently described as 
either predicted, hypothetical or unnamed proteins (Appendix Table 7-8) and might therefore 
not be biologically relevant.  
 
Nonetheless, due to a sequence identity of 32% with the characterized human extracellular 
protein C16orf89 (chromosome 16 Open Reading Frame 89), ORF1 protein was predicted with 
the LocTree3 algorithm to produce a secreted peptide with a confidence score of 50 on a 0 to 
100 scale (Figure 4-25) (Goldberg et al., 2014). The localization of ORF1 to the extracellular 
compartment is in line with a predicted SignalP-4.1 signal peptide cleaved after amino acid 
number eighteen (Petersen et al., 2011). 
 
Figure 4-25 ORF1 shares identity with the extracellular protein C16orf89 
Pairwise sequence alignment created with Clustal Omega of ORF1 amino acid sequence (Appendix 7.4) 
with C16orf89 protein identified by LocTree. C16orf89 sequence was retrieved from UniProt with the 
accession number Q6UX73. Identical amino acid residues are highlighted in blue and below the 
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conservation plot is a key denoting conserved sequence (*) and conservative mutations (+). Also indicated 
is the consensus sequence.   
 
In summary, DLX6-AS1 T1 was predicted to encode for ORF1. ORF1 shares a high level of identity 
with numerous predicted proteins likely due to the presence of an Alu element. It remains 
therefore unclear whether ORF1 is biological relevant.  
4.5.2 DLX6-AS1 does not code for a protein in vitro  
Since coding potential for DLX6-AS1 T1 into ORF1 was predicted based on an in silico approach, 
it is probable but not certain. To ascertain whether ORF1 is translated and thus biologically 
relevant we complemented the in silico approach with experimental methods.   
A. DLX6-AS1 T1 variant is a cytoplasmic RNA  
RNA fractionation of VCaP, DU145 and HEK293T cells showed an enrichment of DLX6-AS1 
transcript T1 in the cytoplasmic compartment (mean=66, 51 and 43% in VCaP, DU145 and 
HEK293T, respectively), which is higher than for the sense protein-coding gene DLX6 (mean=48, 
49 and 39% cytoplasmic enrichment in VCaP, DU145 and HEK293T, respectively) in all analyzed 
cell lines (Figure 4-26). DLX6-AS1 transcript T2 is instead enriched in the nuclear compartment, 
particularly in DU145 (mean = 74%) and HEK293T (mean=74%) cell lines. This differential 
localization implies different biological roles for both transcripts and is in line with the potential 
existence of ORF1 protein encoded in DLX6-AS1 T1 variant.  
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Figure 4-26 DLX6-AS1 T1 transcript is enriched in the cytoplasmic fraction  
RNA fractionation of VCaP, DU145 and HEK293T cell lysates followed by RT-qPCR analysis of DLX6, DLX6-
AS1 T1 and T2 transcript variants. NEAT1 lncRNA and GAPDH1 transcripts served as a positive control for 
nuclear and cytoplasmic enrichment, respectively. Data are depicted as the mean +/- s.e.m., n= 3 
biological replicates for VCaP and HEK293T and n=2 biological replicates for DU145.  
B. DLX6-AS1 T1 binds to polysomes 
Since DLX6-AS1 T1 is enriched in the cytoplasm, we investigated by polysomal fractionation 
whether this lncRNA is associated with polysomes. In addition, we tested if this association is 
impaired through immobilization of initiating ribosomes at start codons with harringtonine, 
thereby depleting elongating ribosomes from coding RNAs. After polysome fractionation of 
H1299 cells into fourteen fractions treated with harringtonine or without (Control), we measured 
by RT-qPCR the relative enrichment of HPRT1, DLX6-AS1 T1 and T2 in the different fractions 
(Figure 4-27). In line with a nuclear role for DLX6-AS1 T2, this variant could not be detected in 
the monosomic nor polysomic fractions of H1299 cells. Inhibition of translation initiation by 
harringtonine causes the accumulation of HPRT1-bound 80S monosomes, while decreasing the 
fraction of HPRT1-bound polysomes due to polysome run-off. Concordant with a functional role 
for DLX6-AS1 T1 in the cytoplasmic compartment, analysis by RT-qPCR of all fractions 
demonstrates that DLX6-AS1 T1 RNA binds to polysomes (Figure 4-27). This would point toward 
the active translation of DLX6-AS1 T1 RNA. Treatment with harringtonine did however not shift 
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DLX6-AS1 T1 enrichment towards monosomic fractions such as observed for HPRT1 (Figure 4-
27). This result implies that DLX6-AS1 T1 variant binds to ribosomes without being translated.  
 
 
Figure 4-27 DLX6-AS1 T1 transcript is bound to polysomes but not translated  
Relative expression of HPRT1 or DLX6-AS1 T1 transcripts measured by RT-qPCR in all fourteen fractions 
obtained by polysomal fractionation of H1299 cells treated with DMSO only or supplemented with 
harringtonine. Data are depicted as n= 1. (Treated cells were provided by Dr. Michael Daskalakis and 
mono-/polysomal fractions were provided by Dr. Johanna Schott) 
 
A recent study demonstrated that a single 80S monosome is sufficient for the translation of ORFs 
smaller than 590 nt in Saccharomyces cerevisae (Heyer et al., 2016). Consistent with this, the 198 
nt encoding for ORF1 could be translated by a single monosome. The treatment with 
harringtonine would in consequence not impact the distribution of the translated transcript. We 
therefore employed in vitro translation as a direct approach to detect potential DLX6-AS1 
translation products.  
C. DLX6-AS1 T1 does not code for a protein  
To determine if DLX6-AS1 is translated as a small protein, we generated by PCR the full length 
cDNA for DLX6-AS1 T1, T2S and T2L transcripts (Appendix 7-3-cDNA sequences) flanked in 5’ with 
the T7 RNA polymerase promoter. Similarly, the mouse lncRNA 2310015B20Rik reported to 
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encode myoregulin (MLN), a 5kDa micropeptide (Anderson et al.,2015), along with a frameshift 
mutated version of MLN (MLN(FS)) were used as positive and negative controls, respectively. 
Both cDNA sequences were flanked by PCR with a T7 RNA polymerase promoter (Figure 4-28A). 
An equimolar amount of each PCR products was used for the coupled in vitro transcription and 
translation reaction using rabbit reticulocytes lysates in the presence of radiolabeled 14C-leucine. 
The positive control lncRNA encoding for MLN produced a 5kDa peptide visible by 
autoradiography, while the PCR product with a frameshift mutation (MLN(FS)) abolished the 
translation. Among the three DLX6-AS1 transcript variants, only a faint band was detected when 
we used DLX6-AS1 transcript T2S (Figure 4-28B). This result is unexpected, since T2S has no 
unique sequence not shared by T1 or T2L transcripts that could be translated into a peptide. The 
observed peptide is about 6 to7 kDa and does not match the size of the two predicted ORFs for 
the T2S variant (Figure 4-20B).  
 
Figure 4-28 DLX6-AS1 T1 transcript is non-coding  
(A) Gel electrophoresis picture of PCR products generated from MLN, MLN(FS), DLX6-AS1 T1, T2S and T2L 
cDNA flanked in 5’ with a T7 RNA polymerase promoter. (B) Coupled in vitro transcription and translation 
reactions of three DLX6-AS1 transcript variants. MLN and MLN with a frameshift mutation (MLN(FS)) 
transcripts served as positive and negative controls, respectively. 14C-leucine labelled peptides were 
resolved on a 16,8% Tris-Tricine gel and exposed for four weeks to X-ray film. Autoradiography picture is 
representative of three biological replicates. 
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Taken together, DLX6-AS1 T1 variant is enriched in the cytoplasm and can interact with the 
translation machinery but does not code for proteins in vitro. This implies that this variant might 
have regulatory functions of the translational process. In contrast, DLX6-AS1 T2 transcript is 
enriched in the nuclear fraction and is not bound to ribosome. The differential cellular localization 
of both variants might be related to their specific function.  
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5. DISCUSSION 
Increasing evidence supports the crucial role for lncRNAs in guiding or titrating away epigenetic 
modifiers to or from specific genomic loci. In this thesis, we employed an integrative approach to 
identify lncRNAs that mediate DNA (de)methylation of protein-coding gene promoters in cis in 
PCa (section 4.1). We identified the lncRNA DLX6-AS1 as being overexpressed and positively 
correlated with DLX6 expression in human tumor samples (section 4.2) and cancer cell lines 
(section 4.3), and investigated a correlation with clinical features in various human tumor 
entities. Modulation of DLX6-AS1 transcript levels by knockdown or overexpression in various cell 
lines did neither influence DLX6 transcription nor DLX6 promoter DNA methylation levels (section 
4.4). In line with our initial hypothesis, we expected a nuclear function for DLX6-AS1. However, 
the major variant of this lncRNA, DLX6-AS1 T1, is cytoplasmic, binds to polysomes, and does not 
encode for a protein (section 4.5). These results suggest that DLX6-AS1 T1 may have a regulatory 
role at the translational level.  
5.1 Identification of DLX6/DLX6-AS1 pair 
5.1.1 LncRNA screening strategy: a unique approach  
Our first goal was to identify lncRNAs that regulate close-by protein-coding genes through 
modulation of DNA methylation patterns in PCa on a genome-wide scale. For this purpose, we 
employed a unique strategy based on the integration of transcriptome and DNA methylation data 
from PCa patients (section 4.1).  
To date, only two studies have systematically identified lncRNAs as potential regulators of DNA 
(de)methylation patterns, through deep sequencing of lncRNAs that interact with DNMT1 (RIP-
seq) in HCT116 (Merry et al., 2015) and HL60 cell lines (Di Ruscio et al., 2013). Although this 
approach identified DNMT1-interacting lncRNAs, the technique has the disadvantage of being 
cell and protein-specific. Moreover, RIP-seq is based on immunoprecipitation, a technique likely 
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to detect non-specific RNA-proteins interactions, and therefore does not recapitulate the real in 
vivo interactome (Mili et al., 2004).  
Our strategy has the advantage of reflecting the true in vivo situation in human tissue through 
integration of high throughput data from PCa patients, without being limited to specific protein 
partners or cell lines.  
5.1.2 Main limitation: reference human transcriptome and filtering 
for bidirectional promoters 
The lncRNA transcriptome has been described to be highly tissue (Cabili et al., 2011) and cancer 
(Yan et al., 2015) type specific. GENCODE v17 annotations were used to both define 
mRNA/lncRNA pairs and map the RNA-seq data. This reference transcriptome includes only 
13,333 lncRNAs, compared to the 101,700 lncRNA genes annotated so far in the NONCODE 
database, collected by literature mining and from multiple databases including GENCODE (Zhao 
et al., 2016). GENCODE annotations therefore represent an incomplete reference long non-
coding transcriptome.  
 
Ideally, transcript reconstruction through ab initio assembly of RNA-seq reads would allow the 
study of the complete set of transcripts expressed in EO-PCa samples. This strategy has been 
employed by Chinnaiyan and colleagues and allowed the identification of 1,859 unannotated 
lincRNAs in late-onset PCa (Prensner et al., 2011). Nevertheless, the RNA-seq Genome 
Annotation Assessment Project consortium evaluated that transcript reconstruction methods 
achieve at best 60% accuracy, with the additional drawback of inaccurately defining TSS and TTS 
(Steijger et al., 2013). 
 
In addition, the current sequencing approach from the ICGC consortium restricted analysis to 
transcripts with a poly(A) tail, and therefore narrows the analysis to polyadenylated RNAs.  
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With these limitations, we identified nine mRNA/lncRNA pairs, but a screening approach based 
on an updated reference transcriptome would certainly increase the number of positive hits. 
Although it may be beneficial to use the Mitranscriptome assembly (Iyer et al., 2015), the fact 
that this transcript reconstruction has detected only 31% of RefSeq annotated splicing patterns 
may undermine the analysis (Zhao et al., 2016).  
 
It is also important to note that our search is biased for cis coding lncRNAs co-expressed with a 
neighbouring protein-coding gene. Therefore the data are enriched for potentially co-regulated 
sense/antisense pairs by a bidirectional promoter rather than regulating each other. For this 
reason we included the distance filter of 1,500bp between both TSSs, which is only valid in the 
case of a reliable and accurate reference genome. Nevertheless, there are known examples of 
lncRNAs regulating the mRNAs in cis while the distance of their TSS is shorter than 1,500bp (Di 
Ruscio et al., 2013). 
 
5.2 DLX6/DLX6-AS1 pair is overexpressed in several cancers 
5.2.1 Interdependency between DLX6/DLX6-AS1 and TMPRSS2:ERG 
fusion in PCa 
With the aforementioned screening approach we identified the DLX6/DLX6-AS1 pair as a 
candidate for further clinical and functional characterization. We revealed that DLX6 and DLX6-
AS1 transcripts are overexpressed in a subset of PCa samples and expression levels positively 
correlate in two independent PCa datasets. Elevated DLX6 levels were accompanied by loss of 
DNA methylation in DLX6 promoter region in both early-onset and late-onset PCa patients. In line 
with this result, DLX6-AS1 expression levels were not correlated with the age at diagnosis of 
patients, their pathological tumor T-stage, and Gleason score. In contrast, patients with tumors 
harbouring the TMPRSS2:ERG fusion gene were highly and significantly enriched in the subset of 
patients characterized by high DLX6-AS1 levels.  
ICGC and TCGA cohorts were divided into “LOW” and “HIGH” expression subgroups based on 
DLX6-AS1 median expression, and were associated with differential methylation levels in the 
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DLX6 promoter region (Figure 4-5). A similar result can be obtained by separating the cohort 
based on the presence of the TMPRSS2:ERG fusion-gene (Appendix Figure 7-3 and 7-4). Indeed, 
DLX6/DLX6-AS1 transcripts are overexpressed (Appendix Figure 7-3) and DLX6 promoter is 
hypomethylated in patients expressing the ERG fusion gene (ERG+) compared to fusion-negative 
(ERG-) patients (Appendix Figure 7-4). This result is in line with the global increase in DNA 
methylation as previously reported in ERG- patients (Borno et al., 2012). Additionally, preliminary 
analyses indicate that the expression levels of DLX6 and DLX6-AS1 correlate significantly with ERG 
mRNA expression in the PCa cohorts from ICGC and TCGA (Pearson’s correlation with DLX6-AS1 
r=0,7131, p-value<0.0001 and with DLX6 r=0,7586, p-value<0,0001) (Appendix Figure 7-5). The 
positive correlation between ERG, DLX6 and DLX6-AS1 and low DNA methylation levels in ERG+ 
samples suggests that the expression of these three genes is linked by a common mechanism.  
 
Preliminary results suggest that neither DLX6 nor DLX6-AS1 are regulated by ERG after 
overexpression of this gene in TMPRSS2:ERG fusion-negative LNCaP cells (Appendix Figure 7-6A). 
In contrast, DLX6 knockdown induced a significant reduction of ERG transcript levels in the 
TMPRSS2:ERG fusion-positive VCaP cells (Appendix Figure 7-6C). The promoter of the androgen 
regulated TMPRSS2 gene is fused to ERG coding sequence in TMPRSS2:ERG fusion positive 
patients. This rearrangement leads to an androgen-dependent increase in ERG expression 
(Kumar-Sinha et al., 2008). Downregulation of AR mRNA expression after DLX6 silencing 
(Appendix Figure 7-6C) suggests that DLX6 regulates ERG expression by modulating AR 
transcriptional regulation. The specific effect of DLX6 on ERG and AR signalling remains however 
to be evaluated by luciferase reporter assays with constructs comprising the androgen receptor 
promoter upstream of a reporter gene in wild-type or DLX6 knockdown VCaP cell lines. These 
experiments could answer the question whether DLX6 overexpression may facilitate ERG 
activation.  
 
In addition to TMPRSS2:ERG fusion, elevated DLX6-AS1 levels are correlated with the presence 
of 3p13 deletions in PCa (Table 4-3). The concomitant rearrangement of these two chromosomal 
loci was previously associated with an aggressive subset of PCa tumors characterized with early 
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tumor recurrence (Krohn et al., 2013). In our set of samples, higher DLX6-AS1 expression levels 
were in contrast, not linked to adverse clinicopathological parameters including pathological 
stage, Gleason score, overall and disease-free survival (Table 4-3 and Figure 4-8). The discrepancy 
is most likely due to the prevalence of ERG+ tumors (89.5%) in the “HIGH” expression subgroup 
(Table 4-3). Indeed, the clinical impact associated with the presence of this fusion gene is subject 
to controversy, but is mostly unrelated to disease-specific death and disease recurrence in a 
meta-analysis including 11,092 men in 30 studies (reviewed in (Xu et al., 2014)). 
 
5.2.2 DLX6/DLX6-AS1 overexpression is not restricted to PCa 
Differential expression analysis between tumor and normal tissues conducted by the TCGA 
consortium identified DLX6-AS1 as being upregulated in all analysed cancer types with the 
exception of breast carcinoma (Yan et al., 2015). We could confirm the overexpression of the 
lncRNA and its correlation to DLX6 levels in PRAD, LUSC, HNSC, COAD, LUAD, and KIRC (Figure 4-
7A).  
The approach used by the TCGA however, fails to identify overexpressed genes in a subset of 
patients, as exemplified by DLX6/DLX6-AS1 upregulation in a restricted number of breast 
carcinoma tissue samples from the TCGA (Appendix Figure 7-7). A search for outlier samples such 
as with the COPA (cancer outlier profile analysis) algorithm (Wang et al., 2012), would allow the 
exhaustive identification of tumors characterized by DLX6-AS1 overexpression.  
 
We also showed that DLX6 expression is inversely correlated with DLX6 promoter DNA 
methylation levels in all studied cancer types with the exception of KIRC and subsets of samples 
in COAD and LUAD cohorts (Figure 4-7B). DLX6 expression is therefore dependent on DNA 
methylation in the majority of tumors. It apparently depends on alternative regulatory 
mechanisms in KIRC and the subset of samples in LUAD and COAD cohorts, such as copy number 
changes or altered expression of potential microRNA or transcription factors. To identify the 
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regulatory mechanism in these samples, expression levels could be integrated with whole 
genome sequencing data, or differentially expressed transcription factors could be investigated.  
 
5.2.3 DLX6/DLX6-AS1 expression influences patient prognosis 
The common upregulation of this sense/antisense pair in at least six cancer types suggests that 
they hold a conserved function in cancer initiation and/or progression. In line with a role for 
DLX6/DLX6-AS1 in carcinogenesis, elevated DLX6 expression was reported to be linked to 
increased invasive potential in bone and lung metastatic cells derived from a breast cancer 
xenograft model with MDA-MB-231 cells (Morini et al., 2010). In addition, we showed that 
elevated levels of the DLX6-AS1/DLX6 pair could predict patient’s prognosis in LUSC, KIRC and 
LUAD. Indeed, high DLX6-AS1 expression was associated with favourable survival in LUSC and 
KIRC, whereas elevated DLX6 levels were linked to bad prognosis in LUAD (Figure 4-8A). Similarly, 
high expression levels of the lncRNA in neuroblastoma tissue were reported to be associated with 
bad overall survival (Olsson et al., 2016). The dual behaviour of DLX6-AS1 on patient’s prognosis 
seems to be dependent on the tissue type. Variations in the type of transcript variant being 
expressed and genetic aberrations affecting either the lncRNA or components crucial for its 
function are inherent to a specific tumor type. The presence of such aberrations may alter the 
function of the lncRNA and in consequence influence patient prognosis.  
5.3 Functional role of DLX6-AS1 overexpression in cancer 
5.3.1 DLX6-AS1 (Evf2) regulates DLX5/6 transcription in mouse 
Although DLX6/DLX6-AS1 upregulation seems to play an important role during carcinogenesis; 
nonetheless, the nature of its function in cancer etiology is largely unexplored. The role of 
DLX6/DLX6-AS1 in normal development is, on the other hand, better understood. Homozygous 
deletion of the locus comprising DLX5, DLX6 and Evf2 (mouse homologue of DLX6-AS1 also known 
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as Dlx6os1) is associated with craniofacial and skeletal abnormalities in mouse embryo, leading 
to perinatal lethality (Robledo et al., 2002). 
 
Transcriptional arrest of Evf2 through knock-in of a polyA termination signal downstream of the 
Evf2 TSS results in viable and fertile mice, but is coupled with a drastic reduction of the GABAergic 
interneurons in the forebrain, suggesting a role for this lncRNA in brain development (Bond et 
al.,2009). Detailed analysis of the Evf2 mutant mouse forebrain at embryonic day 13.5 revealed 
an increased expression of DLX6 and DLX5 transcripts in response to Evf2 transcriptional 
repression (Bond et al., 2009). In addition, Evf2 repression was associated with increased DNA 
methylation levels at two CpG sites located within or near DLX5/-6 enhancer (named ei enhancer) 
(Berghoff et al., 2013). Rescue of the Evf2 mutant phenotype through expression of the lncRNA 
in trans, recapitulated DLX5 transcript (Bond et al., 2009) and enhancer DNA methylation levels 
(Berghoff et al.,2013), while DLX6 expression remained unchanged (Bond et al., 2009). Therefore, 
the authors suggested that Evf2 regulates DLX6 in cis by the simple act of transcription, whereas 
DLX5 and DNA methylation is regulated by Evf2 RNA product in trans (Bond et al., 2009, Berghoff 
et al., 2013).  
5.3.2 DLX6-AS1 does not regulate DLX5/6 transcription and DLX6 
promoter methylation in human cell lines  
In contrast to Evf2, manipulation of DLX6-AS1 expression did not affect local transcription and 
DNA methylation levels. To study the impact of DLX6-AS1 in trans, we employed shRNAs, siRNAs, 
LNAs and RNA transfections. We demonstrated that all the different strategies did neither affect 
DLX6 (Figure 4-16 and 4-18) nor DLX5 transcript levels (Appendix – Figure 7-8). In addition, DNA 
methylation levels of the differentially methylated DLX6 promoter (Figure 4-17 and 4-19) as well 
the ei enhancer region (Appendix - Figure 7-9) remained unchanged. However, Kohtz and 
colleagues supported a model where Evf2 can act through trans and cis mechanisms (Bond et al., 
2009, Berghoff et al., 2013). To interrogate the cis regulatory mode of action of DLX6-AS1, 
alteration of the lncRNA transcription rather than solely modulating its RNA levels is required. 
Genomic engineering tools can allow insertion of transcriptional terminator sequences or 
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deletion of the entire lncRNA loci by TALE nucleases (transcription activator-like effector) (Boch 
et al., 2009) or the CRISPR clustered regularly interspersed palindromic repeats)/Cas9 (CRISPR-
associated protein 9) systems (Jinek et al., 2012). Alternatively, an endonuclease-deficient Cas9 
can allow the recruitment of transcriptional activators or repressors to defined loci (Gilbert et al., 
2013, Cheng et al., 2013). These techniques are, however, not suited for the study of DLX6-AS1 
since its promoter proximal region intersects with DLX6. Insertion of exogenous sequences as 
well as the targeting of programmable nucleases to DLX6-AS1 TSS would inevitably perturb DLX6 
transcription (Goyal et al., 2016).  
Although we were hampered by the complexity of the genomic locus to study the in cis effect of 
DLX6-AS1 on DLX6, all evidence currently point towards the co-regulation of both transcripts. 
Indeed, 5'RACE demonstrated that DLX6-AS1 TSS is localized within the first intron of DLX6 
(Figure 4-10). Consequently, the region that separates the transcription start sites of both sense 
and antisense transcripts is small enough to be defined as a bidirectional promoter (TSS distance 
811nt). This assumption is supported by the positive correlation between DLX6 and DLX6-AS1 as 
well as a single RNA polymerase II peak in VCaP compared to LNCaP cells around the DLX6 
promoter (Figure 4-15). The existence of a bidirectional promoter could be confirmed through 
probing the promoter activity by luciferase assay of the fragment separating both TSSs in sense 
and antisense direction.  
5.3.3 Alternative transcripts, alternative functions  
Alignments of CAGE-seq data obtained from 975 human and 399 mouse tissues, primary cells, 
and cell lines, revealed that only 57% of human TSSs are conserved in the mouse genome 
(Consortium et al., 2014). In line with this result, only the second exon of Evf2, which correspond 
to the region overlapping with ei enhancer, is conserved between human, mouse, rat, zebrafish, 
and chicken (Feng et al., 2006). Serial deletion of Evf2 transcript revealed that the region 
including the second exon (nucleotide 117 to 395) is essential for DLX5/-6 ei enhancer activation 
(Feng et al., 2006).  
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Through the in silico screening approach (section 4.1.1) we identified the human DLX6-AS1 
transcript ENST00000430027.3. Experimental investigation of the dominant DLX6-AS1 transcript 
expressed in PCa tissue and in immortalized cell lines revealed, however, two DLX6-AS1 splice 
variants T1 and T2, generated by alternate usage of the second exon. DLX6-AS1 T1 and T2 differ 
from ENST0000430027.3 and Evf2 mouse transcript by an alternative TSS, and consequently first 
exon. Indeed, Evf2 is transcribed across the ei enhancer element located between DLX6 and 
DLX5, while DLX6-AS1 T1/T2 TSSs overlap with the DLX6 first exon. In consequence, DLX6-AS1 
T1/T2 transcript variants do not contain the evolutionary conserved and functional second exon 
of Evf2 associated with ei enhancer activation and gene repression.  
The structural difference between Evf2 and DLX6-AS1 might underlie their contrasting result on 
neighbouring gene regulation. Alternative TSS usage might produce transcripts with different 
functional roles. For example in human cells, PTENpg1as, a pseudogene-derived antisense 
transcript, is alternatively transcribed into α and β variants harbouring distinct functions. 
PTENpg1as α was shown to operate in trans by recruiting PRC2 and DNMT3 to repress PTEN 
promoter. Conversely, the variant β duplexes with PTENpg1 sense transcript thanks to their 
overlapping and complementary sequences. The formation of this RNA-RNA duplex enables 
PTENpg1 to exert its function as a microRNA sponge by ensuring its stability (Johnsson et al., 
2013).  
5.3.4 Does DLX6-AS1 function by enhancing DLX6 translation? 
The formation of an RNA-RNA duplex is a common phenomenon among mRNA/lncRNA pairs, 
such as UCHL1 (ubiquitin carboxyl-terminal hydrolase L1)/AS UCHL1 (antisense UCHL1) in mice 
(Carrieri et al., 2012) and PPP1R12A (protein phosphatase 1 regulatory subunit 12A)/ R12A-AS1 
in humans (Schein et al., 2016). These lncRNAs are, similar to DLX6-AS1, co-regulated and share 
an overlapping region with their anti-sense protein-coding gene. Through heterodimer formation 
with their respective mRNA, UCHL1-AS and R12A-AS1 lncRNAs stimulate the protein synthesis of 
their sense counterpart without affecting their mRNA levels (Carrieri et al., 2012; Schein et al., 
2016). Protein synthesis activation is dependent on the presence of a SINE B2 or Alu element 
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embedded within the non-overlapping region of UCHL1-AS (Carrieri et al., 2012) or R12-AS1 
(Schein et al., 2016), respectively. Similar RNA features could be found in 31 additional mouse 
(Carrieri et al., 2012) and 129 human (Schein et al., 2016) antisense lncRNAs, termed the SINEUPs 
(SINE element-containing translation UP-regulators) family. Design of synthetic SINEUPs that 
comprise of an effector and a binding domain targeting an mRNA of interest was shown to 
successfully enhance translation of the target (Carrieri et al., 2012) (Zucchelli et al., 2015).  
 
Similarly to UCHL1-AS and R12A-AS1, DLX6-AS1 depletion did not affect DLX6 mRNA levels (Figure 
4-16), while DLX6 protein levels could not be examined due to the limited specificity of available 
antibodies raised against DLX6 protein.  
 
In contrast to DLX6-AS1 T2, the T1 variant comprises the two essential SINEUPs RNA features. 
Indeed, both DLX6-AS1 splice variants share a 55-nucleotide overlapping region with the first 
exon of DLX6, while only the second exon of the T1 variant embeds an AlusZ repeat. Dimerization 
of both transcripts would explain the enrichment of the DLX6-AS1 transcript T1 in the cytoplasmic 
compartment (Figure 4-26), where this variant could influence DLX6 translation. This in turn 
might explain polysomes binding of DLX6-AS1 T1 lncRNA, although DLX6-AS1 T1 is non-coding. 
The absence of ribosome binding of the nuclear DLX6-AS1 T2 transcript allows rule out a role for 
this RNA on translation regulation. With the help of the overlapping region shared with DLX6 
RNA, DLX6-AS1 T2 could, similar to PTENpg1as β, ensure the stability of its partner by escaping 
ribonuclease, or miRNA-mediated degradation. 
 
All together, we envision that DLX6-AS1 T1 does not regulate DLX6 at the RNA level, but so far, 
we do not exclude a role in post-transcriptional regulation. Concomitant expression of DLX6 and 
DLX6-AS1 T1 RNAs could favour their dimerization and subsequent DLX6 translational regulation.  
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5.3.5 Does DLX6-AS1 function in trans? 
Based on the co-expression pattern of DLX6 and DLX6-AS1 RNAs we suggested in this study that 
both transcripts serve a common and complementary function. We therefore focused our 
attention on the cis and local action of the lncRNA on its sense protein counterpart. The majority 
of lncRNAs were, however shown to exert their function on more distant genomic locations 
(Guttman et al., 2011).  
 
DLX6-AS1 T2 could act in cis by stabilizing DLX6 through heterodimer formation. But the 
regulation of more distant loci through, for instance, recruitment of chromatin modifiers cannot 
be excluded. In turn, the presence of an Alu element within T1 RNA sequence points towards the 
regulation of genes other than DLX6 by alternative mechanisms. Indeed, Alu elements within 
cytoplasmic lncRNAs can duplex with complementary Alu elements located within the 3’-
untranslated region of an mRNA. The double-stranded RNA binding protein STAU1 (Staufen 1) 
recognizes and binds to the formed duplex before initiating mRNA decay (Gong et al., 2011). 
Alternatively, Alu/Alu paring between 5S-OT (5S rRNA overlapped transcript) lncRNA and a subset 
of mRNAs was recently reported to create a binding site for splicing factors. The formation of 
such heteroduplexes was shown to regulate the splicing of the respective mRNA partner in trans 
(Hu et al., 2016). This mechanism was, however, shown to be restricted to the nuclear 
compartment, and could therefore only involve DLX6-AS1 T1 before its export to the cytoplasm. 
 
Differences in the RNA sequence and localization seems to underlie a different functional role for 
the two DLX6-AS1 variants. Based on their respective features, both RNAs may work in cis or trans 
by involving different regulatory pathways. To infer the function of each transcript variant we 
could envision identifying the protein partners of biotin labelled DLX6-AS1 T1 or T2 variants by 
mass spectroscopy (Feng et al., 2014). Alternatively, a bioinformatics approach termed guilt-by-
association employs transcriptome data to infer genes and pathways co-expressed with a given 
lncRNA. Based on the known function of the coregulated protein-coding genes this method 
allows to infer the function of a lncRNA (Guttman et al., 2009). This strategy could be employed 
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on the RNA-sequencing datasets employed in this study to infer the function of DLX6-AS1 and 
potential genes regulated by this lncRNA.  Nevertheless, to distinguish the function of both splice 
variants such approach should be applied to RNA-seq data generated after modulation of the 
expression of a single variant.  
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6. CONCLUSION AND FUTURE ASPECTS  
Our initial goal was to i) identify lncRNAs that potentially regulate a close-by protein-coding gene 
by DNA (de)methylation mechanism in PCa and ii) unravel the regulatory mechanism of action of 
the most promising lncRNA candidate.  
Through an in silico screening approach, we identified the DLX6/DLX6-AS1 pair. We showed that 
the expression of both RNA species is correlated and that the DLX6 promoter is differentially 
methylated in tumor compared to normal tissue in two independent prostate cancer datasets. 
DLX6/DLX6-AS1 overexpression and differential DLX6 promoter methylation is a common 
phenomenon in cancer, and predicts good or bad patient prognosis in function of the tumor type. 
The overexpression of both transcripts in PCa correlates with the presence of TMPRSS2:ERG 
fusion gene, and preliminary results suggest that DLX6 modulates ERG levels by influencing 
androgen receptor signaling.  
Under certain environmental conditions our genome creates multiple versions of a gene 
transcript through the process of alternative splicing. The mouse homologue of DLX6-AS1 (Evf2) 
was shown to regulate DLX6 and DLX5 expression by influencing ei enhancer DNA methylation in 
the developing mouse brain. Through alternative transcriptional start site usage, DLX6-AS1 T1 
and T2 variants are expressed in human cancerous cells. In contrast with Evf2, the human DLX6-
AS1 splice variants do not regulate DLX6 or DLX5 transcription by mediating local DNA 
methylation changes. The proximity of the coding and non-coding transcript start sites in 
humans, suggests however, a coordinated regulation of DLX6/DLX6-AS1 expression through 
differential methylation of their common promoter.  
The exclusion of the exon overlapping with ei enhancer in human DLX6-AS1 and the inclusion of 
an Alu element in the T1 variant, participated in the diversification of the lncRNA biological 
function. This is supported by the differential cellular localization and ribosome binding of DLX6-
AS1 transcript variants. Based on their respective features, both RNAs may work in cis or trans by 
involving different regulatory pathways. To infer the function of each transcript variant we could 
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envision the direct identification of DLX6-AS1 T1 and T2 protein partners by mass spectrometry 
or infer the function of the lncRNA through the guilt by association approach.  
In PCa we showed that T1 and T2 are overexpressed, where T1 transcript predominated. 
Differences in patient’s prognosis in LUAD and LUSC might reflect the expression of different 
splice variants or the disruption of the balance between T1 and T2 transcripts. Detailed 
investigation of the splice variants expressed in LUAD and LUSC based on TCGA raw RNA-seq data 
could reveal which transcript is expressed and linked to favourable and worse patient’s 
prognosis.  
 
 
 
 
APPENDIX 
 
115 
 
7. APPENDIX  
7.1 Oligonucleotide sequences  
Table 7-1 shRNA template oligonucleotides 
Table 7-2 siRNA and LNA sequences 
Name Primer Sequence 5’-3’ Target 
DLX6 
sh#2 
FORWARD ACCGGGCTTCCTTAGGATTGACATAAGTTAATATTCATAGCTTGTGTCAGTCCT
AAGGAAGCTTTT 
DLX6 
SECOND 
EXON 
REVERSE CGAAAAAAGCTTCCTTAGGACTGACACAAGCTATGAATATTAACTTATGTCAA
TCCTAAGGAAGCC 
DLX6 
sh#6 
FORWARD ACCGAAGAATCTGCACAAACTTGGCGTTAATATTCATAGCGCCAAGTTTGTGC
AGATTCTTTTTT 
DLX6 3’UTR 
REVERSE CGAAAAAAAAGAATCTGCACAAACTTGGCGCTATGAATATTAACGCCAAGTTT
GTGCAGATTCTT 
AS 
sh#4 
FORWARD ACCGGGGTCAGATTAAACACAAAGTTAATATTCATAGCTTTGTGTTTAATCTG
ACCCTTTT DLX6-AS1 
THIRD EXON REVERSE CGAAAAAAGGGTCAGATTAAACACAAAGCTATGAATATTAACTTTGTGTTTAA
TCTGACCC 
AS 
sh#5 
FORWARD ACCGGGGTTGGAAGTAATGATTTGGTTAATATTCATAGCCAAATCATTACTTC
CAACCCTTTT DLX6-AS1 
THIRD EXON REVERSE CGAAAAAAGGGTTGGAAGTAATGATTTGGCTATGAATATTAACCAAATCATT
ACTTCCAACCC 
LUC5 FORWARD ACCGGATCACAGAATCGTCGTATGTAGTTAATATTCATAGCTGCATACGACGA
TTCTGTGATTTTT 
N/A 
REVERSE CGAAAAAAATCACAGAATCGTCGTATGCAGCTATGAATATTAACTACATACGA
CGATTCTGTGATC 
ID 
RNA 
target 
Name Sequence 5’-3’ Manufacturer 
si NT1 none Lincode Non-targeting siRNA #1 
5nmol 
UGGUUUACAUGUCGACUAA GE Dharmacon 
si NT2 none Lincode Non-targeting siRNA #2 
5nmol 
UGGUUUACAUGUUGUGUGA GE Dharmacon 
AS si #1 DLX6-
AS1 
Lincode Human DLX6-AS1 siRNA  GCUCACUCAACCAAGAAUA GE Dharmacon 
AS si #2 DLX6-
AS1 
Lincode Human DLX6-AS1 siRNA  GCUAGAUUGUUUAUGACCA GE Dharmacon 
AS si #3 DLX6-
AS1 
Lincode Human DLX6-AS1 siRNA  ACAUGUCAAUAGUAGGCUA GE Dharmacon 
AS si #4 DLX6-
AS1 
Lincode Human DLX6-AS1 siRNA  GCGUAGGAGCUUCAAAAUU GE Dharmacon 
si NT none ON-TARGETplus Non-Targeting pool UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
GE Dharmacon 
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Table 7-3 Primers used for RT-qPCR analysis 
cDNA Target Forward primer (5’-3’) Reverse primer (5’-3’) 
UPL 
probe 
DLX6 CATGCCTGGCTATTCTCACTG ACGTTTCCCTAGGGTGTTCC 55 
DLX6-AS1_T1 TGATTCCTGTATGTATGGCAGCTA GGTTTTCCTTTGTCTCAGCAAT 63 
DLX6-AS1_T2 TGCTGTTGTGGTAGGACTGG TGGGAAGAATTACAGGAAAAGG 25 
HPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 73 
ALAS1 CAGTAATGACTACCTAGGAATGAGTCG CCATGTTGTTTCAAAGTGTCCA 43 
SDHA TCCACTACATGACGGAGCAG TCCACTACATGACGGAGCAG 70 
ERG AACGAGCGCAGAGTTATCGT CGTCTGGAAGGCCATATTCT 19 
Rabbit  
β-globin 
GAAGGCTCATGGCAAGAAGG ATGATGAGACAGCACAATAACCAG 
N/A 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 60 
NEAT1 AGGCCTGGTCTTGTGGAAC AGCGCCAAACCTAGAGAAAA 87 
Table 7-4 Primers used for the 5’RACE assay 
Primer 
Name 
Primer Sequence (5’-3’) 
GSP1 TAGCTGCCATACATACAGGAATCA 
GSP2 CCTTTTGGTCTATCTGCATGG 
GSP3 CCAAGGATTTCCCTTTCCAT 
Q0 CCAGTGAGCAGAGTGACG 
Q1 GAGGACTCGAGCTCAAGC 
QT CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT 
 
 
 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
si DLX6 
#pool 
DLX6 ON-TARGET plus Human DLX6 siRNA  CGAACUGGCAGCUUCCUUA 
GGAAAUCAGGUUCAAUGGA 
UACGAUGGCUGACGGCUUG 
GGACGACACAGAUCAACAA 
GE Dharmacon 
 
LNA #2 DLX6-
AS1  
LNA™ longRNA GapmerR, in vitro 
standard, 5 nmol 
GTGAATGCATGAGAGT Exiqon 
LNA #4 DLX6-
AS1  
LNA™ longRNA GapmerR, in vitro 
standard, 5 nmol 
ACTTTACTAGCCTCAT Exiqon 
Negative 
Control A 
none LNA™ longRNA GapmerR, negative 
control A, in vitro standard, 5 nmol 
AACACGTCTATACGC Exiqon 
APPENDIX 
 
117 
 
Table 7-5 Primers used for PCR amplification of bisulfite treated DNA 
ID 
Target 
region 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Amplicon 
coordinates 
(hg19) 
DLX6  
Region 1 
DLX6 
promoter 
AGGAAGAGAGGTGTAGTAGGATTA
GAGTGGTAG 
CAGTAATACGACTCACTATAGG
GAGAAGGCTCTTTCCCCCCTTA
AATTTTTTAAAAAC 
chr7 :97005141
-97005668 
DLX6  
Region 2 
DLX6  
promoter 
AGGAAGAGAGTTGTTGTTGTGGTA
GGATTGGAGGTAAGGGTT 
CAGTAATACGACTCACTATAGG
GAGAAGGCTACCCCCAAAATTT
TTAATAATAACC 
chr7 :97005961
-97006381 
DLX6  
Region 3 
DLX6  
promoter 
AGGAAGAGAGGTTTTTATTTTTAGT
TTTATTATAATAGTAG 
CAGTAATACGACTCACTATAGG
GAGAAGGCTCAAAATAAACCA
CTACCTACCCAA 
chr7 :97006350
-97006850 
DLX6  
Region 4 
DLX6 
promoter 
AGGAAGAGAGTTGGGTAGGTAGTG
GTTTATTTTG 
CAGTAATACGACTCACTATAGG
GAGAAGGCTCAAAACACAACC
AACAACTC 
chr7 :97006826
-97007139 
DLX6  
Region 5 
Enhancer 
ei 
AGGAAGAGAGTTTTTTATTGTGAAA
TTTTGGGTT 
CAGTAATACGACTCACTATAGG
GAGAAGGCTAACAAAACCCCA
CTACCAACTATAC 
chr7 :96641276
-96641698 
DLX6  
Region 6 
 
Enhancer 
ei + 
extension 
AGGAAGAGAGTGGAAGAGGTTGTA
GAAGTATAGTTGG 
CAGTAATACGACTCACTATAGG
GAGAAGGCTACCCTTAAAATTC
AAAAAATCCAAA 
chr7 :96641661
-96641987 
DLX6  
Region 7 
Extension 
enhancer 
ei 
AGGAAGAGAGGGTTAATATTTTTAT
TTTTTAGAATG 
CAGTAATACGACTCACTATAGG
GAGAAGGCTCTATAAATAACTC
TATTTCCTAAC 
chr7 :96641985
-96642432 
In blue is highlighted the T7 RNA polymerase promoter, in green additional nucleotides as a mass tag and 
in black the sequence complementary to the target DNA.  
Table 7-6 Primers used for DLX6-AS1 and MLN cDNA cloning and PCR amplification 
Target cDNA Primer Primer Name Primer Sequence (5’-3’) 
DLX6-AS1 T1 
FORWARD DLX6AS1_T1/T2_F1_T7_MluI 
CCGACGCGTTAATACGACTCACTATAGGGG
GCGGGAGAAGCGAGCTG 
REVERSE DLX6AS1_T1_R1_T7_HindIII 
CCCAAGCTTTACATTCAACCTGGATTCAAAG
ATGTC 
DLX6-AS1 T2L 
FORWARD DLX6AS1_T1/T2_F1_T7_MluI 
CCGACGCGTTAATACGACTCACTATAGGGG
GCGGGAGAAGCGAGCTG 
REVERSE DLX6AS1_T2_R3_T7_HindIII 
CCCAAGCTTTTGTTCAATCTTTATTAGAGGA
AAGG 
DLX6-AS1 T2S 
FORWARD DLX6AS1_T1/T2_F1_T7_MluI 
CCGACGCGTTAATACGACTCACTATAGGGG
GCGGGAGAAGCGAGCTG 
REVERSE DLX6AS1_T1_R1_T7_HindIII 
CCCAAGCTTTACATTCAACCTGGATTCA
AAGATGTC 
2310015B20RiK 
FORWARD 2310015B20RiK_T7_F 
GCTGAAATTAATACGACTCACTATAGGGGA
GCTTTTCGTCCATGGAGA 
REVERSE 2310015B20RiK_R TCAGATTAAAATGTAGATCTTTATTTGC 
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In blue is highlighted the T7 RNA polymerase promoter, in violet the respective restriction sites for MluI 
or HindIII and in bold are the additional nucleotides allowing not only restriction digest close to the end 
of the PCR product, but ensures as well efficient transcription.  
Table 7-7 Primers used for Sanger sequencing 
Target Primer Sequence (5’-3’) 
pRS CAAGGCTGTTAGAGAGATAATTG 
M13 CAGGAAACAGCTATGACC 
T7 TAATACGACTCACTATAGGG 
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7.2 Supplementary results 
7.2.1 Supplementary figures  
 
Figure 7-1 Coordinated upregulation of DLX6 and DLX6-AS1 in ICGC EO-PCA cohort   
(A) DLX6 and DLX6-AS1 RNA expression levels measured by RNA sequencing in all tumors as well as 
separated into LOW and HIGH tumor subgroups compared to normal tissue (NORMAL=10 ,LOW=46 and 
HIGH=45) from ICGC EO-PCa cohort. Patients were divided into “LOW” and “HIGH” expression groups 
relative to the median expression value of DLX6-AS1. Mann-Whitney U test **** =p<0.0001, **=p<0.01. 
(B) Corresponding Spearman correlation plot of DLX6-AS1 and DLX6 expression measured by RNA 
sequencing in the ICGC EO-PCa cohort.  
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Figure 7-2 DLX6-AS1 ORF2 is not conserved in primates  
Multiple sequence alignment created with Mafft version 7 of ORF2 homologs predicted by ORFinder 
(NCBI) in DLX6-AS1 T2L homologs found by nucleotide BLAST (NCBI) from seven primate species. All the 
cDNA sequences were retrieved from Genbank with the following accession numbers; Pan troglodytes 
(LOC104007329), Pongo abelii (LOC103891166), Nomascus leucogenys (LOC100579968), Rhynopithecus 
roxellana (LOC104662289), Colobus angolensis (LOC105512765) and Mandrillus leucophaeus 
(LOC105535579). Sequence identity across the seven species is indicated in dark blue and the number of 
sequences with identical amino acids residues are indicated in the conservation plot.   
 
 
Figure 7-3 DLX6/DLX6-AS1 pair is overexpressed in ERG fusion-positive PCa  
DLX6 (A) and DLX6-AS1 (B) RNA expression levels measured by RNA sequencing in ERG- tumors compared 
to ERG+ tumors from ICGC EO-PCa (ERG-=18, ERG+=23) and TCGA (ERG-=21, ERG+=22) cohort. Mann-
Whitney U test (ICGC) or Wilcoxon signed-rank (TCGA) tests were used to calculate statistical significances 
between each group.  ****p<0.0001, ***p<0.001.  
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Figure 7-4 Hypomethylation of DLX6 promoter in ERG fusion-positive PCa 
(A) Representation of HumanMethylation450 beadchip probes and Mass-Array amplicons overlapping 
with DLX6 promoter region and CGIs. (B and C) DNA methylation levels are displayed on the y-axis as a 
percentage ranging from 0% to 100%. Each point represents mean methylation levels of single CpG sites 
in TMPRSS2:ERG positive (ERG+) and negative (ERG-) tumor samples from the (B) ICGC or (C) the TCGA 
cohort. (B) Mann-Whitney U test or (C) Wilcoxon signed-rank test were used to calculate statistical 
significances between each group by comparing the mean DNA methylation levels across the eight CpG 
sites highlighted in light blue.  ****p<0.0001, ***p<0.001.  
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Figure 7-5 Coordinated upregulation of DLX6/DLX6-AS1 with ERG  
Spearman correlation plots between ERG and DLX6-AS1 or DLX6 expression measured by RNA sequencing 
in the ICGC cohort of EO-PCa patients (normal= 10 and tumor= 91).  
 
Figure 7-6 Downregulation of DLX6 leads to ERG downregulation  
 
 
Relative expression levels of DLX6-AS1 T1 and T2, DLX6, ERG and AR after knockdown of (A) ERG, (B) DLX6-
AS1 (AS) or (C) DLX6 in fusion-positive VCaP cells. Data are depicted as the mean +/- s.e.m., n= 2 for (A) 
and mean +/- s.e.m., n=3 for (B) and (C) biological replicates.  
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Figure 7-7 DLX6/DLX6-AS1 expression in breast carcinoma   
DLX6-AS1 (A) and DLX6 (B) RNA expression levels measured by RNA sequencing in tumors compared to 
matched normal tissue (NORMAL=111 TUMOR=111) from TCGA breast carcinoma cohort. Wilcoxon 
signed-rank test ****p<0.0001, *p<0.05. 
 
 
Figure 7-8 Downregulation of DLX6-AS1 does not impact DLX5 RNA levels  
Relative expression levels of DLX6-AS1 and DLX5 after knockdown of DLX6-AS1 (AS) in fusion-positive VCaP 
cells. Data are depicted as the mean +/- s.e.m., n= 2 biological replicates. We detected no statistically 
significant differences between the control group and each knockdown experiment using two-tailed 
unpaired t-test. 
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Figure 7-9 DLX6-AS1 or DLX6 downregulation does not impact ei enhancer DNA methylation 
(A) Representation of Mass-Array amplicons overlapping with the conserved ei enhancer region and its 
extension. (B and C) DNA methylation levels are displayed on the y-axis as a percentage ranging from 50% 
to 100%. Each point represents mean methylation levels of single CpG sites in VCaP cells after knockdown 
of DLX6-AS1 (B) or DLX6 (C) for 8 days. Data are depicted as the mean +/- s.e.m., n= 3 biological replicates. 
We detected no statistically significant differences between treatment groups and the control using 
Mann-Whiney U test. 
 
APPENDIX 
 
125 
 
7.1.2 Supplementary tables  
Table 7-8 ORF1 identity matches 
ID Description Species 
Bit-
score 
Identity 
(%) 
e-
value 
Evidence 
XP_016876486.
1 
PREDICTED: mirror-image 
polydactyly gene 1 protein 
isoform X1 
Homo sapiens 90.5 76.471 6.41E-20 
Prediction 
 
EAX04212.1 
polymerase (DNA directed), 
eta, isoform CRA_c 
Homo sapiens 89.4 80.769 2.22E-22 
Conceptual 
translation 
EAW62471.1 unnamed protein product Homo sapiens 85.5 82.353 1.08E-19 
Conceptual 
translation 
EHH60270.1 
hypothetical protein 
EGM_11598 
Macaca fascicularis 85.5 80.392 1.94E-20 
Conceptual 
translation 
XP_011731548.
1 
PREDICTED: sphingosine 1-
phosphate receptor 2 isoform 
X1 
Macaca 
nemestrina 
83.6 76 1.62E-17 
Prediction 
 
BAC87498.1 unnamed protein product Homo sapiens 83.2 78.846 4.07E-19 Unknown 
BAC85949.1 unnamed protein product Homo sapiens 83.2 78.846 4.16E-19 Unknown 
EHH55556.1 
hypothetical protein 
EGM_04788 
Macaca fascicularis 83.2 78 1.61E-19 
Conceptual 
translation 
XP_007985368.
1 
PREDICTED: uncharacterized 
protein LOC103229289 
Chlorocebus 
sabaeus 
83.2 71.93 1.32E-17 Prediction 
EHH21096.1 
hypothetical protein 
EGK_04085 
Macaca mulatta 82.8 75 2.53E-19 
Conceptual 
translation 
EAW55734.1 hCG2038067 Homo sapiens 82.8 72.222 4.79E-19 
Conceptual 
translation 
EAW56895.1 
ribosomal protein S16, isoform 
CRA_d 
Homo sapiens 82.4 76.923 2.97E-19 
Conceptual 
translation 
EHH64058.1 
hypothetical protein 
EGM_17177 
Macaca fascicularis 82.4 71.154 4.19E-19 
Conceptual 
translation 
BAB15056.1 unnamed protein product Homo sapiens 82 76 1.03E-18 Unknown 
EAW89122.1 hCG2039054 Homo sapiens 82 75 3.73E-19 
Conceptual 
translation 
EHH54116.1 
hypothetical protein 
EGM_14878 
Macaca fascicularis 81.6 76 1.61E-19 
Conceptual 
translation 
EHH20736.1 
hypothetical protein 
EGK_03652 
Macaca mulatta 80.5 74.51 1.73E-18 
Conceptual 
translation 
XP_004045110.
1 
PREDICTED: uncharacterized 
protein LOC101129799 
Gorilla gorilla 
gorilla 
80.1 71.93 1.12E-16 Prediction 
XP_016860586.
1 
PREDICTED: inhibitor of growth 
protein 5 isoform X1 
Homo sapiens 80.1 70.833 1.39E-16 Prediction 
Listed are all proteins or peptides identified by protein BLAST sharing similarity with ORF1 protein with a 
bit-score of at least 80.  
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Table 7-9 ORF2 identity match 
ID Description Species Bit-score 
Identity 
(%) 
e-value Evidence 
WP_020429213.1 hypothetical protein 
Paenibacillus 
riograndensis 
33.1 50 3 Unknown 
 
Table 7-10 DNA accession numbers and coordinates corresponding to ORF1 identity matches 
Protein accession 
number 
DNA accession 
number 
DNA strand 
DNA coordinates corresponding to 
the coding sequence 
XP_016876486.1 XM_017020997.1 + 513-2072 
EAX04212.1 CH471081.1 + 16602455-16602637 
EAW62471.1 AK025116.1 + 387-902 
EHH60270.1 CM001295.1 - 27174454-27174627 + 27265213-27265320 
XP_011731548.1 XM_011733246.1 + 128-1324 
BAC87498.1 AK128554.1 + 1228-1644 
BAC85949.1 AK124786.1 + 1099-1515 
EHH55556.1 CM001288.1 - 46780689-46780888 + 46902969-46903056 
XP_007985368.1 XM_007987177.1 + 1263-2234 
EHH21096.1 CM001263.1 - 100171355-100171666 
EAW55734.1 CH471145.2 - 5597461-5597850 
EAW56895.1 CH471126.1 - 2133982-2134272 
EHH64058.1 CM001283.1 - 25977917-25978195 + 25978215-25978247 
BAB15056.1 AK025047.1 + 734-1117 
EAW89122.1 CH471099.1 + 8361188-8361478 
EHH54116.1 CM001280.1 + 183247767-183247916 
EHH20736.1 CM001263.1 + 48486496-48486804 
XP_004045110.1 XM_004045062.1 + 1-825 
XP_016860586.1 XM_017005097.1 + 914-1816 
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7.3 Nucleic acid sequences 
> DLX6-AS1 T1 
GGCGGGAGAAGCGAGCTGCCCCAGCGGCCTCTCACCTGTGTCGTCCCCTCGCGTCTGGGCGGCTGCGCTGCTGTTGTGGTAGGACTGGAGACAGAGTCTTGCT
CTATTGCCCAGGCTGCAACTGGTGTGATCTCGGCTCACTACAACCTCTGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAAGCTCCCAAGTAGCTGGGATTACAA
GCATGCACCACCATGCCTGGCTAATTTTTGTATTTTTAGTGGAGACGGGGTTTCGCCACATTGGCCAGGGTGGTCTTGAACTCCTGACCTCAAGTGATCCACCTG
CCTTGGCCTCCCAAAGTGCTGGGATTATAAGCATGAGCCACTGCACCCAGCCTTATACTGAACTTTCAATGGGTTCAATTCCACTAGGAGCATAAAGGCCACTGC
ATATGAGTTGTGGAAAGAAGAGATTAGAAGAAGGAAGAACTTGAGATGAGTTCCTCCCTTCAACATTCTGTCTCCTCCTACCTAGCATCTTCTTTCTTTTAGTCTT
TCTAGAATGTCCATCTGTTTTTGGCCATTGCGGAGAGAGAAGCTGAGCTTTAAAGGAGTAGGAGCTTCAAAGGCGTAGGAGCTTCAAAATTCTTGTTTCTTCATG
TTTGATCACCCTTCTAAACCTGTCTTCTGTTCCTTCTGCTATTCTTTTTTCTTAGAGCATAGGAAAGGGGAGCTTTTAAATTAATACTTAAAGCATGGAAAAAAAGA
ACTTGAGAAGAAAGTAAAACAAGGGAGATGAGGCTAGTAAAGTAAGGAAAATGAAGAGGAAGAGGAGGAAGGGTTAGCTTCTAAATTCCAAGTCAAATTGAT
ATGGAACAGGCAAGCCGCTTGTCTTACTTAAACTTCAGAAAAGGATCTGCTGAAACTTGATAGAAATGGAAAGGGAAATCCTTGGGGTGGGGAACCTCCAAAC
ATTAGTAATGATATTGAACAACTCAAAGTATTGAGGAAATCTGCAGGCTACATGCCTGAAGATTACCCATGCAGATAGACCAAAAGGATTAGAATTATCTGTTG
ATATTAGTAATATTTATTGACATCTAGCTAGTATTGGTAATTTTAAGTTTTAGATTAATTTCTTTGGTAATAGCTATGATATATTTTATAGACAAGAATTATATCTAT
AGGCTTGCTATCATAGGCTCTTTTAATCAGCATTAATTTAGTCTACTGATTTTTAGCACATTTGAATCATTCACTTATGCTAGGTAACTCATTGCAAAATAAAAAGA
TGATTCCTGTATGTATGGCAGCTATACATTAAGGAGGAGTCTACCAGAATATGAAAAAGTCAGCTGACCTAAATATTGCTGAGACAAAGGAAAACCCACTCCCT
TGGAGGAGCATGACCTTTTCCTGTAATTCTTCCCACTGCTGTTGTTGAGCTCCTTGGATCCTGGCTCCTGGACACCATCATCAAGAAGACTTTATGGATGGGCTGT
CCACCCACTGAGAGAAGAGGAGCATCAGCTACAGTTTCTCTCTAGATTGCCTTCTTCATTTTGAGTAATGACTGTCAGCAGGGTCAGATTAAACACAAAACAACT
GGACAATTGCTTGGAGGACTAAACTATAAGGGCACTAACATGTCAATAGTAGGCTAACACATCCATGGAAAATATATTTACCAGCTCTTCTCTCAGGGAGGATTC
TGTGTGGGGTTGGAAGTAATGATTTGTTAAATTCCTTAGGGGTAGAAAGTAGGGCATAATCAGAATATAGAGGAATATGCTGTTTGACTTCAGGGTTTCTGTTT
TTCTTACTAGGATATATAAAACAGGGACTCTAGCTAGATTGTTTATGACCACAGAGGGTAGGCTGAGTGCTCCCATGATCTTCCTGCTTGGTTCTTGCCCATACA
GAGGTCAGCCTTTCCTCTAATAAAGATTGAACAA 
> DLX6-AS1 T2S 
GGCGGGAGAAGCGAGCTGCCCCAGCGGCCTCTCACCTGTGTCGTCCCCTCGCGTCTGGGCGGCTGCGCTGCTGTTGTGGTAGGACTGGAGTTGCTGAGACAAA
GGAAAACCCACTCCCTTGGAGGAGCATGACCTTTTCCTGTAATTCTTCCCACTGCTGTTGTTGAGCTCCTTGGATCCTGGCTCCTGGACACCATCATCAAGAAGAC
TTTATGGATGGGCTGTCCACCCACTGAGAGAAGAGGAGCATCAGCTACAGTTTCTCTCTAGATTGCCTTCTTCATTTTGAGTAATGACTGTCAGCAGGGTCAGAT
TAAACACAAAACAACTGGACAATTGCTTGGAGGACTAAACTATAAGGGCACTAACATGTCAATAGTAGGCTAACACATCCATGGAAAATATATTTACCAGCTCTT
CTCTCAGGGAGGATTCTGTGTGGGGTTGGAAGTAATGATTTGTTAAATTCCTTAGGGGTAGAAAGTAGGGCATAATCAGAATATAGAGGAATATGCTGTTTGAC
TTCAGGGTTTCTGTTTTTCTTACTAGGATATATAAAACAGGGACTCTAGCTAGATTGTTTATGACCACAGAGGGTAGGCTGAGTGCTCCCATGATCTTCCTGCTTG
GTTCTTGCCCATACAGAGGTCAGCCTTTCCTCTAATAAAGATTGAACAA 
> DLX6-AS1 T2L  
GGCGGGAGAAGCGAGCTGCCCCAGCGGCCTCTCACCTGTGTCGTCCCCTCGCGTCTGGGCGGCTGCGCTGCTGTTGTGGTAGGACTGGAGTGCTGAGACAAAG
GAAAACCCACTCCCTTGGAGGAGCATGACCTTTTCCTGTAATTCTTCCCACTGCTGTTGTTGAGCTCCTTGGATCCTGGCTCCTGGACACCATCATCAAGAAGACT
TTATGGATGGGCTGTCCACCCACTGAGAGAAGAGGAGCATCAGCTACAGTTTCTCTCTAGATTGCCTTCTTCATTTTGAGTAATGACTGTCAGCAGGGTCAGATT
AAACACAAAACAACTGGACAATTGCTTGGAGGACTAAACTATAAGGGCACTAACATGTCAATAGTAGGCTAACACATCCATGGAAAATATATTTACCAGCTCTTC
TCTCAGGGAGGATTCTGTGTGGGGTTGGAAGTAATGATTTGTTAAATTCCTTAGGGGTAGAAAGTAGGGCATAATCAGAATATAGAGGAATATGCTGTTTGACT
TCAGGGTTTCTGTTTTTCTTACTAGGATATATAAAACAGGGACTCTAGCTAGATTGTTTATGACCACAGAGGGTAGGCTGAGTGCTCCCATGATCTTCCTGCTTGG
TTCTTGCCCATACAGAGGTCAGCCTTTCCTCTAATAAAGATTGAACAAGTAGTGGTCTGAGGGAGACACCAATTCATTACCCTACATGTCTCTTCTCTGCACTCCA
GGGCTTTGATAATAAAGACACTGGCAGACTATCTATCTTCCATTTCTATAATGTGAGCCCTTAGGGAGTCTTCGTTCACTTGGGGGTGAGGGTCATTGCTCACAG
AGTAGTTCAAGTCAAATGGAACTTGAACTCTTTGCCTATGGGCCTGGTGGTCAGACTCTGTGTTGAGTTCATTAGATTATTGGAGACACAAGGTAGAGCTGGAT
GCTTCAAAAATATTTGGCTAAAGGATGACATTGCTGGTTATTTGTAGATAAAGCCATGATGGAACCTGCTTGGAATCATGAAATATGGAACTGGTGGTCATGTTT
AAAAATACAACTAATAGTTAAGTACCTACTGGACACTGTAGAGACTTAGGGGCTAGACAGACATGGTTCCTGCCCCCTTGGAGCTTACACTGTAGCTTCCCCTTA
GGTATGAAGAACAGTGGCTACAACTAACAAATGGCCACAAAGATATAATTGAGCCAGTGTTCCAATTATTAGGGTAATTCCTATTTCCTTAATCATTCCTATTGAC
CATGTTCTATAAGCCTGCATTCTATAAATGGCGTATGACCATGGGCTGTTTCCCCCCAGCAAGTTGTACAAAGTTCTGTGGTACCAGGGAAAGGGCTTAAGGTTA
GCAGGGCCTCTGCGGAAGGACATATGAAGTGACTTGGGTTAGGAAACAGGAAGGGATAGGATTCAAGAACAGCTATTGCTTCTGTTCTATATAGGAAACTGCA
GCGTGAAAAATGCTGGGCTGGGAATTTTGAGACCTGGGTTTTAGTTTGTGTTCTAATACTAACAAGCTATGTGACTGTGGGTAAGTCATTTCACATTCCATTTGG
ATGCCTCTTGAGTGACTCCAGGCCTCTCCAGCTCTAAAACATTAAGATCAGGCCCTACGCTACAGCTGGCCAGTGTGTAATTCTTCTGTTTCTATGCTGTTAGGTC
AAATAGATCTTCAATAGTTACTTGATTGTTATTACTTTTTTCTGAAGTGGGTGTTTTATCAATGTTTTAGGATACAGTGAGTCTGCTTCTCCCCTTTGGAGTTAGGA
AGGTTGTAGGAATATACACTGTAGAGCATATGGGAGCTTTATCCCCTCCTTTTTTCCCCGCTACCTTTCTCCCTCTCCTTCCCTTCATCACATTTCTATTGAGCATAT
GCCATTGCCGTGTACCAGGTGTGTGCTAGGTTTGGAGATACAAGGTAAACCTGAGACTTTCCCAGTCTCCAGGAGACAAAACCCTAATTTCTTTCATCTGCTGTC
TTTCTCTTTGGAAAGAATCAACGATATCCCAGGGGAATGTGCCCATGTCCCAGGGTAACCAACTACAGACAGATGCCCCATTCTACTCAAGCAACTTTTAGAGTG
CCTTGAGATACACATCAGATAATTATGCAGGGCCAGGCATGGTGCTGCACACTTGTAATCACAGCACTTTGGGAGGCCGAGGCAGCAGATTGCTTGAGCCCAG
GAATTCAAGTGTAGCCTAGGGAACATGGCAAAACCCCAGCTCTACAAAAAAATACACAAATTAGCTGCGTGTGGTGGCCTATGACAGGAGGCTGAGATGGGAG
GATTGCTTGAGCCTGTGAGGTCGAGGCTGCAGTGAGCCGAGATCATGCCATTACTCCAGCCTGGGTGACATAGGGAGACCCTGTCTTGAAAAAAAAAAAAAAA
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AGATAATTATTCAGCCCTAGAGTCATTGTGAAAAGATCTATCTTCAGATATAAGGAAGAAACAATCTTTTATTTCTTAGGATAAATCTGTAGAAGGACCTCCAGA
CAGTGAAGGCCACTGACTACTTTATACTCTGTAAGCCATCCCTCCCTGGTAGGAAGGACTATTTCCAATCTTACAGAGTACCTCTCAGCAAATAGACGTTTTCACA
TATACTGTGATTCATACATCCCTATGGCTGGTGACCTCTTTAAAAAGGAAAGGAAAAAGCCTAATCAAACAAAAAGATGCTGCTAGTAATTCTTACCCTATTGTG
AATCCTATATAAGCAAATTTGTATCTTTGTTTTTTCCTACATTAGCAGATCTATTTGATATATCTCTGAGTGCAGAAAATATTTTATGGAAAAATCAATATATGGAA
TTTCAAATTCAGAATTGCTGATACACACTATTTGGTTTCACAATTTTATCCTAGGAAATAGTATTAGAGATTTCAATTTCTGGCTTAAATGGTAGAATTAATTACTC
TTAACTCTTAATTTTACTTCTGAGTTGAGGTCAAGGAACAGGCAGACACCTGCAGTTAACGTCTATACCTCTCCATGGCCAAGAGTTTTAATTTTCTCGTCTTCAAT
TTTGTAGATGTTCATCATTACTAAATGGATTGATTAGTATTTTATCTCCTCTCCTTGTCCTTACTTTCCCTCTGGTAAATATGTTATAAACAGTGTAAGGCTCCTAAG
ATAGAGTAGCTGGTAGGACTTAGAAGAGAAACAAAGGGCACTGATAACTCACATAAATGGAAAATTGGCTCTGGAATAACTGACAACATATTCAAGTATTTTAG
TGCAGTGTCACTCTCATTAAGAAGAAGAGAATCAGTAAATCTATGTGACTCTAAACATTCTAATGAAAAAAGGAATATTCTGCCAATTATCTCACATTTCTAAATA
TCTGGATATTGGCCATTGTAAAGACAAAACATACAGATGATGGACTTGTCTTTCCACCTCTCATTTGCATGGTTTGGAGCATTGTACCTCCAGCCATAGACTCTAA
GGCAATTTATATTTGCTTCCTCTTCCCTCTTGAGAGAAAACGAAAATCTTATTTTTCCAAGCAATTAAAACTCTTCTGCTTCAGCTAGGATGAAAGAATTAGGAGT
TCTGTCTCCTTGTATCTAATTGCATGTTTCATCTTTCTTGTTTTAATGATTGACAGAAAACTAATAAACTGAGACATCTTTGAATCCAGGTTGAATGTA 
 
>ALUSZ (reverse complement) 
GGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGG
TGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGTGGCGCGCGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAAC
CCGGGAGGCGGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCA 
 
7.4 DLX6-AS1 amino acid sequences  
> ORF1 
MHHHAWLIFVFLVETGFRHIGQGGLELLTSSDPPALASQSAGIISMSHCTQPYTELSMGSIPLGA* 
 
> ORF2 
MAYDHGLFPPSKLYKVLWYQGKGLRLAGPLRKDI* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
129 
 
8. REFERENCES 
Abate-Shen, C. and M.M. Shen, Molecular genetics of prostate cancer. Genes Dev, 2000. 14(19): p. 2410-
34. 
Acevedo, L.G., et al., Analysis of the mechanisms mediating tumor-specific changes in gene expression in 
human liver tumors. Cancer Res, 2008. 68(8): p. 2641-51. 
Al Olama, A.A., et al., Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet, 2009. 
41(10): p. 1058-60. 
Altschul, S.F., et al., Basic local alignment search tool. J Mol Biol, 1990. 215(3): p. 403-10. 
Amouroux, R., et al., De novo DNA methylation drives 5hmC accumulation in mouse zygotes. Nat Cell Biol, 
2016. 18(2): p. 225-33. 
Anderson, D.M., et al., A micropeptide encoded by a putative long noncoding RNA regulates muscle 
performance. Cell, 2015. 160(4): p. 595-606. 
Andrews, S.J. and J.A. Rothnagel, Emerging evidence for functional peptides encoded by short open reading 
frames. Nat Rev Genet, 2014. 15(3): p. 193-204. 
Arab, K., et al., Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor 
TCF21 via GADD45A. Mol Cell, 2014. 55(4): p. 604-14. 
Banfai, B., et al., Long noncoding RNAs are rarely translated in two human cell lines. Genome Res, 2012. 
22(9): p. 1646-57. 
Bao, W., K.K. Kojima, and O. Kohany, Repbase Update, a database of repetitive elements in eukaryotic 
genomes. Mob DNA, 2015. 6: p. 11. 
Barbieri, C.E., et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate 
cancer. Nat Genet, 2012. 44(6): p. 685-9. 
Barreto, G., et al., Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. 
Nature, 2007. 445(7128): p. 671-5. 
Barski, A., et al., High-resolution profiling of histone methylations in the human genome. Cell, 2007. 129(4): 
p. 823-37. 
Bassett, A.R., et al., Considerations when investigating lncRNA function in vivo. Elife, 2014. 3: p. e03058. 
Bazzini, A.A., et al., Identification of small ORFs in vertebrates using ribosome footprinting and 
evolutionary conservation. EMBO J, 2014. 33(9): p. 981-93. 
Beckedorff, F.C., et al., The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, 
reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet, 2013. 9(8): p. e1003705. 
Berghoff, E.G., et al., Evf2 (Dlx6as) lncRNA regulates ultraconserved enhancer methylation and the 
differential transcriptional control of adjacent genes. Development, 2013. 140(21): p. 4407-16. 
Bert, S.A., et al., Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer 
Cell, 2013. 23(1): p. 9-22. 
REFERENCES 
 
130 
 
Blackledge, N.P., J.P. Thomson, and P.J. Skene, CpG island chromatin is shaped by recruitment of ZF-CxxC 
proteins. Cold Spring Harb Perspect Biol, 2013. 5(11): p. a018648. 
Blackledge, N.P., et al., CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell, 2010. 38(2): p. 
179-90. 
Boch, J., et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 2009. 
326(5959): p. 1509-12. 
Bond, A.M., et al., Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal 
GABA circuitry. Nat Neurosci, 2009. 12(8): p. 1020-7. 
Borno, S.T., et al., Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate 
cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov, 2012. 
2(11): p. 1024-35. 
Bourc'his, D., et al., Dnmt3L and the establishment of maternal genomic imprints. Science, 2001. 
294(5551): p. 2536-9. 
Brocks, D., et al., Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive 
prostate cancer. Cell Rep, 2014. 8(3): p. 798-806. 
Cabili, M.N., et al., Integrative annotation of human large intergenic noncoding RNAs reveals global 
properties and specific subclasses. Genes Dev, 2011. 25(18): p. 1915-27. 
Carrieri, C., et al., Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 
repeat. Nature, 2012. 491(7424): p. 454-7. 
Carver, B.S., et al., Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression 
in the prostate. Nat Genet, 2009. 41(5): p. 619-24. 
Cheng, A.W., et al., Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided 
transcriptional activator system. Cell Res, 2013. 23(10): p. 1163-71. 
Chooniedass-Kothari, S., et al., The steroid receptor RNA activator is the first functional RNA encoding a 
protein. FEBS Lett, 2004. 566(1-3): p. 43-7. 
Chung, S., et al., Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. 
Cancer Sci, 2011. 102(1): p. 245-52. 
Comings, D.E., The structure and function of chromatin. Adv Hum Genet, 1972. 3: p. 237-431. 
Consortium, E.P., An integrated encyclopedia of DNA elements in the human genome. Nature, 2012. 
489(7414): p. 57-74. 
Consortium, E.P., et al., Identification and analysis of functional elements in 1% of the human genome by 
the ENCODE pilot project. Nature, 2007. 447(7146): p. 799-816. 
Consortium, F., et al., A promoter-level mammalian expression atlas. Nature, 2014. 507(7493): p. 462-70. 
Coolen, M.W., et al., Consolidation of the cancer genome into domains of repressive chromatin by long-
range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol, 2010. 12(3): p. 235-46. 
Cooper, C., et al., Steroid Receptor RNA Activator bi-faceted genetic system: Heads or Tails? Biochimie, 
2011. 93(11): p. 1973-80. 
REFERENCES 
 
131 
 
Cortazar, D., et al., Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic 
stability. Nature, 2011. 470(7334): p. 419-23. 
Cortellino, S., et al., Thymine DNA glycosylase is essential for active DNA demethylation by linked 
deamination-base excision repair. Cell, 2011. 146(1): p. 67-79. 
de Koning, A.P., et al., Repetitive elements may comprise over two-thirds of the human genome. PLoS 
Genet, 2011. 7(12): p. e1002384. 
Deaton, A.M. and A. Bird, CpG islands and the regulation of transcription. Genes Dev, 2011. 25(10): p. 
1010-22. 
Deininger, P., Alu elements: know the SINEs. Genome Biol, 2011. 12(12): p. 236. 
Derrien, T., et al., The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene 
structure, evolution, and expression. Genome Res, 2012. 22(9): p. 1775-89. 
Di Ruscio, A., et al., DNMT1-interacting RNAs block gene-specific DNA methylation. Nature, 2013. 
503(7476): p. 371-6. 
Djebali, S., et al., Landscape of transcription in human cells. Nature, 2012. 489(7414): p. 101-8. 
Doerfler, W., DNA methylation and gene activity. Annu Rev Biochem, 1983. 52: p. 93-124. 
Du, Q., et al., Methyl-CpG-binding domain proteins: readers of the epigenome. Epigenomics, 2015. 7(6): p. 
1051-73. 
Du, Z., et al., Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. 
Nat Struct Mol Biol, 2013. 20(7): p. 908-13. 
Ehrlich, M., DNA methylation in cancer: too much, but also too little. Oncogene, 2002. 21(35): p. 5400-13. 
Ezkurdia, I., et al., Analyzing the first drafts of the human proteome. J Proteome Res, 2014. 13(8): p. 3854-
5. 
Feng, J., et al., The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and 
functions as a Dlx-2 transcriptional coactivator. Genes Dev, 2006. 20(11): p. 1470-84. 
Feng, Y., et al., Methods for the study of long noncoding RNA in cancer cell signaling. Methods Mol Biol, 
2014. 1165: p. 115-43. 
Finn, R.D., et al., The Pfam protein families database: towards a more sustainable future. Nucleic Acids 
Res, 2016. 44(D1): p. D279-85. 
Flatau, E., et al., DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. 
Mol Cell Biol, 1984. 4(10): p. 2098-102. 
Fu, X., et al., Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding 
gene, PCGEM1. DNA Cell Biol, 2006. 25(3): p. 135-41. 
Fu, Y., et al., Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian 
cancer cells. Mol Cancer Res, 2003. 1(8): p. 569-76. 
Fussner, E., R.W. Ching, and D.P. Bazett-Jones, Living without 30nm chromatin fibers. Trends Biochem Sci, 
2011. 36(1): p. 1-6. 
REFERENCES 
 
132 
 
Gagnon, K.T., et al., Analysis of nuclear RNA interference in human cells by subcellular fractionation and 
Argonaute loading. Nat Protoc, 2014. 9(9): p. 2045-60. 
Gilbert, L.A., et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 
2013. 154(2): p. 442-51. 
Goldberg, T., et al., LocTree3 prediction of localization. Nucleic Acids Res, 2014. 42(Web Server issue): p. 
W350-5. 
Goldstein, J., et al., Does Choline PET/CT Change the Management of Prostate Cancer Patients With 
Biochemical Failure? Am J Clin Oncol, 2014. 
Gong, C. and L.E. Maquat, lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs 
via Alu elements. Nature, 2011. 470(7333): p. 284-8. 
Goyal, A., et al., Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res, 
2016. 
Grasso, C.S., et al., The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012. 
487(7406): p. 239-43. 
Greco, S.A., et al., Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that 
exhibits age-related methylation. BMC Cancer, 2010. 10: p. 494. 
Gregory, R.I. and R. Shiekhattar, Chromatin modifiers and carcinogenesis. Trends Cell Biol, 2004. 14(12): 
p. 695-702. 
Guttman, M., et al., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs 
in mammals. Nature, 2009. 458(7235): p. 223-7. 
Guttman, M., et al., lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature, 2011. 
477(7364): p. 295-300. 
Guttman, M., et al., Ribosome profiling provides evidence that large noncoding RNAs do not encode 
proteins. Cell, 2013. 154(1): p. 240-51. 
Gyorffy, B., et al., Online survival analysis software to assess the prognostic value of biomarkers using 
transcriptomic data in non-small-cell lung cancer. PLoS One, 2013. 8(12): p. e82241. 
Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74. 
Hata, K., et al., Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish 
maternal imprints in mice. Development, 2002. 129(8): p. 1983-93. 
Hayward, S.W., et al., Establishment and characterization of an immortalized but non-transformed human 
prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim, 1995. 31(1): p. 14-24. 
He, S., et al., LongTarget: a tool to predict lncRNA DNA-binding motifs and binding sites via Hoogsteen 
base-pairing analysis. Bioinformatics, 2015. 31(2): p. 178-86. 
He, Y., et al., The antisense transcriptomes of human cells. Science, 2008. 322(5909): p. 1855-7. 
He, Y.F., et al., Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. 
Science, 2011. 333(6047): p. 1303-7. 
REFERENCES 
 
133 
 
Hermann, A., R. Goyal, and A. Jeltsch, The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA 
processively with high preference for hemimethylated target sites. J Biol Chem, 2004. 279(46): p. 48350-
9. 
Heyer, E.E. and M.J. Moore, Redefining the Translational Status of 80S Monosomes. Cell, 2016. 164(4): p. 
757-69. 
Holliday, R., The inheritance of epigenetic defects. Science, 1987. 238(4824): p. 163-70. 
Holliday, R. and J.E. Pugh, DNA modification mechanisms and gene activity during development. Science, 
1975. 187(4173): p. 226-32. 
Hu, S., X. Wang, and G. Shan, Insertion of an Alu element in a lncRNA leads to primate-specific modulation 
of alternative splicing. Nat Struct Mol Biol, 2016. 23(11): p. 1011-1019. 
Ingolia, N.T., L.F. Lareau, and J.S. Weissman, Ribosome profiling of mouse embryonic stem cells reveals the 
complexity and dynamics of mammalian proteomes. Cell, 2011. 147(4): p. 789-802. 
Irizarry, R.A., et al., The human colon cancer methylome shows similar hypo- and hypermethylation at 
conserved tissue-specific CpG island shores. Nat Genet, 2009. 41(2): p. 178-86. 
Iyer, L.M., et al., Prediction of novel families of enzymes involved in oxidative and other complex 
modifications of bases in nucleic acids. Cell Cycle, 2009. 8(11): p. 1698-710. 
Iyer, M.K., et al., The landscape of long noncoding RNAs in the human transcriptome. Nat Genet, 2015. 
47(3): p. 199-208. 
Jeltsch, A. and R.Z. Jurkowska, New concepts in DNA methylation. Trends Biochem Sci, 2014. 39(7): p. 310-
8. 
Jin, S.G., C. Guo, and G.P. Pfeifer, GADD45A does not promote DNA demethylation. PLoS Genet, 2008. 4(3): 
p. e1000013. 
Jinek, M., et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. 
Science, 2012. 337(6096): p. 816-21. 
Johnsson, P., et al., A pseudogene long-noncoding-RNA network regulates PTEN transcription and 
translation in human cells. Nat Struct Mol Biol, 2013. 20(4): p. 440-6. 
Jones, M.J., S.J. Goodman, and M.S. Kobor, DNA methylation and healthy human aging. Aging Cell, 2015. 
14(6): p. 924-32. 
Jones, P.A. and S.B. Baylin, The epigenomics of cancer. Cell, 2007. 128(4): p. 683-92. 
Jones, P.A. and G. Liang, Rethinking how DNA methylation patterns are maintained. Nat Rev Genet, 2009. 
10(11): p. 805-11. 
Jones, P.L., et al., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat 
Genet, 1998. 19(2): p. 187-91. 
Kaczkowski, B., et al., Transcriptome Analysis of Recurrently Deregulated Genes across Multiple Cancers 
Identifies New Pan-Cancer Biomarkers. Cancer Res, 2016. 76(2): p. 216-26. 
Kan, Z., et al., Diverse somatic mutation patterns and pathway alterations in human cancers. Nature, 2010. 
466(7308): p. 869-73. 
REFERENCES 
 
134 
 
Kang, S., et al., miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells 
through PACE4 pathway. Prostate, 2014. 74(11): p. 1095-106. 
Kapranov, P., et al., RNA maps reveal new RNA classes and a possible function for pervasive transcription. 
Science, 2007. 316(5830): p. 1484-8. 
Kareta, M.S., et al., Reconstitution and mechanism of the stimulation of de novo methylation by human 
DNMT3L. J Biol Chem, 2006. 281(36): p. 25893-902. 
Khalil, A.M., et al., Many human large intergenic noncoding RNAs associate with chromatin-modifying 
complexes and affect gene expression. Proc Natl Acad Sci U S A, 2009. 106(28): p. 11667-72. 
Kim, J.H., et al., Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome 
Res, 2011. 21(7): p. 1028-41. 
King, J.C., et al., Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate 
oncogenesis. Nat Genet, 2009. 41(5): p. 524-6. 
Kobayashi, Y., et al., DNA methylation profiling reveals novel biomarkers and important roles for DNA 
methyltransferases in prostate cancer. Genome Res, 2011. 21(7): p. 1017-27. 
Kondo, Y., et al., Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter 
DNA methylation. Nat Genet, 2008. 40(6): p. 741-50. 
Kotake, Y., et al., Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of 
p15(INK4B) tumor suppressor gene. Oncogene, 2011. 30(16): p. 1956-62. 
Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 128(4): p. 693-705. 
Kozak, M., Initiation of translation in prokaryotes and eukaryotes. Gene, 1999. 234(2): p. 187-208. 
Krohn, A., et al., Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a 
distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol, 2013. 231(1): p. 130-41. 
Kron, K., et al., Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island 
microarrays. PLoS One, 2009. 4(3): p. e4830. 
Kumar-Sinha, C., S.A. Tomlins, and A.M. Chinnaiyan, Recurrent gene fusions in prostate cancer. Nat Rev 
Cancer, 2008. 8(7): p. 497-511. 
Lamprecht, B., et al., Derepression of an endogenous long terminal repeat activates the CSF1R proto-
oncogene in human lymphoma. Nat Med, 2010. 16(5): p. 571-9, 1p following 579. 
Lander, E.S., et al., Initial sequencing and analysis of the human genome. Nature, 2001. 409(6822): p. 860-
921. 
Lanz, R.B., et al., A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 
complex. Cell, 1999. 97(1): p. 17-27. 
Li, J., et al., Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int, 2015. 
15: p. 48. 
Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR 
and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402-8. 
REFERENCES 
 
135 
 
Lorincz, M.C., et al., Dynamic analysis of proviral induction and De Novo methylation: implications for a 
histone deacetylase-independent, methylation density-dependent mechanism of transcriptional 
repression. Mol Cell Biol, 2000. 20(3): p. 842-50. 
Luger, K., et al., Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997. 
389(6648): p. 251-60. 
Maiti, A. and A.C. Drohat, Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-
carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem, 2011. 286(41): 
p. 35334-8. 
Marchler-Bauer, A., et al., CDD: NCBI's conserved domain database. Nucleic Acids Res, 2015. 43(Database 
issue): p. D222-6. 
Maruyama, R. and H. Suzuki, Long noncoding RNA involvement in cancer. BMB Rep, 2012. 45(11): p. 604-
11. 
Mayer, W., et al., Demethylation of the zygotic paternal genome. Nature, 2000. 403(6769): p. 501-2. 
Merry, C.R., et al., DNMT1-associated long non-coding RNAs regulate global gene expression and DNA 
methylation in colon cancer. Hum Mol Genet, 2015. 24(21): p. 6240-53. 
Metivier, R., et al., Cyclical DNA methylation of a transcriptionally active promoter. Nature, 2008. 
452(7183): p. 45-50. 
Mili, S. and J.A. Steitz, Evidence for reassociation of RNA-binding proteins after cell lysis: implications for 
the interpretation of immunoprecipitation analyses. RNA, 2004. 10(11): p. 1692-4. 
Mills, I.G., Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat 
Rev Cancer, 2014. 14(3): p. 187-98. 
Morini, M., et al., Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic 
potential of the human breast cancer cell line MDA-MB-231. BMC Cancer, 2010. 10: p. 649. 
N. Mottet, J.B., E. Briers, R.C.N. van den Bergh, M. Bolla, N.J. van Casteren, P. Cornford, S. Culine, S. Joniau, 
T. Lam, M.D. Mason, V. Matveev, H. van der Poel, T.H. van der Kwast, O. Rouvière, T. Wiegel, Guidelines 
on Prostate Cancer. European Association of Urology, 2015. 2015. 
Nan, X., et al., Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone 
deacetylase complex. Nature, 1998. 393(6683): p. 386-9. 
Nelson, B.R., et al., A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA 
activity in muscle. Science, 2016. 351(6270): p. 271-5. 
Neri, F., et al., Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation 
at gene bodies in ESCs. Cell, 2013. 155(1): p. 121-34. 
Nuytten, M., et al., The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene 
silencing. Oncogene, 2008. 27(10): p. 1449-60. 
Ohno, S., So much "junk" DNA in our genome. Brookhaven Symp Biol, 1972. 23: p. 366-70. 
Okano, M., et al., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and 
mammalian development. Cell, 1999. 99(3): p. 247-57. 
REFERENCES 
 
136 
 
Olsson, M., et al., Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma 
tumors. Epigenetics, 2016. 11(1): p. 74-84. 
Orom, U.A., et al., Long noncoding RNAs with enhancer-like function in human cells. Cell, 2010. 143(1): p. 
46-58. 
Oswald, J., et al., Active demethylation of the paternal genome in the mouse zygote. Curr Biol, 2000. 10(8): 
p. 475-8. 
Paul, J. and J.D. Duerksen, Chromatin-associated RNA content of heterochromatin and euchromatin. Mol 
Cell Biochem, 1975. 9(1): p. 9-16. 
Pedersen, A.G. and H. Nielsen, Neural network prediction of translation initiation sites in eukaryotes: 
perspectives for EST and genome analysis. Proc Int Conf Intell Syst Mol Biol, 1997. 5: p. 226-33. 
Pellacani, D., et al., DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial 
differentiation and hyperproliferation. Cell Death Differ, 2014. 21(5): p. 761-73. 
Petersen, T.N., et al., SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat 
Methods, 2011. 8(10): p. 785-6. 
Peterson, C.L. and J.L. Workman, Promoter targeting and chromatin remodeling by the SWI/SNF complex. 
Curr Opin Genet Dev, 2000. 10(2): p. 187-92. 
Petrovics, G., et al., Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting 
function, is associated with high-risk prostate cancer patients. Oncogene, 2004. 23(2): p. 605-11. 
Pienta, K.J. and P.S. Esper, Risk factors for prostate cancer. Ann Intern Med, 1993. 118(10): p. 793-803. 
Plass, C., et al., Mutations in regulators of the epigenome and their connections to global chromatin 
patterns in cancer. Nat Rev Genet, 2013. 14(11): p. 765-80. 
Ponting, C.P., P.L. Oliver, and W. Reik, Evolution and functions of long noncoding RNAs. Cell, 2009. 136(4): 
p. 629-41. 
Potosky, A.L., et al., The role of increasing detection in the rising incidence of prostate cancer. JAMA, 1995. 
273(7): p. 548-52. 
Prensner, J.R., et al., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an 
unannotated lincRNA implicated in disease progression. Nat Biotechnol, 2011. 29(8): p. 742-9. 
Prensner, J.R., et al., The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and 
antagonizes the SWI/SNF complex. Nat Genet, 2013. 45(11): p. 1392-8. 
Prensner, J.R., et al., The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate 
cancer. Oncotarget, 2014. 
Quek, X.C., et al., lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs. 
Nucleic Acids Res, 2015. 43(Database issue): p. D168-73. 
Quinn, J.J. and H.Y. Chang, Unique features of long non-coding RNA biogenesis and function. Nat Rev 
Genet, 2016. 17(1): p. 47-62. 
Rashid, F., A. Shah, and G. Shan, Long Non-coding RNAs in the Cytoplasm. Genomics Proteomics 
Bioinformatics, 2016. 14(2): p. 73-80. 
REFERENCES 
 
137 
 
Ren, S., et al., RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene 
fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res, 2012. 22(5): 
p. 806-21. 
Riggs, A.D., X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet, 1975. 14(1): p. 9-
25. 
Riggs, A.D., R.A. Martienssen, and V.E.A. Russo, Introduction. 1996. 1996. 
Rinn, J.L. and H.Y. Chang, Genome regulation by long noncoding RNAs. Annu Rev Biochem, 2012. 81: p. 
145-66. 
Rinn, J.L., et al., Functional demarcation of active and silent chromatin domains in human HOX loci by 
noncoding RNAs. Cell, 2007. 129(7): p. 1311-23. 
Robledo, R.F., et al., The Dlx5 and Dlx6 homeobox genes are essential for craniofacial, axial, and 
appendicular skeletal development. Genes Dev, 2002. 16(9): p. 1089-101. 
Rougier, N., et al., Chromosome methylation patterns during mammalian preimplantation development. 
Genes Dev, 1998. 12(14): p. 2108-13. 
Salamov, A.A., T. Nishikawa, and M.B. Swindells, Assessing protein coding region integrity in cDNA 
sequencing projects. Bioinformatics, 1998. 14(5): p. 384-90. 
Salinas, C.A., et al., Prostate cancer in young men: an important clinical entity. Nat Rev Urol, 2014. 11(6): 
p. 317-23. 
Schein, A., et al., Identification of antisense long noncoding RNAs that function as SINEUPs in human cells. 
Sci Rep, 2016. 6: p. 33605. 
Schmitz, K.M., et al., TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter 
of rRNA genes leading to active DNA demethylation. Mol Cell, 2009. 33(3): p. 344-53. 
Scotto-Lavino, E., G. Du, and M.A. Frohman, 5' end cDNA amplification using classic RACE. Nat Protoc, 
2006. 1(6): p. 2555-62. 
Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7-30. 
Sigrist, C.J., et al., New and continuing developments at PROSITE. Nucleic Acids Res, 2013. 41(Database 
issue): p. D344-7. 
Slavoff, S.A., et al., Peptidomic discovery of short open reading frame-encoded peptides in human cells. 
Nat Chem Biol, 2013. 9(1): p. 59-64. 
Society, A.C., Global Cancer Facts & Figures 3rd Edition American Cancer Society 2015(2015). 
Srikantan, V., et al., PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad 
Sci U S A, 2000. 97(22): p. 12216-21. 
Steijger, T., et al., Assessment of transcript reconstruction methods for RNA-seq. Nat Methods, 2013. 
10(12): p. 1177-84. 
Steurer, S., et al., TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate 
cancer. Eur Urol, 2014. 66(6): p. 978-81. 
REFERENCES 
 
138 
 
Strahl, B.D. and C.D. Allis, The language of covalent histone modifications. Nature, 2000. 403(6765): p. 41-
45. 
Taberlay, P.C., et al., Three-dimensional disorganisation of the cancer genome occurs coincident with long 
range genetic and epigenetic alterations. Genome Res, 2016. 
Tahiliani, M., et al., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by 
MLL partner TET1. Science, 2009. 324(5929): p. 930-5. 
Takayama, K., et al., Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO 
J, 2013. 32(12): p. 1665-80. 
Taylor, B.S., et al., Integrative genomic profiling of human prostate cancer. Cancer Cell, 2010. 18(1): p. 11-
22. 
Thillainadesan, G., et al., TGF-beta-dependent active demethylation and expression of the p15ink4b tumor 
suppressor are impaired by the ZNF217/CoREST complex. Mol Cell, 2012. 46(5): p. 636-49. 
Thomson, J.P., et al., CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature, 
2010. 464(7291): p. 1082-6. 
Tomlins, S.A., et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 
Science, 2005. 310(5748): p. 644-8. 
Trinklein, N.D., et al., An abundance of bidirectional promoters in the human genome. Genome Res, 2004. 
14(1): p. 62-6. 
Troshin, P.V., J.B. Procter, and G.J. Barton, Java bioinformatics analysis web services for multiple sequence 
alignment--JABAWS:MSA. Bioinformatics, 2011. 27(14): p. 2001-2. 
van Heesch, S., et al., Extensive localization of long noncoding RNAs to the cytosol and mono- and 
polyribosomal complexes. Genome Biol, 2014. 15(1): p. R6. 
Venter, J.C., et al., The sequence of the human genome. Science, 2001. 291(5507): p. 1304-51. 
Waddington, C.H., The epigenotype. 1942. Int J Epidemiol, 2012. 41(1): p. 10-3. 
Wang, C., et al., mCOPA: analysis of heterogeneous features in cancer expression data. J Clin Bioinforma, 
2012. 2(1): p. 22. 
Wang, Z.A., et al., Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep, 2014. 8(5): p. 
1339-46. 
Waterhouse, A.M., et al., Jalview Version 2--a multiple sequence alignment editor and analysis workbench. 
Bioinformatics, 2009. 25(9): p. 1189-91. 
Weischenfeldt, J., et al., Integrative genomic analyses reveal an androgen-driven somatic alteration 
landscape in early-onset prostate cancer. Cancer Cell, 2013. 23(2): p. 159-70. 
Weiss, M., C. Plass, and C. Gerhauser, Role of lncRNAs in prostate cancer development and progression. 
Biol Chem, 2014. 395(11): p. 1275-90. 
Wilhelm, M., et al., Mass-spectrometry-based draft of the human proteome. Nature, 2014. 509(7502): p. 
582-7. 
REFERENCES 
 
139 
 
Wolff, E.M., et al., Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET 
oncogene in bladders with cancer. PLoS Genet, 2010. 6(4): p. e1000917. 
Xu, B., et al., The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study 
including 454 cases and review of the literature. Hum Pathol, 2014. 45(3): p. 488-97. 
Yan, X., et al., Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. 
Cancer Cell, 2015. 28(4): p. 529-40. 
Yang, L., et al., lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. 
Nature, 2013. 500(7464): p. 598-602. 
Yap, K.L., et al., Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by 
polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell, 2010. 38(5): p. 662-74. 
Yegnasubramanian, S., et al., DNA hypomethylation arises later in prostate cancer progression than CpG 
island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res, 2008. 68(21): p. 
8954-67. 
Yu, J., et al., An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in 
prostate cancer progression. Cancer Cell, 2010. 17(5): p. 443-54. 
Yuasa, K., et al., Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: possible 
role of E2F-mediated upregulation of PACE4 in tumor progression. Gene, 2007. 402(1-2): p. 103-10. 
Zhao, J., et al., Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell, 2010. 40(6): 
p. 939-53. 
Zhao, Y., et al., NONCODE 2016: an informative and valuable data source of long non-coding RNAs. Nucleic 
Acids Res, 2016. 44(D1): p. D203-8. 
Zucchelli, S., et al., SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target 
proteins in cells. Front Cell Neurosci, 2015. 9: p. 174. 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
140 
 
 
 
 
 
 
PUBLICATIONS DURING THE THESIS 
 
141 
 
9. PUBLICATIONS DURING THE THESIS 
9.1 Publications 
Weiss, M., Plass C. and Gerhäuser C. Role of lncRNAs in prostate cancer development and 
progression Biological. Chemistry, 2014: 395(11): p.1275–1290 
 
Gu, L., Frommel S., Oakes C. C., Simon, R., Grupp, K., Gerig, Y. C., Bär, D., Robinson D. M., Baer C., 
Weiss, M., Gu, Z., Schapira, M., Kuner, R., Sültmann, H., Provenzano M., ICGC project on Early 
Onset Prostate Cancer, Yaspo, M-L., Brors, B., Korbel, J., Schlomm, T., Sauter, G., Eils, R., Plass, C. 
and Santoro, R., BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its 
overexpression predicts disease recurrence Nature Genetics, 2015. 47(1): p. 22-30. 
 
9.2 Presentations 
Weiss, M., Bogatyrova O., ICGC project on Early Onset Prostate Cancer, Gerhäuser, C. and Plass, 
C., Epigenetic alterations of TERT promoter in pancreatic cancer  
Annual DKFZ PhD Student Poster Session, November 2015, Heidelberg, Germany. (poster 
presentation) 
 
Weiss, M., Bogatyrova O., ICGC project on Early Onset Prostate Cancer, Gerhäuser, C. and Plass, 
C., Mechanisms of lncRNAs as mediators of DNA (de)methylation in prostate cancer  
EMBL non-coding genomes October 2015, Heidelberg, Germany. (poster presentation) 
 
Weiss, M.,Feuerbach, L., Plass, C., Brors, B. and Gerhäuser, C., Integrative analysis of tumor 
suppressor-ncRNAs associated with recurrently deleted regions in prostate cancer  
RNA@DKFZ November 2015, Heidelberg, Germany. (oral presentation) 
 
 
 
 
PUBLICATIONS DURNG THE THESIS 
 
142 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
143 
 
10. ACKNOWLEDGMENTS  
4 years older, a Germanized French-English accent and “some” white hairs later, I have reached 
the final chapter of my thesis! This thesis covers only a brief history of my time spent in this 
Division. Many persons helped me on many different projects in many ways and I would like to 
thank them through the following part.  
THANK YOU:  
o Prof. Dr. Christoph Plass and Dr. Clarissa Gerhäuser for offering me the opportunity to 
pursue my thesis in your respective groups, as well as for your invaluable support and 
guidance throughout the last four years. I especially appreciated having the freedom to 
develop and pursue my own scientific ideas during my time working with you. 
o Special thanks to Clarissa for having helped me improving my writing skills through correction 
of my TAC reports, the review and this thesis. 
o PD. Dr. Popanda, Prof. Dr. Wiemann and Dr. Tamás Fischer my TAC members for their 
support, time, and insightful help during my TAC committees.  
o Olga Bogatyrova for her help with the integration of RNA sequencing and DNA methylation 
data presented in this thesis.  
o Brigitta Dapkute, Mariana Pardo-Contreras and Valentin Swingle, the young and bright 
working force I had the pleasure to train and work with. You helped me so much; I can’t thank 
you enough for your help.  
o To the colleagues who also became my friends, Schmanneke, Schmusti, Schmoni, Schmoli 
and Schtania. I miss you all very much as well as our troubleshooting, helping, singing, 
witheling, laughing, and sometimes more emotional moments! I appreciated your ongoing 
support in good and bad times. It wouldn’t have been such pleasant working place without 
all of you, my dear Sch-company! 
o Annette, Karin, Oli, Marion, Moni, Peter and Reinhard I for your availability, help and 
support.  
o Constance Baer, Oliver Mücke, Chris Oakes, Olga Bogatyrova, Soo-Zin and Christopher 
Schmidt for guiding me through the lab and learning the scientific techniques on your side 
during my first year. 
o To my dear Annika for translating my summary and being such a great (spreading) desk 
sharer. I will miss listening to your phone calls with Mani about brötchen.  
ACKNOWLEDGMENTS 
 
144 
 
o To the best office mates ever Tania, Justyna and Annika for letting me take control over the 
heater ;).  
o All present and past members of the Plass and Gerhäuser group, Daniel, Daniela, David, 
Dieter, “little” Clarissa, Constance, Katharina, Maria, Michael, Miriam, Mridul, Pavlo, 
Reinhard II, Reka, Simin, Sina, Suzanna, Yassen,.. 
 
Et plus personnellement un immense MERCI :  
o A mes parents et Jean-Pierre de me suivre et de me trimballer moi et mes affaires aux quatre 
coins de l´Europe et comme vous le savez, bientôt ça continue..  
Un merci tout spécial à mon petit  frère de spécialement venir à Heidelberg pour décoincer 
une chaussette de ma machine à laver.  Oui, je me devais d’écrire ça dans ma thèse!  
Plus sérieusement, merci d’être toujours là pour moi. 
  
o A Bonbon, de m’encourager, me soutenir, me conseiller, me supporter, de m’écouter me 
plaindre (très, très rarement..) tout au long de mes thèses, mes changements de villes, mes 
changements de projets et tellement plus.. Un énormissime merci d’avoir corrigé cette thèse 
et surtout de toujours trouver le temps et des solutions.  
Bien que loin des yeux, merci d’avoir été la personne la plus présente pour moi ces dernières 
années.   
 
Merci à vous tous, I thank all of you  
Mélanie  
 
